var title_f27_11_27824="Ultrasound median nerve movement in sagittal view";
var content_f27_11_27824=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/NEURO/53081/US_median_nerve_conv.mp4?title=Ultrasound+median+nerve+movement+in+sagittal+view\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound median nerve movement in sagittal view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a sagittal view of the median nerve at the wrist (proximal is to the left) with a normal subject flexing and extending the fingers. Note that the flexor digitorum superficialis (FDS) and flexor digitorum profundus (FDP) tendons and the median nerve (N) all move in the same directions, but that the tendons show greater excursions during these movements.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis O Walker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_11_27824=[""].join("\n");
var outline_f27_11_27824=null;
var title_f27_11_27825="Diagram of nondisjunction";
var content_f27_11_27825=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chromosomal nondisjunction in meiosis I resulting in trisomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_11_27825=[""].join("\n");
var outline_f27_11_27825=null;
var title_f27_11_27826="TB risk assessment";
var content_f27_11_27826=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Risk-assessment questionnaire",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 584px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_11_27826=[""].join("\n");
var outline_f27_11_27826=null;
var title_f27_11_27827="Treatment of metastatic breast cancer";
var content_f27_11_27827=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Treatment of metastatic breast cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/11/27827/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/11/27827/contributors\" id=\"au4959\">",
"       Daniel F Hayes, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/11/27827/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/11/27827/contributors\" id=\"se2926\">",
"       Julie R Gralow, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/11/27827/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/11/27827/contributors\" id=\"de8229\">",
"       Don S Dizon, MD, FACP",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?27/11/27827?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Metastatic breast cancer is not a curable condition. However, treatment can prolong life, delay the progression of the cancer, relieve cancer-related symptoms, and improve quality of life. The median survival of individuals with metastatic breast cancer is 18 to 24 months, although the range in survival spans between a few months to many years. This article will review the treatment options for metastatic breast cancer. More detailed information about metastatic breast cancer is available by subscription.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H282190569\">",
"     <span class=\"h1\">",
"      GOALS OF TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     In addition to the goal of prolonging survival, treatment may help relieve cancer-associated symptoms, leading to an improvement or stability in quality of life.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H554276112\">",
"     <span class=\"h1\">",
"      APPROACH TO PATIENTS WITH A CHEST WALL OR BREAST RECURRENCE",
"     </span>",
"    </p>",
"    <p>",
"     Women treated for breast cancer are at risk of a local recurrence. For women who underwent breast conserving treatment (BCT), this may present as a new breast lesion. For women who underwent a mastectomy, it may present as a mass on the skin or chest wall. Regardless of primary surgery, all patients may also present with new disease in the axilla.",
"    </p>",
"    <p>",
"     The approach to treatment will depend on the tumor size and location, as well as whether or not prior radiation was administered. Talk to your surgeon to determine the most appropriate treatment. If surgery is not an option, radiation therapy (RT) may be an alternative treatment.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H104510926\">",
"     <span class=\"h1\">",
"      APPROACH TO PATIENTS WITH METASTATIC DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     All patients with metastatic breast cancer should receive systemic therapy. However, in certain circumstances, treatment may also involve surgery or radiation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H630539986\">",
"     <span class=\"h2\">",
"      Symptomatic metastases",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatment to a specific lesion may be required if symptoms are present or there is a threat of complications (ie, spinal cord compression or fracture, brain metastases at risk for herniation, or a pending fracture due to a lesion in the hip). This may require either a surgical approach or RT to stabilize the affected area. The approach must be tailored to the specific situation and the patient&rsquo;s clinical status.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H104510782\">",
"     <span class=\"h2\">",
"      Systemic therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Systemic therapy includes the use of endocrine therapy, chemotherapy,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     biologic agents. A choice between them depends on the tumor burden, patient symptoms, and several predictive factors including:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Status of hormone receptors &mdash; Individuals with hormone-receptor (estrogen [ER]",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       progesterone [PR] receptor) positive cancers tend to do better than those whose tumors are ER-",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       PR-negative. Hormone-receptor positive patients are candidates for anti-estrogen therapy, but hormone-receptor negative patients are not. It is important that reassessment of both ER and PR be done during relapse because metastatic breast cancer does not necessarily have the same characteristics as the ones found in the primary breast cancer. (See",
"       <a class=\"local\" href=\"#H282191720\">",
"        'Anti-estrogen treatment'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       HER2 expression &mdash; With the availability of treatment targeted against the human epidermal growth factor 2 (HER2) receptor, a protein that is sometimes made by certain types of aggressive breast cancers, HER2 overexpression in breast cancer cells predicts who should receive HER2-targeted treatment. It is important to reassess the HER2 status of recurrent disease, as discrepancy between the primary and recurrent cancer occurs at least five percent of the time. (See",
"       <a class=\"local\" href=\"#H282191900\">",
"        'HER2-targeted agents'",
"       </a>",
"       below.).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H630540013\">",
"     <span class=\"h3\">",
"      Treatment options",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H282191720\">",
"     <span class=\"h4\">",
"      Anti-estrogen treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anti-estrogen treatment is also known as endocrine therapy. This includes:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Selective estrogen receptor modulators (SERMs) &mdash; tamoxifen or toremifene",
"      </li>",
"      <li>",
"       Aromatase inhibitors (AIs) &mdash; anastrazole, letrozole, exemestane",
"      </li>",
"      <li>",
"       Selective estrogen receptor downregulators (SERDs) &mdash; fulvestrant",
"      </li>",
"      <li>",
"       Progestogens &mdash; Megestrol acetate or medroxyprogesterone",
"      </li>",
"      <li>",
"       Other sex steroid hormones &mdash; Progestins, estrogens, androgens",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     For premenopausal women, treatment aimed at preventing the ovaries from making estrogen, such as surgery to remove the ovaries (oophorectomy) or medications (ie, gonadotropin-releasing hormone antagonists, such as goserelin or leuprolide) are also effective. &nbsp;",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H282191942\">",
"     <span class=\"h5\">",
"      Selective Estrogen Receptor Modulators (SERM)",
"     </span>",
"     &nbsp;&mdash;&nbsp;These agents block estrogen from stimulating breast cells. The one used in the treatment of breast cancer is tamoxifen.",
"    </p>",
"    <p>",
"     Tamoxifen is a pill that you take by mouth. It is commonly used as a first-line endocrine therapy for premenopausal women and for men with advanced breast cancer.",
"    </p>",
"    <p>",
"     Most individuals with ER",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     PR-positive breast cancer will respond to tamoxifen therapy. However, some do not respond at all to tamoxifen. Others originally respond to tamoxifen but later become resistant. Unfortunately, most if not all breast cancers eventually stop responding to tamoxifen.",
"    </p>",
"    <p>",
"     A subset of individuals with metastatic breast cancer experience a \"flare\" of their breast cancer within two days to three weeks after starting tamoxifen. This may cause an increase in bone pain, a high blood calcium level, and in individuals with breast cancer involving the skin, an increase in the size",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     number of these skin nodules, or skin redness. Tumor flares usually subside within four to six weeks. In the meantime, the symptoms can be treated with measures that reduce pain and lower blood levels of calcium. In severe cases, your doctor may tell you to temporarily stop taking tamoxifen until the flare subsides. Many doctors consider a flare reaction to be a sign that endocrine therapy is working. Side effects of tamoxifen include hot flashes, an increased risk of blood clots, uterine bleeding, and endometrial cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H282191972\">",
"     <span class=\"h5\">",
"      Aromatase inhibitors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Aromatase inhibitors (AIs) are drugs that reduce estrogen levels in the body by blocking the protein that helps make estrogen outside of the ovary (aromatase). Drugs in this class include anastrozole, letrozole, and exemestane. They are indicated for use in postmenopausal women and can be used in men with metastatic breast cancer. However, AIs should not be given to women with intact ovarian function. Side effects of aromatase inhibitors include bone loss and bone fractures and pain in the muscles and joints.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H282192001\">",
"     <span class=\"h5\">",
"      Pure antiestrogens",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pure antiestrogens block the influence of estrogen on breast cancer cells. The agent from this class used in metastatic breast cancer is fulvestrant. It is given as a monthly intramuscular (IM) injection and is approved for use in postmenopausal women whose cancers have progressed on tamoxifen",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     an AI. Whether it is as useful for premenopausal women or for men with metastatic breast cancer is not known, but there is no reason to believe it would not have the same efficacy and toxicity in older women.",
"    </p>",
"    <p>",
"     Side effects of fulvestrant include hot flashes, increases in your liver enzymes, injection site pain, and joint pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H282192160\">",
"     <span class=\"h5\">",
"      Sex steroid hormones",
"     </span>",
"     &nbsp;&mdash;&nbsp;Progestins, estrogens, and androgens may play a role in the third- or fourth-line treatment of metastatic breast cancer.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Progestins &mdash; These include both medroxyprogesterone or megestrol acetate and are taken as a pill. It is sometimes used in women who have stopped responding to tamoxifen. The side effects of treatment include blood clot formation, weight gain, fluid retention, and vaginal bleeding. In some studies, a reduction in the quality of life has been seen in women taken these drugs.",
"      </li>",
"      <li>",
"       Estrogen &mdash; For women who have progressed on multiple treatments with antiestrogens, the use of estradiol may be used. It is given as a pill and is taken daily. Side effects include vaginal bleeding, breast tenderness, nausea and vomiting, and venous thrombosis. Women on estrogen may also experience a tumor flare. For women who experience bleeding on estrogens, progestin treatment can provide control of symptoms. &nbsp;",
"      </li>",
"      <li>",
"       Androgens &mdash; The use of androgens in metastatic breast cancer is rarely used. Despite evidence that it can help tumors shrink, the side effects of treatment (virilization, edema, and jaundice) make it a less attractive option for both women and their clinicians.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H282191734\">",
"     <span class=\"h3\">",
"      Chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy is a treatment given to slow or stop the growth of cancer cells. Chemotherapy is not given every day but instead is given in cycles. A cycle is the time it takes to give the treatment and then allow the body to recover from the side effects of the medicines. A typical cycle of chemotherapy is 21 or 28 days.",
"    </p>",
"    <p>",
"     Chemotherapy drugs may be given alone, one after another, or in combination. There are a variety of drugs that can be used to treat breast cancer as both single agents or in combination. You should discuss which treatment is right for you with your doctor.",
"    </p>",
"    <p>",
"     It is not clear how many doses of chemotherapy are best for individuals with metastatic breast cancer. Several studies have compared the benefit of continuous chemotherapy (giving chemotherapy until it becomes ineffective) versus intermittent chemotherapy (giving approximately six cycles of chemotherapy followed by no chemotherapy until the cancer progresses). In general, overall survival is the same in women treated with continuous or intermittent chemotherapy, although tumor growth may be slowed somewhat in women treated with continuous therapy. Intermittent chemotherapy may allow for a better quality of life. This is a reasonable option if your cancer-related symptoms stay under control during treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H282191743\">",
"     <span class=\"h3\">",
"      Biologic therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Biologic therapy aims to target a specific protein or pathway in an effort to stop cancer cells from growing or dividing. For individuals with metastatic breast cancer, these agents include HER2-targeted agents and bone modifying agents.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H282191900\">",
"     <span class=\"h4\">",
"      HER2-targeted agents",
"     </span>",
"     &nbsp;&mdash;&nbsp;Individuals whose breast cancers produce high levels of HER2 benefit from treatments that target this protein. There are two drugs in this category, trastuzumab and lapatinib. These are often used with chemotherapy or endocrine therapy in the treatment of metastatic breast cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H282191850\">",
"     <span class=\"h5\">",
"      Trastuzumab",
"     </span>",
"     &nbsp;&mdash;&nbsp;Trastuzumab is generally given IV once per week or once every three weeks. The most common side effect of trastuzumab is fever",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     chills. Heart failure develops in about 3 to 5 percent of women treated with trastuzumab. Trastuzumab-related heart damage may not be permanent, and improvements have been seen once trastuzumab is discontinued.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H282191857\">",
"     <span class=\"h5\">",
"      Lapatinib",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lapatinib is an oral medication that targets HER2 in a different way than trastuzumab. Lapatinib may be used alone, in combination with chemotherapy, or even in combination with trastuzumab. The most common side effects of lapatinib alone are diarrhea, a skin rash that resembles acne, and nausea.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H626620881\">",
"     <span class=\"h4\">",
"      Bevacizumab",
"     </span>",
"     &nbsp;&mdash;&nbsp;The angiogenesis inhibitor, bevacizumab, is an active agent for the treatment of metastatic breast cancer, particularly when combined with the drug paclitaxel. It is often used as a first-line treatment of metastatic breast cancer. However, the benefit of bevacizumab is not clear and the Food and Drug Administration has recently rescinded its approval of this agent in metastatic breast cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H104510875\">",
"     <span class=\"h3\">",
"      Bone modifying agents",
"     </span>",
"     &nbsp;&mdash;&nbsp;While not used to treat breast cancer metastases, bone modifying agents are an important component of the treatment of bone metastases. These agents prevent the complications of breast cancer involving bones, such as fractures, spinal cord compression, and hypercalcemia of malignancy. Two classes of agents used are the bisphosphonates (pamidronate, zoledronic acid, clodronate and ibandronate) and the RANK (receptor activator of nuclear factor kappa B) ligand inhibitor, denosumab.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H630539956\">",
"     <span class=\"h2\">",
"      Role of surgery or radiation therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some patients will develop metastatic disease that is confined to one organ, such as involvement in one area of the liver or one lobe of the lung. In these cases, treatment directed at the tumor site may be an option. This may consist of surgical resection, targeted radiation, radiation frequency ablation, chemoembolization, or other methods.",
"    </p>",
"    <p>",
"     For those who are considered to be candidates for a local treatment approach, criteria are used to select patients most likely to benefit from site-specific treatment. Some criteria used to help identify patients most likely to benefit include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Good functional status&mdash; Patients who are minimally symptomatic from their cancer and independent with their activities of daily living tend to do better following surgery for metastatic disease.",
"      </li>",
"      <li>",
"       Limited number of sites of disease &mdash; Patients with limited disease appear to benefit from surgery compared to those with multiple sites of disease or with multi-organ involvement.",
"      </li>",
"      <li>",
"       Long disease-free interval &mdash; Patients who experienced a recurrence after a long period of remission do better than those with rapidly progressive cancer.",
"      </li>",
"      <li>",
"       Likelihood of a complete tumor resection &mdash; The outcomes following surgery are best in patients who undergo a complete resection of their disease with negative margins at pathologic review.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H282191884\">",
"     <span class=\"h1\">",
"      TREATMENT RECOMMENDATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Treating metastatic breast cancer takes in to account the type of cancer that you have and whether your cancer expresses hormone receptors",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     HER2. It also takes in to account the extent of cancer you are living with.",
"    </p>",
"    <p>",
"     Most clinicians recommend initial treatment with chemotherapy for rapidly progressive disease or in women with symptoms related to metastatic breast cancer. Combination chemotherapy is associated with increased responses compared to single-agent chemotherapy. However, treatment using single agents in a sequential fashion is associated with less toxicity than the use of a combination regimen. For all individuals with metastatic breast cancer the following recommendations apply:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Individuals with hormone-receptor positive metastatic breast cancer who are not terribly symptomatic, do not have life-threatening disease, or evidence of visceral involvement do not require chemotherapy and can be treated with endocrine therapy.",
"      </li>",
"      <li>",
"       Some clinicians prefer to combine ovarian suppression (OS) or ablation (OA) with tamoxifen for peri- or premenopausal women with metastatic breast cancer. Although some clinicians also use an aromatase inhibitor in combination with OS or OA, the studies are too small to render a conclusion on the benefits of this approach.",
"      </li>",
"      <li>",
"       Sequential endocrine therapy is recommended to treat hormone positive breast cancer. Most clinicians will recommend chemotherapy only for individuals who progress despite two or three trials of endocrine therapy.",
"      </li>",
"      <li>",
"       For individuals who have not received prior treatment (ie, those who present with metastatic disease), those with ER-negative breast cancer, and those with tumors that do not respond to endocrine therapy, chemotherapy is indicated as primary treatment. There is no one standard of care.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Available options include anthracyclines (eg, doxorubicin), taxanes (eg, paclitaxel or docetaxel), capecitabine, vinorelbine, gemcitabine, ixabepilone, and eribulin.",
"      </li>",
"      <li>",
"       Combination options include capecitabine and docetaxel, gemcitabine and paclitaxel. For chemotherapy na&iuml;ve patients, doxorubicin (alone or as part of a combination regimen) is also used.",
"      </li>",
"      <li>",
"       Chemotherapy with biologic therapy, such as the angiogenesis inhibitor, bevacizumab.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Individuals with HER2-positive breast cancers should receive HER2-directed therapy.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       For individuals with ER-positive cancer that is not life-threatening or symptomatic, endocrine therapy plus HER2-directed treatment (eg, lapatinib or trastuzumab) should be used. For similar patients with ER-negative cancer, single agent trastuzumab is an appropriate choice.",
"      </li>",
"      <li>",
"       For individuals with symptomatic, life-threatening disease, or disease that is involving the organs (eg, liver or lungs), combination chemotherapy with trastuzumab should be used. Most clinicians combine HER2-directed treatment with chemotherapy, such as paclitaxel, docetaxel, vinorelbine, carboplatin, and gemcitabine.",
"      </li>",
"      <li>",
"       Lapatinib can be used in combination with capecitabine, aromatase inhibitors, paclitaxel, or trastuzumab. It is indicated for individuals who have disease progression on trastuzumab.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H799247188\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H799247195\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H799247221\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link\">",
"      Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35831?source=see_link\">",
"      Metastatic breast cancer: Local treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29528?source=see_link\">",
"      Systemic treatment for metastatic breast cancer: Single agent chemotherapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11705?source=see_link\">",
"      Systemic treatment for metastatic breast cancer: Combination chemotherapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40903?source=see_link\">",
"      Treatment of metastatic breast cancer in older women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8042?source=see_link\">",
"      Osteoclast inhibition in the management of bone metastases from breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link\">",
"      Breast cancer in men",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"        www.cancer.net/portal/site/patient",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Comprehensive Cancer Network",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nccn.com/\">",
"        www.nccn.com",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Cancer Institute 1-800-4-CANCER (226237)",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nci.nih.gov/\">",
"        www.nci.nih.gov",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Cancer Society 1-800-ACS-2345",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.cancer.org/\">",
"        www.cancer.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Susan G. Komen Breast Cancer Foundation",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.komen.org/\">",
"        www.komen.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Breast Cancer Forum",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://breastcancer.about.com/forum\">",
"        file://breastcancer.about.com/forum",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?27/11/27827/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 21, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?27/11/27827?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27827/abstract/1\">",
"      Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27827/abstract/2\">",
"      Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27827/abstract/3\">",
"      Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008; 26:1980.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f27_11_27827=[""].join("\n");
var outline_f27_11_27827=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H282190569\">",
"           GOALS OF TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H554276112\">",
"           APPROACH TO PATIENTS WITH A CHEST WALL OR BREAST RECURRENCE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H104510926\">",
"           APPROACH TO PATIENTS WITH METASTATIC DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H282191884\">",
"           TREATMENT RECOMMENDATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f27_11_27828="Acanthosis nigricans with acrochordae";
var content_f27_11_27828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Acanthosis nigricans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 496px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A velvety hyperpigmented plaque with associated acrochordae is present&nbsp;in the axilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_11_27828=[""].join("\n");
var outline_f27_11_27828=null;
var title_f27_11_27829="Cefaclor: Drug information";
var content_f27_11_27829=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefaclor: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/31/29172?source=see_link\">",
"    see \"Cefaclor: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/22/12644?source=see_link\">",
"    see \"Cefaclor: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cefaclor&reg;;",
"     </li>",
"     <li>",
"      Ceclor&reg;;",
"     </li>",
"     <li>",
"      Novo-Cefaclor;",
"     </li>",
"     <li>",
"      Nu-Cefaclor;",
"     </li>",
"     <li>",
"      PMS-Cefaclor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F146943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Cephalosporin (Second Generation)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F146904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Treatment of infections:  Oral: Dosing range: 250-500 mg every 8 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F146923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/22/12644?source=see_link\">",
"      see \"Cefaclor: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of infections:",
"     </b>",
"     Oral: Children &gt;1 month: Dosing range: 20-40 mg/kg/day divided every 8-12 hours; maximum dose: 1 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Otitis media:",
"     </b>",
"     Oral: 40 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pharyngitis:",
"     </b>",
"     Oral: 20 mg/kg/day divided every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F146905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F146906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 50% to 100% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Moderately dialyzable (20% to 50%)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F146876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: 125 mg/5 mL (150 mL); 250 mg/5 mL (150 mL); 375 mg/5 mL (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F146860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F146879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer around-the-clock to promote less variation in peak and trough serum levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral suspension: Shake well before using.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F146877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible bacterial infections including otitis media, lower respiratory tract infections, acute exacerbations of chronic bronchitis, pharyngitis and tonsillitis, urinary tract infections, skin and skin structure infections",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F146951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cefaclor may be confused with cephalexin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F146941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (maculopapular, erythematous, or morbilliform) (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Eosinophilia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Moniliasis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agitation, agranulocytosis, anaphylaxis, angioedema, aplastic anemia, arthralgia, cholestatic jaundice, CNS irritability, confusion, dizziness, hallucinations, hemolytic anemia, hepatitis, hyperactivity, insomnia, interstitial nephritis, nausea, nervousness, neutropenia, paresthesia, PT prolonged, pruritus, pseudomembranous colitis, seizure, serum-sickness, somnolence, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Abdominal pain, cholestasis, fever, hemorrhage, renal dysfunction, superinfection, toxic nephropathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F146882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefaclor, any component of the formulation, or other cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F146864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;",
"     <i>",
"      H. influenzae",
"     </i>",
"     infections: Beta-lactamase-negative, ampicillin-resistant (BLNAR) strains of",
"     <i>",
"      H. influenzae",
"     </i>",
"     should be considered resistant to cefaclor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Extended release tablets are not approved for use in children &lt;16 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F146869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F146896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Food: Cefaclor serum levels may be decreased slightly if taken with food. The bioavailability of cefaclor extended release tablets is decreased 23% and the maximum concentration is decreased 67% when taken on an empty stomach.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F146872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5953385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. An increased risk of teratogenic effects has not been observed following maternal use of cefaclor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F146910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F146885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of cefaclor are excreted in breast milk. The manufacturer recommends that caution be exercised when administering cefaclor to nursing women. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F146886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsule and suspension may be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F146884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Cefaclor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (30): $59.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (30): $116.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Cefaclor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg/5 mL (150 mL): $146.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/5 mL (150 mL): $292.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     375 mg/5 mL (100 mL): $292.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Cefaclor ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $498.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F146874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor renal function. Observe for signs of anaphylaxis during first dose.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F146887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aclor (AU);",
"     </li>",
"     <li>",
"      Aczebri (PH);",
"     </li>",
"     <li>",
"      Alfatil (FR);",
"     </li>",
"     <li>",
"      Alfatil LP (FR);",
"     </li>",
"     <li>",
"      Beinuoke (CL);",
"     </li>",
"     <li>",
"      CEC (AT, BG, DO, ZA);",
"     </li>",
"     <li>",
"      Cec (MX);",
"     </li>",
"     <li>",
"      CEC 500 (DE);",
"     </li>",
"     <li>",
"      Ceclobid (PH);",
"     </li>",
"     <li>",
"      Ceclor (AT, AU, BB, BF, BJ, BM, BR, BS, BZ, CH, CI, CL, CO, CZ, EC, ES, ET, GH, GM, GN, GR, GY, HK, HN, JM, KE, KP, LR, MA, ML, MR, MU, MW, MX, NE, NG, NL, PE, PH, PK, PL, PT, RU, SC, SD, SL, SN, SR, TN, TR, TT, TZ, UG, VE, ZM, ZW);",
"     </li>",
"     <li>",
"      Ceclor AF (PE);",
"     </li>",
"     <li>",
"      Ceclor CD (AU, PH);",
"     </li>",
"     <li>",
"      Ceclor MR (BF, BJ, CI, ET, GH, GM, GN, HK, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Ceclor Retard (CH, ES);",
"     </li>",
"     <li>",
"      Ceclor SR (NZ);",
"     </li>",
"     <li>",
"      Cecrun (KP);",
"     </li>",
"     <li>",
"      Cefabac (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Cefacle (KP);",
"     </li>",
"     <li>",
"      Cefclor (TH);",
"     </li>",
"     <li>",
"      Ceflacid (MX);",
"     </li>",
"     <li>",
"      Cefmed (PH);",
"     </li>",
"     <li>",
"      Cefral (AR);",
"     </li>",
"     <li>",
"      Cektin (KP);",
"     </li>",
"     <li>",
"      Cephlor (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ceracl (KP);",
"     </li>",
"     <li>",
"      Cero (TW);",
"     </li>",
"     <li>",
"      Cleancef (SG);",
"     </li>",
"     <li>",
"      Clex (KP);",
"     </li>",
"     <li>",
"      Cloracef (ID);",
"     </li>",
"     <li>",
"      Cloracef MR (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Clorcef (PH);",
"     </li>",
"     <li>",
"      Distaclor (CO, GB, IE, MY, SG, TH);",
"     </li>",
"     <li>",
"      Doccefaclo (BE);",
"     </li>",
"     <li>",
"      Efaclor (MY);",
"     </li>",
"     <li>",
"      Faclor (BR);",
"     </li>",
"     <li>",
"      Fasiclor (MX);",
"     </li>",
"     <li>",
"      Forbatec (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Forifek (ID);",
"     </li>",
"     <li>",
"      Haxifal (FR);",
"     </li>",
"     <li>",
"      Karlor (AU);",
"     </li>",
"     <li>",
"      Karlor CD (AU);",
"     </li>",
"     <li>",
"      Kefaclor (TZ);",
"     </li>",
"     <li>",
"      Keflor (AU, CL, CN, IN);",
"     </li>",
"     <li>",
"      Keflor CD (AU);",
"     </li>",
"     <li>",
"      Kefolor (FI);",
"     </li>",
"     <li>",
"      Kemocin (KP);",
"     </li>",
"     <li>",
"      Kerfenmycin (TW);",
"     </li>",
"     <li>",
"      Kwicap (AR);",
"     </li>",
"     <li>",
"      Lorcef (PH);",
"     </li>",
"     <li>",
"      Medoclor (BG);",
"     </li>",
"     <li>",
"      Miclor (KP);",
"     </li>",
"     <li>",
"      Ozcef (AU);",
"     </li>",
"     <li>",
"      Panacef (IT);",
"     </li>",
"     <li>",
"      Panoral (DE);",
"     </li>",
"     <li>",
"      Panoral Forte (DE);",
"     </li>",
"     <li>",
"      Pharmaclor (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Qualiceclor (HK);",
"     </li>",
"     <li>",
"      Qualiphor (HK);",
"     </li>",
"     <li>",
"      Ranclor (MX);",
"     </li>",
"     <li>",
"      Seporin (KP);",
"     </li>",
"     <li>",
"      Serviclor (MX);",
"     </li>",
"     <li>",
"      Sifaclor (TH);",
"     </li>",
"     <li>",
"      Soficlor (HK, MY);",
"     </li>",
"     <li>",
"      Surecef (PH);",
"     </li>",
"     <li>",
"      Swiflor (TW);",
"     </li>",
"     <li>",
"      U-Clor (TW);",
"     </li>",
"     <li>",
"      Vefarol (PH);",
"     </li>",
"     <li>",
"      Vercef (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Versef (PH);",
"     </li>",
"     <li>",
"      Wonclor (KP);",
"     </li>",
"     <li>",
"      Xelent (PH);",
"     </li>",
"     <li>",
"      Zaike (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F146863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F146881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed, acid stable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely throughout the body and reaches therapeutic concentration in most tissues and body fluids, including synovial, pericardial, pleural, peritoneal fluids; bile, sputum, and urine; bone, myocardium, gallbladder, skin and soft tissue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Partially hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 0.5-1 hour; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Capsule: 60 minutes; Suspension: 45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society, &ldquo;Guidelines for the Initial Management of Adults With Community-Acquired Pneumonia: Diagnosis, Assessment of Severity, and Initial Antimicrobial Therapy,&rdquo;",
"      <i>",
"       Am Rev Respir Dis",
"      </i>",
"      , 1993, 148(5):1418-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/11/27829/abstract-text/8239186/pubmed\" id=\"8239186\" target=\"_blank\">",
"        8239186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boguniewicz M and Leung DYM, &ldquo;Hypersensitivity Reactions to Antibiotics Commonly Used in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(3):221-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/11/27829/abstract-text/7761188/pubmed\" id=\"7761188\" target=\"_blank\">",
"        7761188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(7):419-26 and 318(8):490-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/11/27829/abstract-text/3277054/pubmed\" id=\"3277054\" target=\"_blank\">",
"        3277054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hyslop DL, &ldquo;Cefaclor Safety Profile: A Ten Year Review,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 1988, 11(Suppl A):83-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/11/27829/abstract-text/3242837/pubmed\" id=\"3242837\" target=\"_blank\">",
"        3242837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine LR, &ldquo;Quantitative Comparison of Adverse Reactions to Cefaclor vs Amoxicillin in a Surveillance Study,&rdquo;",
"      <i>",
"       Pediatr Infect Dis",
"      </i>",
"      , 1985, 4(4):358-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/11/27829/abstract-text/3161007/pubmed\" id=\"3161007\" target=\"_blank\">",
"        3161007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(2):187-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/11/27829/abstract-text/10069359/pubmed\" id=\"10069359\" target=\"_blank\">",
"        10069359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saxon A, Beall GN, Rohr AS, et al, &ldquo;Immediate Hypersensitivity Reactions to Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1987, 107(2):204-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/11/27829/abstract-text/3300459/pubmed\" id=\"3300459\" target=\"_blank\">",
"        3300459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith GH, &ldquo;Oral Cephalosporins in Perspective,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1990, 24(1):45-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/11/27829/abstract-text/2405586/pubmed\" id=\"2405586\" target=\"_blank\">",
"        2405586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wright AJ, &ldquo;The Penicillins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(3):290-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/11/27829/abstract-text/10090000/pubmed\" id=\"10090000\" target=\"_blank\">",
"        10090000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9211 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-110.170.48.130-F96105F60D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_11_27829=[""].join("\n");
var outline_f27_11_27829=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146901\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146943\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146904\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146923\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146905\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146906\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682508\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146876\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146860\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146879\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146877\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146951\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146941\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146882\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146864\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298983\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146869\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146896\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146872\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5953385\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146910\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146885\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146886\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146884\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146874\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146887\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146863\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146881\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9211\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9211|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/31/29172?source=related_link\">",
"      Cefaclor: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/22/12644?source=related_link\">",
"      Cefaclor: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_11_27830="Avascular spaces female pelvis";
var content_f27_11_27830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F83011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F83011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Avascular spaces of the female pelvis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 511px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic sectional drawing of the pelvis shows the firm connective tissue covering. The bladder, cervix, and rectum are surrounded by a connective tissue covering. The Mackenrodt ligament extends from the lateral cervix to the lateral abdominal pelvic wall. The vesicouterine ligament originating from the anterior edge of the Mackenrodt ligament leads to the covering of the bladder on the posterior side. The sagittal rectum column spreads both to the connective tissue of the rectum and the sacral vertebrae closely nestled against the back of the Mackenrodt ligament and lateral pelvic wall. Between the firm connective tissue bundles is loose connective tissue (paraspaces).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Von Peham H, Amreich JA. Gynaekologische Operationslehre. S Karger, Berlin, Germany 1930.",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_11_27830=[""].join("\n");
var outline_f27_11_27830=null;
var title_f27_11_27831="Triamcinolone (systemic): Pediatric drug information";
var content_f27_11_27831=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triamcinolone (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31768?source=see_link\">",
"    see \"Triamcinolone (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/49/5910?source=see_link\">",
"    see \"Triamcinolone (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15387300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Fungal Meningitis Outbreak Associated with Contaminated Injectables",
"     </span>",
"     <span class=\"collapsible-date\">",
"      October 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For information regarding the recent meningitis outbreak from products compounded by the New England Compounding Center (NECC), including treatment recommendations, please refer to the following websites:",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       <a href=\"file://www.cdc.gov/hai/outbreaks/meningitis.html\" target=\"_blank\">",
"        file://www.cdc.gov/hai/outbreaks/meningitis.html",
"       </a>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm285497.htm\" target=\"_blank\">",
"        file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm285497.htm",
"       </a>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm323947.htm?source=govdelivery\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm323947.htm?source=govdelivery",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9606510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aristospan&reg;;",
"     </li>",
"     <li>",
"      Kenalog&reg;-10;",
"     </li>",
"     <li>",
"      Kenalog&reg;-40",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9606511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aristospan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10531039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Systemic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10531264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31768?source=see_link\">",
"      see \"Triamcinolone (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjust dose depending upon condition being treated and response of patient. The lowest possible dose should be used to control the condition; when dose reduction is possible, the dose should be reduced gradually. In life-threatening situations, parenteral doses larger than the oral dose may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M. (as",
"     <b>",
"      acetonide",
"     </b>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: Initial: 0.11&ndash;1.6 mg/kg/day (or 3.2&ndash;48 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day) in 3&ndash;4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 6-12 years: Initial: 40 mg; some centers use 0.03-0.2 mg/kg at 1- to 7-day intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents &gt;12 years and Adults: Initial: 60 mg; usual dose: 40&ndash;80 mg; some patients may respond to 20 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hay fever/pollen asthma: 40-100 mg as a single injection/season",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Multiple sclerosis (acute exacerbation): 160 mg daily for 1 week, followed by 64 mg every other day for 1 month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intra-articular (as",
"     <b>",
"      hexacetonide",
"     </b>",
"     ): Children &gt;12 years and Adults: Large joints: 10-20 mg; small joints: 2-6 mg; usual frequency: Every 3-4 weeks; more frequent administration is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intra-articular, intrabursal, tendon-sheath injection (as",
"     <b>",
"      acetonide",
"     </b>",
"     ): Adults: Initial: Smaller joints: 2.5-5 mg; larger joints: 5-15 mg; may require up to 10 mg for small joints and up to 40 mg for large joints; maximum dose/treatment (several joints at one time): 20-80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intra-articular, intrasynovial (as",
"     <b>",
"      acetonide",
"     </b>",
"     ): Children &gt;12 years and Adults: 2.5-40 mg, repeat as needed when signs and symptoms recur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intradermal (as",
"     <b>",
"      acetonide",
"     </b>",
"     ): Adults: Initial: 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intralesional, sublesional (as",
"     <b>",
"      acetonide",
"     </b>",
"     ): Children &gt;12 years and Adults: Up to 1 mg per injection site and may be repeated 1 or more times weekly; multiple sites may be injected if they are 1 cm or more apart, not to exceed 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intralesional, sublesional (as",
"     <b>",
"      hexacetonide",
"     </b>",
"     ): Children &gt;12 years and Adults: Up to 0.5 mg/square inch of affected skin; initial range: 2-48 mg; frequency of dose is determined by clinical response",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9606831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension, as acetonide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kenalog&reg;-10: 10 mg/mL (5 mL) [contains benzyl alcohol, polysorbate 80;",
"     <b>",
"      not",
"     </b>",
"     for I.V., I.M., intraocular, epidural, or intrathecal use]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kenalog&reg;-40: 40 mg/mL (1 mL, 5 mL, 10 mL) [contains benzyl alcohol, polysorbate 80;",
"     <b>",
"      not",
"     </b>",
"     for I.V., intradermal, intraocular, epidural, or intrathecal use]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension, as hexacetonide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aristospan&reg;: 5 mg/mL (5 mL); 20 mg/mL (1 mL, 5 mL) [contains benzyl alcohol, polysorbate 80;",
"     <b>",
"      not",
"     </b>",
"     for I.V. use]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9606532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10531265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Avoid SubQ use;",
"     <b>",
"      do not inject I.V.",
"     </b>",
"     ; shake well prior to use; acetonide or hexacetonide may be administered I.M.; for I.M. administration: Inject deep in large muscle mass; avoid deltoid.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10531138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetonide injectable suspension: All products: Avoid freezing; protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kenalog&reg;: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hexacetonide injectable suspension: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); avoid freezing. Protect from light. Avoid diluents containing parabens, phenol, or other preservatives (may cause flocculation). Diluted suspension stable up to 1 week. Suspension for intralesional use may be diluted with D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     NS, NS, or SWI to a 1:1, 1:2, or 1:4 concentration. Solutions for intra-articular use may be diluted with lidocaine 1% or 2%.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10531043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intra-articular (soft tissue): Acute gouty arthritis, acute/subacute bursitis, acute tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intralesional (injectable suspension): Alopecia areata; discoid lupus erythematosus; infiltrated, inflammatory lesions associated with granuloma annulare, lichen planus, neurodermatitis, and psoriatic plaques; keloids; necrobiosis lipoidica diabeticorum; possibly helpful in cystic tumors of an aponeurosis or tendon (ganglia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Systemic: Immunosuppression; relief of severe inflammation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9606492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Kenalog&reg; may be confused with Ketalar&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       TAC (occasional abbreviation for triamcinolone) is an error-prone abbreviation (mistaken as tetracaine-adrenaline-cocaine)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9606577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia, cardiac arrest, cardiac enlargement, CHF, circulatory collapse, edema, hypertension, hypertrophic cardiomyopathy (premature infants), myocardial rupture (following recent MI), syncope, tachycardia, thromboembolism, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Arachnoiditis (I.T.), depression, emotional instability, euphoria, headache, insomnia, intracranial pressure increased, malaise, meningitis (I.T.), mood changes, neuritis, neuropathy, personality change, pseudotumor cerebri (with discontinuation), seizure, spinal cord infarction, stroke, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Abscess (sterile), acne, allergic dermatitis, angioedema, atrophy (cutaneous/subcutaneous), bruising, dry skin, erythema, hair thinning, hirsutism, hyper-/hypopigmentation, hypertrichosis, impaired wound healing, lupus erythematosus-like lesions, petechiae, purpura, rash, skin test suppression, striae, thin skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Carbohydrate intolerance, Cushingoid state, diabetes mellitus, fluid retention, glucose intolerance, growth suppression (children), hypokalemia, hypokalemic alkalosis, menstrual irregularities, negative nitrogen balance, sodium retention, sperm motility altered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, appetite increased, GI hemorrhage, GI perforation, nausea, pancreatitis, peptic ulcer, ulcerative esophagitis, weight gain",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Hepatomegaly, liver function tests increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Aseptic necrosis of femoral and humeral heads, calcinosis, Charcot-like arthropathy, fractures, joint tissue damage, muscle mass loss, myopathy, osteoporosis, parasthesia, paraplegia, quadriplegia, tendon rupture, vertebral compression fractures, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Ocular: Cataracts, cortical blindness, exophthalmos, glaucoma, ocular pressure increased, papilledema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Renal: Glycosuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Abnormal fat deposits, anaphylactoid reaction, anaphylaxis, diaphoresis, hiccups, infection, moon face",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10531124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to triamcinolone or any component; systemic fungal infections; cerebral malaria; serious infections (except septic shock or tuberculous meningitis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressive doses: Contraindicated with immunization with live or live-attenuated vaccines",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Contraindicated with idiopathic thrombocytopenic purpura",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10531126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended doses; suppression of HPA axis function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, hypercorticism (Cushing's syndrome), hyperglycemia, or glucosuria may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients by any route (monitor growth). Use with extreme caution in patients with respiratory tuberculosis or untreated systemic infections. Use with caution in patients with hypertension, HF, or renal impairment; long-term use has been associated with fluid retention and hypertension. Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to risk of GI bleeding and perforation. High-dose corticosteroids should not be used for management of head injury; increased mortality was observed in patients receiving high-dose I.V. methylprednisolone. Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids. Use with caution in patients with hepatic impairment, including cirrhosis; enhanced pharmacologic effect due to decreased metabolism and long-term use has been associated with fluid retention. Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with diabetes; corticosteroids may alter glucose regulation leading to hyperglycemia. Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use, consider routine eye exams in chronic users. Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis. Use with caution in patients with thyroid dysfunction; changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones. Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered. Use with caution in patients with thromboembolic tendencies or thrombophlebitis. Avoid injection into an infected site.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10531125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypothalamic-pituitary-adrenal (HPA) suppression may occur, particularly in younger children or in patients receiving high doses for prolonged periods; acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress; withdrawal and discontinuation of corticosteroids should be done carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immunosuppression may occur; patients may be more susceptible to infections; prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral or fungal infections, activate latent opportunistic infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex; use caution in patients with a history of ocular herpes simplex. Corticosteroids should not be used for cerebral malaria or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with &gt;4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Acute myopathy may occur with high doses, usually in patients with neuromuscular transmission disorders; myopathy may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed. Rare cases of anaphylactoid reactions have been reported with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection may contain benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates; the \"gasping syndrome\" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse; avoid use of triamcinolone products containing benzyl alcohol or sodium benzoate in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites. Injection also contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986;",
"     <i>",
"      MMWR",
"     </i>",
"     , 1984).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9606603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Orally Inhaled) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May enhance the adverse/toxic effect of Triamcinolone (Systemic). Specifically, risks of developing iatrogenic Cushing syndrome and secondary adrenal insufficiency may be increased. Ritonavir may increase the serum concentration of Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10531131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic use of corticosteroids may require a diet with increased potassium, folate, calcium, zinc, phosphorus, and vitamins A, B",
"     <sub>",
"      6",
"     </sub>",
"     , C, and D, as well as with decreased sodium",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9887154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9606535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Triamcinolone was shown to be teratogenic in animal reproduction studies. Some studies have shown an association between first trimester corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10531267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure (if therapy &gt;6 weeks); weight, height, and linear growth of pediatric patients (with chronic use); assess HPA suppression. Monitor blood pressure, serum glucose, potassium, calcium, hemoglobin, occult blood loss, and clinical presence of adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10531139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10531140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 99.5 &plusmn; 27.5 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~68%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic to 3 identified metabolites (significantly less active than parent drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: Elimination: 88 minutes; Biologic: 18-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: I.M.: Within 8-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: 40% of dose is excreted in urine; 60% in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10531254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/49/5910?source=see_link\">",
"      see \"Triamcinolone (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if condition being treated persists or worsens; avoid exposure to chicken pox or measles; if exposed, seek medical advice without delay; avoid alcohol",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/11/27831/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/11/27831/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leonard MB, \"Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 119 (Suppl 2):S166-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/11/27831/abstract-text/17332238/pubmed\" id=\"17332238\" target=\"_blank\">",
"        17332238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16061 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_11_27831=[""].join("\n");
var outline_f27_11_27831=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15387300\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606510\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606511\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531039\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531264\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606831\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606532\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531265\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531138\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531043\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606492\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606577\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531124\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531126\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531125\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300167\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606603\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531131\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887154\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606535\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531267\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531139\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531140\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10531254\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16061\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16061|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5637?source=related_link\">",
"      Triamcinolone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/10/16548?source=related_link\">",
"      Triamcinolone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/56/16260?source=related_link\">",
"      Triamcinolone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/55/8052?source=related_link\">",
"      Triamcinolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/31/19955?source=related_link\">",
"      Triamcinolone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/36/16963?source=related_link\">",
"      Triamcinolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31768?source=related_link\">",
"      Triamcinolone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/49/5910?source=related_link\">",
"      Triamcinolone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/30/32229?source=related_link\">",
"      Triamcinolone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/46/36580?source=related_link\">",
"      Triamcinolone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/10/14500?source=related_link\">",
"      Triamcinolone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_11_27832="Red cell transfusion in infants and children: Selection of blood products";
var content_f27_11_27832=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Red cell transfusion in infants and children: Selection of blood products",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/11/27832/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/11/27832/contributors\">",
"     Jun Teruya, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/11/27832/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/11/27832/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/11/27832/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/11/27832/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/11/27832/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusions of red blood cells (RBCs) are given to children in a wide variety of clinical settings. This includes children with anemia due to congenital or acquired disease, or blood loss from trauma or surgery. Once the decision to transfuse RBCs has been made, the most appropriate RBC product must be chosen. Donated whole blood used for transfusion is modified in several ways that remove varying proportions of non-red cell components, thereby allowing selection of RBC products based upon clinical needs.",
"   </p>",
"   <p>",
"    This topic will review the different RBC products and indications for their use in infants and children who require RBC transfusions. The indications, methods of administration, and complications of RBC transfusion in infants and children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=see_link\">",
"     \"Indications for red blood cell transfusion in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=see_link\">",
"     \"Administration and complications of red cell transfusion in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RED BLOOD CELL PRODUCTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Whole blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of whole blood in pediatric patients is limited. Whole blood is most often used for patients undergoing major cardiac surgery. Whole blood has also been given for exchange transfusion in newborns for severe hemolytic disease or hyperbilirubinemia, and in patients undergoing massive transfusion; however, reconstituted blood (packed red cells and fresh frozen plasma) is more commonly used for these indications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/1\">",
"     1",
"    </a>",
"    ]. Some clinicians have advocated whole blood when patients are placed on extracorporeal membrane oxygenation (ECMO) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fresh whole blood (generally less than 48 hours old) has been reported to improve hemostasis in infants undergoing cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This was shown in a randomized trial of 61 infants less than one month of age who underwent cardiac surgery and cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients who received blood reconstituted with fresh red blood cells (RBCs), platelets, and plasma from a single donor had less postoperative chest tube volume loss, lower need for inotropic support, shorter ventilatory time, and shorter hospital stay, as compared to those who received packed RBCs. It should be noted, however, that the control group in this study used relatively old packed RBCs (14 &plusmn; 8 days old).",
"   </p>",
"   <p>",
"    On the other hand, a randomized trial of 96 infants requiring cardiopulmonary bypass found no advantage, and perhaps disadvantages, in the use of fresh whole blood compared to reconstituted packed RBCs and fresh frozen plasma for priming the pump circuit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, fresh whole blood increased perioperative fluid accumulation and the length of stay in the intensive care unit. Thus, use of fresh whole blood for pediatric cardiac surgery remains controversial. In addition, whole blood is not readily available in most areas of the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Packed red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Packed RBCs is the blood product of choice for replacement during surgery, red cell loss, and sporadic transfusion therapy. The hematocrit (Hct) of the unit varies depending upon the preservative solution. In the United States, commonly used solutions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CPDA-1 (citrate, phosphate, dextrose, adenine), which have a Hct of 65 to 80 percent. These products can be used for 35 days after collection [",
"      <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nutrient preparations, such as Adsol&trade; (AS-1) and Nutricel&trade; (AS-2), which have a Hct of 55 to 65 percent. These products can be used for 42 days after collection [",
"      <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link\">",
"     \"Use of red blood cells for transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Leukoreduced red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;White blood cells (WBCs) can be removed from blood products by highly efficient filters that reduce the number of WBCs by more than 99.9 percent, generally to &lt;1 x 10",
"    <sup>",
"     6",
"    </sup>",
"    WBCs per red cell unit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/6\">",
"     6",
"    </a>",
"    ]. The few that remain are capable of replication and can cause transfusion-associated-graft-versus-host disease (TA-GVHD). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Irradiated red cells'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following is a brief summary of the adverse consequences of transfused WBCs that are reduced by the use of leukoreduced red cells. A more complete discussion of the role of leukoreduction in preventing adverse effects of transfused WBCs is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link\">",
"     \"Leukoreduction to prevent complications of blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Febrile nonhemolytic transfusion&nbsp;reaction &ndash; Febrile nonhemolytic transfusion reactions appear to be mediated by leukocyte-derived cytokines and direct donor cell leukocyte interactions. Leukoreduction significantly reduces but does not completely eliminate these reactions.",
"     </li>",
"     <li>",
"      HLA alloimmunization &ndash; HLA alloimmunization can be induced by HLA antigens expressed on donor leukocytes in recipients who receive multiple transfusions. Allosensitization increases the risk of graft rejection in children who subsequently receive organ or hematopoietic cell transplantation. It also increases platelet refractoriness in patients who need multiple platelet transfusions, (eg, children with leukemia or other malignancies). Leukoreduction reduces the incidence of alloimmunization.",
"     </li>",
"     <li>",
"      Infection &ndash; The elimination of WBCs by leukoreduction reduces the transmission of infectious agents that are harbored in WBCs, notably cytomegalovirus (CMV).",
"     </li>",
"     <li>",
"      Transfusion-associated immunomodulation &ndash; The most controversial purported benefit from leukoreduction is its role in decreasing transfusion-associated immunomodulation (TRIM), which primarily results in immunosuppression in the recipient. WBCs are felt to have a major causative role in TRIM and leukoreduction is thought to reduce immunosuppression. Indirect support for this hypothesis is provided by reports of decreased postoperative infections in adults who received leukoreduced RBCs.",
"      <br/>",
"      <br/>",
"      TRIM may also result in autoimmune tissue damage, as illustrated in a study of young children undergoing surgery for congenital heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients who received leukoreduced blood had lower levels of malondialdehyde (a marker of cardiac ischemic injury) compared to those who received blood without leukoreduction. Despite these reports, the role of leukoreduction in decreasing TRIM remains uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to reducing adverse effects of RBC transfusion, it has been suggested that the removal of WBCs makes transfusion physically easier, especially through the small catheters that may be required in newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/8\">",
"     8",
"    </a>",
"    ]. However, there is little evidence to support this argument.",
"   </p>",
"   <p>",
"    Because leukoreduction reduces febrile non-hemolytic transfusion reactions, prevents alloimmunization, and reduces the transmission of certain infections, many blood centers in the United States and other countries have adopted a policy of \"universal leukoreduction,\" in which all RBC and apheresis platelet products are leukoreduced. However, local variation is substantial, and there is debate about the wisdom of this policy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link\">",
"     \"Leukoreduction to prevent complications of blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician should be aware of the policies of the local blood center and should specifically order leukoreduced products if they are desired [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/1\">",
"     1",
"    </a>",
"    ]. Although many children receiving transfusions will need leukoreduced products under specific guidelines, the necessity for universal leukoreduction in pediatric patients, particularly neonates, remains disputed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;While acknowledging local variation in transfusion policies and the need for local judgment, guidelines developed by pediatric transfusion medicine specialists recommend leukoreduced components in the following clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/1\">",
"     1",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have experienced febrile nonhemolytic transfusion reactions, to prevent recurrence",
"     </li>",
"     <li>",
"      For patients who may require frequent transfusions (eg, those with aplastic anemia, leukemia, or future transplant candidates), to reduce the risk of HLA alloimmunization",
"     </li>",
"     <li>",
"      For patients at risk for CMV related disease (as described below), to prevent CMV transmission",
"     </li>",
"     <li>",
"      For patients undergoing cardiopulmonary bypass, to prevent lung injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     CMV-safe products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many hospitals use the term \"CMV-safe\" (or \"CMV-reduced-risk\") to describe blood products that are either leukoreduced or seronegative [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/10\">",
"     10",
"    </a>",
"    ]. However, it remains unclear whether leukoreduction and CMV-seronegative products are equivalent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Irradiation does not produce a CMV-safe product because the dose of radiation used is not sufficient to kill viruses.",
"   </p>",
"   <p>",
"    The transmission of cytomegalovirus (CMV) by transfusion is well known. The following groups of patients are at particular risk: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetuses receiving intrauterine transfusions [",
"      <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Premature infants born to CMV-seronegative mothers who have no protective antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Children with congenital or acquired immunodeficiency, including CMV-seronegative children receiving bone marrow or solid organ transplants from CMV-negative donors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CMV-seronegative children receiving bone marrow or solid organ transplants from CMV-positive donors are also at risk for developing CMV infection, and are generally treated with prophylactic or preemptive antiviral agents in addition to using leukoreduced or CMV-negative blood for transfusion. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    The risk of CMV transmission is eliminated almost entirely by the transfusion of blood from donors who are CMV-seronegative. However, rare transmission of CMV has been documented, when the donor is in the \"window period\" following exposure to the virus, before the development of antibodies, or when the antibody titer is below the limits of detection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In American populations, 40 to 90 percent of donors are CMV-seropositive. As a result, there may not be sufficient CMV-seronegative donors to fill the need for CMV-safe blood products. Fortunately, leukoreduction also reduces the risk of transmission of CMV, although rare cases of CMV have been associated with transfusion of either leukoreduced or seronegative components [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link&amp;anchor=H11#H11\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Viral diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Irradiated red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion-associated graft-versus-host disease (TA-GVHD) is caused by viable donor lymphocytes that are transfused into a patient who either does not recognize these cells as foreign or does not have the capacity to destroy them. TA-GVHD usually begins 8 to 10 days following transfusion and is almost inevitably fatal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link\">",
"     \"Transfusion-associated graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At a standard dose, gamma irradiation of the blood product prior to transfusion stops proliferation of foreign lymphocytes, which entirely prevents TA-GVHD. However, the dose of radiation used for cellular blood products is not sufficient to kill viruses. Thus, irradiation does not provide a CMV-safe product, and does not eliminate the need for either leukoreduction or CMV-seronegative blood products if a CMV-safe product is required [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/1\">",
"     1",
"    </a>",
"    ]. Conversely, leukoreduction does not eliminate all viable donor lymphocytes, and a leukoreduced product can cause TA-GVHD disease if it was not irradiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link&amp;anchor=H10#H10\">",
"     \"Transfusion-associated graft-versus-host disease\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7\">",
"     'CMV-safe products'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Leukoreduced red cells'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;GVHD does not occur after most transfusions because the donor lymphocytes are destroyed by the recipient's immune system. However, this protective response does not occur in two settings:",
"   </p>",
"   <p>",
"    <strong>",
"     &ldquo;Directed donor&rdquo; blood products",
"    </strong>",
"    &ndash; The first occurs in immunocompetent individuals. TA-GVHD may develop in a partial HLA match when the recipient is heterozygous at an HLA allele for which the donor is homozygous. In these instances, donor WBCs will not be recognized as foreign by the host, but the donor cells may recognize host cells as foreign and mount a TA-GVHD reaction. There is an increased likelihood of this occurring in blood relatives. As a result, blood products donated by family members should be irradiated before transfusing into a blood relative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link&amp;anchor=H4#H4\">",
"     \"Transfusion-associated graft-versus-host disease\", section on 'Partial HLA matching'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Immunodeficient recipients",
"    </strong>",
"    &ndash; The second setting is in the recipient with decreased cellular immunity who is unable to mount a response against donor lymphocytes. Settings in which this complication can occur include (",
"    <a class=\"graphic graphic_table graphicRef81912 \" href=\"UTD.htm?10/37/10844\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/1,19\">",
"     1,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with hematologic disorders who will undergo hematopoietic cell transplantation (HCT).",
"     </li>",
"     <li>",
"      Children with Hodgkin lymphoma.",
"     </li>",
"     <li>",
"      Intrauterine transfusions.",
"     </li>",
"     <li>",
"      Premature infants weighing less than 1200 g at birth [",
"      <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neonatal exchange transfusions.",
"     </li>",
"     <li>",
"      Children with congenital cell-mediated immunodeficiencies (eg, severe combined immunodeficiency or DiGeorge syndrome).",
"     </li>",
"     <li>",
"      Children with severe immunosuppression due to chemotherapy or irradiation for oncologic or autoimmune disease.",
"     </li>",
"     <li>",
"      Children with immunosuppression who have received HCT transplants; solid organ transplant recipients receive irradiated blood in some but not all institutions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TA-GVHD has been rarely reported in low birth weight newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/20\">",
"     20",
"    </a>",
"    ]. Although the need for irradiated blood products in neonates is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], many but not all institutions routinely irradiate blood for newborns, or at least for premature newborns. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irradiated red cell units are not entirely benign. The levels of irradiation necessary to inactivate lymphocytes also induce a lesion in the red cell membrane. This can lead to reduced red cell viability and a leakage of potassium, which decreases the shelf life of irradiated products to no more than 28 days of total storage time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link&amp;anchor=H9#H9\">",
"     \"Use of red blood cells for transfusion\", section on 'Potassium leakage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link&amp;anchor=H15#H15\">",
"     \"Use of red blood cells for transfusion\", section on 'Irradiated red cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of special concern to pediatricians is the elevation in potassium concentration that may occur in irradiated units, particularly if they are stored for some days after irradiation. For the ordinary small-volume, slow transfusion, levels of potassium in a unit are safe at any time before expiration, whether or not the unit has been irradiated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/23\">",
"     23",
"    </a>",
"    ]. However, clinically significant hyperkalemia can occur in certain unusual clinical situations, such as infusion of this blood into the heart during ECMO cannulation or other instances of massive and rapid transfusion into a central line [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. One case report, for example, described hyperkalemia in an infant following the transfusion of red cells that were six days old and had been irradiated 48 hours prior to transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To minimize increases in serum potassium, red cells should be irradiated shortly before transfusion to decrease the amount of potassium leak. However, this may not be possible in all cases, particularly in hospitals that do not have an irradiator on site.",
"   </p>",
"   <p>",
"    For patients who are receiving massive transfusion (defined as replacement &gt;50 percent of a patient's blood volume in 24 hours, those receiving exchange transfusions, or other clinical settings with anticipated large volumes of transfused blood), the supernatant solution containing excess potassium can be removed by washing the RBCs prior to transfusion. Washing of irradiated RBCs is the most effective method for removing excess potassium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/29\">",
"     29",
"    </a>",
"    ]. Washing of irradiated RBCs should be reserved for these situations since it reduces the volume of red cells available and may minimize the efficacy of the transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sickle cell negative blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood that is \"sickle cell negative\" has been tested by a rapid screen for the presence of hemoglobin S (HbS). A negative screen indicates that the blood contains &lt;30 percent HbS.",
"   </p>",
"   <p>",
"    Cells that contain &gt;30 percent HbS might sickle in vivo under hypoxic conditions. Therefore, sickle cell negative blood is usually used for transfusion to patients in the following categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Newborns",
"     </li>",
"     <li>",
"      Intrauterine transfusions",
"     </li>",
"     <li>",
"      Exchange transfusions for patients with sickle cell disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Autologous donations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood donated by a patient exclusively for his or her own use is termed autologous, while blood from another person is termed allogeneic. Autologous donations have been widely used in adults when elective surgery that routinely requires blood transfusion is planned. Use of autologous blood avoids most (but not all) of the infectious risks associated with transfusion. Blood should only be drawn if the donor's hemoglobin level is at least 11.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or the hematocrit is at least 33 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=see_link\">",
"     \"Preoperative autologous blood donation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31605?source=see_link\">",
"     \"Controversial areas in preoperative autologous blood donation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the standard minimum age and weight for allogeneic blood donation is 16 years old (17 years of age in some states), special programs allow children to donate blood for their own anticipated use. In any consideration of autologous donation for children, one must consider the ability of the child to donate, both in physical size (including ease of venous access) and developmental maturity. Pediatric autologous donations have generally been well-received, and children as young as eight years have been donors. The units are usually used as whole blood, but the platelets and plasma from such units cannot be assumed to have procoagulant activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most programs, no more than 10 percent of the child's blood volume is withdrawn at any donation and the procedure is well tolerated. An alternative to estimating blood volume in preteens and adolescents weighing less than 50 kg is to lower the definition of one unit (normally 500 mL) according to the following formula [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;Amount to draw &nbsp; = &nbsp; 500 mL &nbsp;x &nbsp;(weight [kg] &nbsp;&divide; &nbsp;50)",
"   </p>",
"   <p>",
"    The amount of anticoagulant to leave in the primary container (normally 95 to 102 mL for a full unit) can then be calculated from:",
"   </p>",
"   <p>",
"    &nbsp;Amount of anticoagulant &nbsp; = &nbsp; 95 mL &nbsp;x &nbsp;(amount to draw &nbsp;&divide; &nbsp;500)",
"   </p>",
"   <p>",
"    Such units may be collected weekly for the four or five weeks before elective surgery. Iron supplementation is provided, and blood is not withdrawn on any day when the hemoglobin concentration is &lt;11",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p>",
"    Such programs have been shown to be safe and to reduce allogeneic blood use. In several studies of autologous transfusion programs in children, only 25 percent of children required allogeneic transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Autologous donation has also been widely used in scoliosis surgery, because patients are often older children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Directed donations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Directed units are allogeneic units designated specifically for a particular patient. Most often, parents or other family members directly donate, but friends or other acquaintances are also recruited. These donors must meet all the usual criteria for donation, although a reduced interval between donations may be authorized if medically appropriate. Delays may arise in finding donors of appropriate type, or in finding CMV-seronegative donors if such are requested. Direct units have a risk of transmission of infectious disease similar to the general blood supply, but families are often more comfortable with such transfusions than with donations from the population at large. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11061?source=see_link\">",
"     \"Directed (designated) blood donation programs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Directed donations reduce the number of donor exposures for children who will be multiply transfused, since platelets and red blood cells can be obtained repeatedly from the same donor, particularly if apheresis techniques are used. Under most conditions, directed units will be used for other patients if not needed by the specified patient. If blood relatives donate, the units should be irradiated to prevent the development of graft-versus-host disease. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Irradiated red cells'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link&amp;anchor=H4#H4\">",
"     \"Transfusion-associated graft-versus-host disease\", section on 'Partial HLA matching'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SPECIFIC CLINICAL SITUATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hemolytic disease of the fetus and newborn",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alloimmune hemolytic disease of the fetus and newborn (HDFN) is a condition in which the red cells of the fetus or newborn are destroyed by maternally derived alloantibodies. These antibodies arise in the mother as the direct result of a blood group incompatibility between the mother and fetus. The selection of blood products is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=see_link&amp;anchor=H10#H10\">",
"     \"Red blood cell transfusions in the newborn\", section on 'Hemolytic disease of the newborn'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=see_link\">",
"     \"Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many hematopoietic cell transplants occur from ABO-incompatible donors. Transfusion in this setting can be complex; because erythroid engraftment may be delayed if the recipient has strong antibodies to donated cells. Generally, donor type O or compatible red cells are washed to remove incompatible plasma. Products containing plasma should be compatible with both donor and recipient cells. These precautions are continued until recipient antibodies are no longer detected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H12#H12\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'ABO and Rh status'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Reduced serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABO reverse typing is not necessary for infants less than four months of age, since anti-A or anti-B antibodies do not generally develop during this period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/6\">",
"     6",
"    </a>",
"    ]. During same admission to a hospital, antibody screening does not have to be repeated until four months of age. As a result, it is safe to rely on an initial negative antibody screen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/36\">",
"     36",
"    </a>",
"    ]. This approach minimizes the amount of blood that must be drawn from small infants for laboratory testing.",
"   </p>",
"   <p>",
"    After four months of age, any potential recipient who has been transfused or pregnant within the preceding three months should be screened for the presence of red cell antibodies. The screening should be performed no more than three days before transfusion, since such antibodies can develop quickly [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=see_link\">",
"     \"Compatibility testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Emergency release of blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;When blood is needed urgently, it may be provided uncrossmatched, through an emergency release process that is available in all blood banks. If the child's ABO group and Rh type are known to the blood bank on the current specimen, ABO compatible red blood cell (RBC) and other components will be provided, without crossmatching. If the group and type are not known, O red cells and AB plasma are used; if the recipient is a female of child-bearing age, the red cells should be Rh-negative.",
"   </p>",
"   <p>",
"    Uncrossmatched blood for emergent transfusion is generally safe, particularly if the child has not been previously transfused and cannot be expected to have developed red cell antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=see_link&amp;anchor=H15#H15\">",
"     \"Compatibility testing\", section on 'Release of blood in emergency situations when compatibility testing has not been completed'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Massive transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive transfusion in pediatric patients is usually defined as any one of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transfusion of more than 50 percent of total blood volume within three hours",
"     </li>",
"     <li>",
"      Transfusion of more than 100 percent of total blood volume in 24 hours",
"     </li>",
"     <li>",
"      Transfusion support to replace ongoing blood loss of more than 10 percent of total blood volume per minute",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Type-specific blood is used, without further serologic testing. Massive transfusion increases risk for a variety of metabolic and hemostatic abnormalities, particularly in neonates and infants. Dilutional coagulopathy may occur if only RBCs have been transfused; as a result, plasma and platelets should be included for patients receiving a massive transfusion. Trauma also can contribute to an acute coagulopathy, through a variety of mechanisms. Electrolytes and acid-base balance should be monitored carefully, since the large amount of stored blood products transfused in this setting may lead to serious hyperkalemia. Hypokalemia associated with metabolic alkalosis is also possible, due to the large amount of citrate metabolized to bicarbonate. Other abnormalities associated with massive transfusion include hypocalcemia, hyper- or hypoglycemia, and hypothermia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=see_link&amp;anchor=H16#H16\">",
"     \"Administration and complications of red cell transfusion in infants and children\", section on 'Metabolic toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Alloantibodies in sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of antibodies is common in patients needing repeated transfusions, such as those with sickle cell disease (SCD). Approximately 30 to 40 percent of patients with SCD will develop at least one antibody and, over the course of years of transfusion, multiple antibodies. In order to find compatible units for transfusion, it may be necessary to procure frozen units from a rare donor bank; however, it may be impossible to provide fully compatible blood. Some patients with SCD develop autoantibodies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have an unexplained delayed hemolytic transfusion reaction, a phenomenon that is poorly understood. The condition is called a \"hyperhemolysis syndrome\" if a patient's hemoglobin decreases after transfusion. In this condition, the patient's own red cells are destroyed without involvement of red cell antibodies. Therefore, the patient's reticulocyte count also drops from the baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27832/abstract/38\">",
"     38",
"    </a>",
"    ] [37]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of the management of sickle cell disease\", section on 'Alloimmunization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Autoimmune hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants and children with autoimmune hemolytic anemia (AIHA), a condition in which the patient's red cells are destroyed by autoantibodies, transfusion can be challenging because most autoantibodies are reactive with virtually all red cells (ie, \"panreactive\"). As a result, every available donor unit may appear to be incompatible by crossmatch. It is important for the blood bank to exclude the simultaneous presence of antibodies that have developed from previous transfusion(s), called alloantibodies. If alloantibodies can be excluded, hemolytic transfusion reactions will be rare even if the blood that is incompatible in vitro is used. Despite the risks, transfusion therapy should never be withheld from a patient with AIHA and life-threatening anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link&amp;anchor=H32#H32\">",
"     \"Autoimmune hemolytic anemia in children\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27480?source=see_link&amp;anchor=H5#H5\">",
"     \"The incompatible crossmatch\", section on 'Alloantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many modifications to the basic red cell unit for transfusion are offered, and the correct product varies with the clinical setting. Although packed red blood cells (RBCs) are most often used, there are specific clinical situations when another product is more appropriate. Blood bank personnel can help to determine the correct blood product, but they must be informed of the relevant clinical information.",
"   </p>",
"   <p>",
"    Other RBC products used in infants and children include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukoreduced red cells &ndash; Leukoreduction reduces febrile non-hemolytic transfusion reactions, prevents alloimmunization, and reduces the transmission of certain infections (notably CMV). However, leukoreduction does not eliminate all lymphocytes. Therefore, leukoreduced red cell units can cause transfusion-associated-graft-versus-host disease (TA-GVHD) if the blood product is not also irradiated. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Leukoreduced red cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMV-safe red cells &ndash; CMV-safe products (including CMV-seronegative and leukoreduced red cells) reduce the transmission of CMV. These products are recommended for CMV-seronegative recipients with special risks for CMV disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'CMV-safe products'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Irradiated red cells &ndash; Irradiation prevents transfusion-associated graft versus host disease (TA-GVHD) in susceptible recipients. Indications for irradiation include directed donor blood products that will be transfused into a blood relation, and a variety of conditions in which the transfusion recipient is at risk for TA-GVHD because of immunodeficiency (",
"      <a class=\"graphic graphic_table graphicRef81912 \" href=\"UTD.htm?10/37/10844\">",
"       table 1",
"      </a>",
"      ). The dose of radiation is not sufficient to kill viruses and irradiation does not provide a CMV-safe product. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Irradiated red cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sickle cell negative blood &ndash; Sickle cell negative blood (HbS &lt;30 percent) is usually used for transfusion to newborns, intrauterine transfusions, and in exchange transfusions for patients with sickle cell disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Sickle cell negative blood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of blood product is often influenced by the specific clinical situations, including hemolytic disease of the fetus and newborn, hematopoietic cell transplantation, and sickle cell disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Specific clinical situations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/1\">",
"      Roseff SD, Luban NL, Manno CS. Guidelines for assessing appropriateness of pediatric transfusion. Transfusion 2002; 42:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/2\">",
"      Manno CS, Hedberg KW, Kim HC, et al. Comparison of the hemostatic effects of fresh whole blood, stored whole blood, and components after open heart surgery in children. Blood 1991; 77:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/3\">",
"      Kwiatkowski JL, Manno CS. Blood transfusion support in pediatric cardiovascular surgery. Transfus Sci 1999; 21:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/4\">",
"      Gruenwald CE, McCrindle BW, Crawford-Lean L, et al. Reconstituted fresh whole blood improves clinical outcomes compared with stored component blood therapy for neonates undergoing cardiopulmonary bypass for cardiac surgery: a randomized controlled trial. J Thorac Cardiovasc Surg 2008; 136:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/5\">",
"      Mou SS, Giroir BP, Molitor-Kirsch EA, et al. Fresh whole blood versus reconstituted blood for pump priming in heart surgery in infants. N Engl J Med 2004; 351:1635.",
"     </a>",
"    </li>",
"    <li>",
"     Menitove JE. Standards for blood banks and transfusion services, 21st ed, American Association of Blood Banks, Bethesda 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/7\">",
"      Hayashi Y, Sawa Y, Nishimura M, et al. Clinical evaluation of leukocyte-depleted blood cardioplegia for pediatric open heart operation. Ann Thorac Surg 2000; 69:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/8\">",
"      Derleth DP. Use of white cell-reduced red cells for transfusion through peripheral arterial lines. Transfusion 1994; 34:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/9\">",
"      Fergusson D, H&eacute;bert PC, Barrington KJ, Shapiro SH. Effectiveness of WBC reduction in neonates: what is the evidence of benefit? Transfusion 2002; 42:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/10\">",
"      Przepiorka D, LeParc GF, Werch J, Lichtiger B. Prevention of transfusion-associated cytomegalovirus infection. Practice parameter. American Society of Clinical Pathologists. Am J Clin Pathol 1996; 106:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/11\">",
"      Laupacis A, Brown J, Costello B, et al. Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement. Transfusion 2001; 41:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/12\">",
"      Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003; 101:4195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/13\">",
"      Benson JW, Bodden SJ, Tobin JO. Cytomegalovirus and blood transfusion in neonates. Arch Dis Child 1979; 54:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/14\">",
"      Adler SP, Chandrika T, Lawrence L, Baggett J. Cytomegalovirus infections in neonates acquired by blood transfusions. Pediatr Infect Dis 1983; 2:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/15\">",
"      Lamberson HV, Dock NL. Prevention of transfusion-transmitted cytomegalovirus infection. Transfusion 1992; 32:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/16\">",
"      Logan S, Barbara J, Kovar I. Cytomegalovirus screened blood for neonatal intensive care units. Arch Dis Child 1988; 63:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/17\">",
"      Miller WJ, McCullough J, Balfour HH Jr, et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991; 7:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/18\">",
"      Roback JD. CMV and blood transfusions. Rev Med Virol 2002; 12:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/19\">",
"      Pelszynski MM, Moroff G, Luban NL, et al. Effect of gamma irradiation of red blood cell units on T-cell inactivation as assessed by limiting dilution analysis: implications for preventing transfusion-associated graft-versus-host disease. Blood 1994; 83:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/20\">",
"      Funkhouser AW, Vogelsang G, Zehnbauer B, et al. Graft versus host disease after blood transfusions in a premature infant. Pediatrics 1991; 87:247.",
"     </a>",
"    </li>",
"    <li>",
"     Strauss RG. Blood banking and transfusion issues in perinatal medicine. In: Hematologic problems of the neonate, Christensen RD (Ed), WB Saunders, Philadelphia 2000. p.405.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/22\">",
"      Strauss RG. Practical issues in neonatal transfusion practice. Am J Clin Pathol 1997; 107:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/23\">",
"      Strauss RG, Sacher RA, Blazina JF, et al. Commentary on small-volume red cell transfusions for neonatal patients. Transfusion 1990; 30:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/24\">",
"      Brown KA, Bissonnette B, MacDonald M, Poon AO. Hyperkalaemia during massive blood transfusion in paediatric craniofacial surgery. Can J Anaesth 1990; 37:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/25\">",
"      Carvalho B, Quiney NF. 'Near-miss' hyperkalaemic cardiac arrest associated with rapid blood transfusion. Anaesthesia 1999; 54:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/26\">",
"      Hall TL, Barnes A, Miller JR, et al. Neonatal mortality following transfusion of red cells with high plasma potassium levels. Transfusion 1993; 33:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/27\">",
"      Horsey PJ. Hyperkalaemia associated with transfusion of plasma reduced blood. Anaesthesia 2000; 55:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/28\">",
"      Baz EM, Kanazi GE, Mahfouz RA, Obeid MY. An unusual case of hyperkalaemia-induced cardiac arrest in a paediatric patient during transfusion of a 'fresh' 6-day-old blood unit. Transfus Med 2002; 12:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/29\">",
"      Strauss RG. Routinely washing irradiated red cells before transfusion seems unwarranted. Transfusion 1990; 30:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/30\">",
"      Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. Second of two parts--blood conservation. N Engl J Med 1999; 340:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/31\">",
"      Silvergleid AJ. Safety and effectiveness of predeposit autologous transfusions in preteen and adolescent children. JAMA 1987; 257:3403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/32\">",
"      Novak RW. Autologous blood transfusion in a pediatric population. Safety and efficacy. Clin Pediatr (Phila) 1988; 27:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/33\">",
"      Murto KT, Splinter WM. Perioperative autologous blood donation in children. Transfus Sci 1999; 21:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/34\">",
"      Anand N, Idio FG Jr, Remer S, Hoppenfeld S. The effects of perioperative blood salvage and autologous blood donation on transfusion requirements in scoliosis surgery. J Spinal Disord 1998; 11:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/35\">",
"      Murray DJ, Forbes RB, Titone MB, Weinstein SL. Transfusion management in pediatric and adolescent scoliosis surgery. Efficacy of autologous blood. Spine (Phila Pa 1976) 1997; 22:2735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/36\">",
"      Floss AM, Strauss RG, Goeken N, Knox L. Multiple transfusion fail to provoke antibodies against blood cell antigens in human infants. Transfusion 1986; 26:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/37\">",
"      Diab YA, Wong EC, Luban NL. Massive transfusion in children and neonates. Br J Haematol 2013; 161:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27832/abstract/38\">",
"      Win N, Doughty H, Telfer P, et al. Hyperhemolytic transfusion reaction in sickle cell disease. Transfusion 2001; 41:323.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5935 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_11_27832=[""].join("\n");
var outline_f27_11_27832=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RED BLOOD CELL PRODUCTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Whole blood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Packed red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Leukoreduced red cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CMV-safe products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Irradiated red cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sickle cell negative blood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Autologous donations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Directed donations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SPECIFIC CLINICAL SITUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hemolytic disease of the fetus and newborn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Reduced serologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Emergency release of blood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Massive transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Alloantibodies in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Autoimmune hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5935\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5935|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/37/10844\" title=\"table 1\">",
"      Irradiation blood indications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=related_link\">",
"      Administration and complications of red cell transfusion in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=related_link\">",
"      Autoimmune hemolytic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=related_link\">",
"      Compatibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31605?source=related_link\">",
"      Controversial areas in preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11061?source=related_link\">",
"      Directed (designated) blood donation programs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=related_link\">",
"      Indications for red blood cell transfusion in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=related_link\">",
"      Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=related_link\">",
"      Preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=related_link\">",
"      Red blood cell transfusions in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27480?source=related_link\">",
"      The incompatible crossmatch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_11_27833="Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)";
var content_f27_11_27833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/11/27833/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/11/27833/contributors\">",
"     Terry F Davies, MD, FRCP, FACE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/11/27833/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/11/27833/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/11/27833/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/11/27833/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/11/27833/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hashimoto's thyroiditis (chronic autoimmune thyroiditis) is the most common cause of hypothyroidism in iodine-sufficient areas of the world. Thyroid failure is seen in up to 10 percent of the population and its prevalence increases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/1\">",
"     1",
"    </a>",
"    ]. It is characterized clinically by gradual thyroid failure, goiter formation, or both, due to autoimmune-mediated destruction of the thyroid gland involving apoptosis of thyroid epithelial cells. Nearly all patients have high serum concentrations of antibodies against one or more thyroid antigens, diffuse lymphocytic infiltration of the thyroid, which includes predominantly thyroid-specific B and T cells, and follicular destruction.",
"   </p>",
"   <p>",
"    The cause of Hashimoto's thyroiditis is thought to be a combination of genetic susceptibility and environmental factors. The familial association with Graves' disease and the fact that Graves' disease may sometimes evolve into Hashimoto's thyroiditis (and vice versa) indicate that the two disorders are closely related pathophysiologically, albeit not functionally [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The pathogenesis and precipitating factors for Hashimoto's thyroiditis are discussed here. The treatment of hypothyroidism and the pathogenesis of Graves' disease are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=see_link\">",
"     \"Pathogenesis of Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The name Hashimoto's thyroiditis is derived from the 1912 pathology report by Hashimoto describing patients with goiter and intense lymphocytic infiltration of the thyroid as \"struma lymphomatosa\" (",
"    <a class=\"graphic graphic_picture graphicRef57542 \" href=\"UTD.htm?36/18/37158\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/4\">",
"     4",
"    </a>",
"    ]. Some clinicians reserve this term for patients with goiter and hypothyroidism. However, many patients do not have hypothyroidism, and others have no goiter or even have an atrophic thyroid gland. These are considered manifestations of the same disease with differing clinical phenotypes.",
"   </p>",
"   <p>",
"    Some clinicians consider the presence of serum thyroid autoantibodies as sufficient evidence for Hashimoto's disease. This logic is based upon the observation that thyroid antibodies correlate well with the presence of a lymphocytic infiltrate in the thyroid gland at autopsy examination of individuals with no history of thyroid failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hence, the two major forms of the disorder are goitrous autoimmune thyroiditis and atrophic autoimmune thyroiditis, with the common pathologic feature being lymphocytic infiltration and the common serological feature being the presence of high serum concentrations of antibodies to thyroid peroxidase and thyroglobulin. Given the pathogenetic and pathologic similarities, we use the term Hashimoto's thyroiditis for all forms of chronic autoimmune thyroiditis. Although the thyroid enlargement that can occur is usually asymptomatic, rare patients have thyroid pain and tenderness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/6\">",
"     6",
"    </a>",
"    ], and such patients may require surgical relief.",
"   </p>",
"   <p>",
"    Hashimoto's thyroiditis is primarily a disease of women, with a sex ratio of approximately 7:1; it can also occur in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=see_link\">",
"     \"Acquired hypothyroidism in childhood and adolescence\"",
"    </a>",
"    .) Variant mild forms of Hashimoto's thyroiditis include silent (or painless) thyroiditis and postpartum thyroiditis, both of which are transient but may be followed years later by thyroid failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24694?source=see_link\">",
"     \"Painless thyroiditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/15/248?source=see_link\">",
"     \"Postpartum thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While hypothyroidism is the characteristic functional abnormality, the inflammatory process early in the course may involve enough apoptosis to cause thyroid follicular disruption and thyroid hormone release, causing transient hyperthyroidism sometimes referred to as Hashitoxicosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/7\">",
"     7",
"    </a>",
"    ]. Some of these patients have a transiently increased radioiodine uptake, and rare patients may cycle between hypothyroidism and Graves' disease, perhaps secondary to alternating production of thyrotropin (TSH) receptor blocking and stimulating antibodies (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Antibodies to the TSH receptor'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/3,8\">",
"     3,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual course of Hashimoto's thyroiditis is gradual loss of thyroid function. Among patients with this disorder who have mild (subclinical) hypothyroidism, exhibited as slight increases in TSH and the presence of thyroid antibodies, overt hypothyroidism occurs at a rate of about 5 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Overt hypothyroidism, once present, is permanent in nearly all cases, except in some children and postpartum women in whom it is often transient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INTRATHYROIDAL LYMPHOCYTIC INFILTRATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic histopathological abnormalities are profuse lymphocytic infiltration, lymphoid germinal centers, and destruction of thyroid follicles (",
"    <a class=\"graphic graphic_picture graphicRef57542 \" href=\"UTD.htm?36/18/37158\">",
"     picture 1",
"    </a>",
"    ). Fibrosis and areas of follicular-cell hyperplasia, presumably induced by TSH, are also seen in patients with severe disease and the fibroblast reaction may become excessive as seen in Reidel's thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/11\">",
"     11",
"    </a>",
"    ]. The intrathyroidal lymphocytes are both T and B lymphocytes. T cells and plasma cells may be seen between the follicular cells within a thyroid follicle, a phenomenon called \"peripolesis.\" There has been recent insight into the development of intrathyroidal germinal centers and lymph vessels suggesting the importance of local chemokines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     THYROID ANTIGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several antibodies and antigen-specific T-cells directed against thyroid antigens have been described in chronic autoimmune thyroiditis. The major antigens are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thyroglobulin (Tg)",
"     </li>",
"     <li>",
"      Thyroid peroxidase (TPO, formerly known as the microsomal antigen)",
"     </li>",
"     <li>",
"      The TSH receptor",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thyroglobulin and thyroid peroxidase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroglobulin (Tg) is synthesized by follicular cells and secreted into the lumen of the thyroid follicle, where it is stored as colloid. Thyroid peroxidase (TPO) catalyzes the iodination of tyrosine residues of Tg to form monoiodotyrosine and diiodotyrosine (",
"    <a class=\"graphic graphic_figure graphicRef76931 \" href=\"UTD.htm?26/29/27088\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=see_link\">",
"     \"Thyroid hormone synthesis and physiology\"",
"    </a>",
"    .) The induction of experimental autoimmune thyroiditis in mice using either Tg or TPO as antigens provides evidence for their potential role in the pathogenesis of Hashimoto's thyroiditis in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The thyroglobulin gene may be a susceptibility gene for autoimmune thyroiditis coding for thyroglobulin variants of different immunogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When stimulated by TSH, the thyroid follicular cells take up Tg from the colloid. The Tg is then cleaved by peptidases yielding thyroxine (T4) and triiodothyronine (T3), which are released into the extracellular fluid. Some Tg is detectable in the serum of normal subjects, and the concentration may be increased in patients with any thyroid disease.",
"   </p>",
"   <p>",
"    Tg is a large glycoprotein dimer, each subunit being approximately 330 kD. About 45 of its 72 tyrosine residues can be iodinated in vitro, but only a few are primary iodine acceptors in vivo. These few are located in defined amino-acid sequences near the amino and carboxyl terminals of the Tg molecule. Both the extent of iodination and posttranslational modifications of Tg are probably important determinants of its immunogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TPO is a key enzyme in thyroid hormonogenesis. It is located on the luminal surface of the microvilli of thyroid epithelial cells. The gene for human TPO [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/17\">",
"     17",
"    </a>",
"    ] codes for an enzyme that is a 107 kD glycoprotein (933 amino acids) with 10 percent carbohydrate and a membrane-spanning region close to the carboxy-terminus. TPO catalyzes both tyrosine iodination and coupling of iodotyrosyl residues to form T3 and T4. The TPO gene has not been associated with Hashimoto's thyroiditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     The TSH receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TSH receptor contains 764 amino acids and is G-protein coupled receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The first 415 amino acids define a large extracellular domain, encoded by 10 exons. The remaining 349 amino acids constitute the seven transmembrane segments, the intracytoplasmic segments between them, and the intracytoplasmic tail (",
"    <a class=\"graphic graphic_figure graphicRef72949 \" href=\"UTD.htm?12/42/12960\">",
"     figure 2",
"    </a>",
"    ). TSH binds to multiple sites in the extracellular domain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/21\">",
"     21",
"    </a>",
"    ]. TSH receptor mRNA has been detected in many tissues (eg, fibroblasts, adipocytes, cardiac muscle cells, pituitary cells, bone cells and brain). Although the role of the receptor in many of these tissues is unclear, data suggest that TSH can modulate bone cell and adipocyte function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The retro-orbital expression of the TSHR has been implicated in Graves' ophthalmopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=see_link\">",
"     \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ROLE OF B CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;B cells from thyroid tissue of patients with Hashimoto's thyroiditis are activated, as indicated by their ability to secrete thyroid antibodies spontaneously in vitro. Thus, the thyroid gland may be a major site of thyroid antibody secretion. Additional evidence for this possibility is the decline in serum thyroid antibody concentrations that occurs after surgery and during administration of an antithyroid drug (carbimazole) to patients with this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/24\">",
"     24",
"    </a>",
"    ]. However, there is also evidence that extrathyroidal lymphoid tissues may contribute to antibody production [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antibodies to Tg and TPO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all patients with Hashimoto's thyroiditis have high serum concentrations of antibodies to Tg and TPO. These antibodies are also found, although usually in lower concentration, in patients with other thyroid diseases including Graves' disease and in some subjects with no clinical or biochemical evidence of thyroid disease but who presumably have a mild thyroiditis (",
"    <a class=\"graphic graphic_table graphicRef76522 \" href=\"UTD.htm?31/7/31867\">",
"     table 1",
"    </a>",
"    ). On average, up to 20 percent of all women may have such antibodies. The antibodies are polyclonal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/26\">",
"     26",
"    </a>",
"    ] and are usually IgG1 or IgG3 antibodies, but may be of any subclass and, therefore, their ability to fix complement (primarily IgG1 and IgG3) and pass through the placenta varies. Some Tg and TPO antibodies can lyse thyroid cells in vitro, and some TPO antibodies may inhibit TPO enzyme activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], although such observations are in dispute [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/29\">",
"     29",
"    </a>",
"    ]. These autoantibodies are considered to be secondary to the thyroid damage inflicted by T cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antibodies to the TSH receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;TSH receptor antibodies of the stimulating variety were first identified by their prolonged thyroid-stimulating activity when serum from patients with Graves' hyperthyroidism was injected into animals; this activity was originally called the long-acting thyroid stimulator (LATS) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/30\">",
"     30",
"    </a>",
"    ]. Subsequently, IgG fractions of serum from these patients were found to have thyroid-stimulating actions qualitatively similar to those of TSH in many bioassays and to block binding of radiolabeled TSH to thyroid membranes; in other words the IgG fraction contained TSH receptor antibodies that acted as TSH agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=see_link\">",
"     \"Pathogenesis of Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Later, with the use of TSH binding competition assays, TSH receptor antibodies were detected in the serum of some patients with Hashimoto's thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. However, these antibodies, which are also usually polyclonal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/34\">",
"     34",
"    </a>",
"    ], block the action of TSH more than activating thyroid tissue (",
"    <a class=\"graphic graphic_figure graphicRef69820 \" href=\"UTD.htm?12/54/13165\">",
"     figure 3",
"    </a>",
"    ). Stimulating and TSH blocking antibodies bind to the leucine rich repeat region of the extracellular domain of the receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stimulating TSH receptor antibodies are specific for Graves' disease, in contrast to blocking type TSH receptor antibodies and autoantibodies to TPO and Tg, which are found in patients with overt and subclinical thyroiditis as well as some of the apparently euthyroid \"normal\" population. As noted above, patients who had Hashimoto's thyroiditis and Graves' hyperthyroidism at different times have also been described; at the appropriate times their serum contained a predominance of TSH receptor-blocking antibodies or TSH receptor-stimulating antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Both types of antibodies may cross the placenta and influence thyroid function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Function of thyroid antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-Tg and anti-TPO antibodies have the potential to fix complement if they are of the appropriate IgG subclass. As a result, complement-dependent antibody-mediated cytotoxicity may contribute to thyroid damage in patients with Hashimoto's thyroiditis. As discussed earlier, Tg and TPO antibodies can lyse thyroid cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/27\">",
"     27",
"    </a>",
"    ], but the importance of this action, in comparison with T-cell and cytokine-mediated apoptosis, is minor. More important is likely to be the role of thyroid antibody secreting B cells in presenting thyroid antigen to the T cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     THE ROLE OF T CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cells in patients with Hashimoto's thyroiditis react with processed thyroid antigens and peptides derived from these antigens. These activated T cells secrete cytokines which themselves activate a variety of other immune cells. T cells have two roles in this disease: a role in antibody production (a Th2 type of function [see below]) and a role in the apoptotic destruction of thyroid cells by activating cytotoxic T cells (a Th1 function) (",
"    <a class=\"graphic graphic_table graphicRef53741 \" href=\"UTD.htm?2/55/2939\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Th1 CD4+ lymphocytes, when stimulated by antigen, secrete interleukin-2 (IL-2), interferon gamma, and tumor necrosis factor-beta. In contrast, Th2 cells, when stimulated by antigens, secrete IL-4 and IL-5. Both types of T cells are found in thyroid tissue of patients with Hashimoto's thyroiditis, but Th1 cells predominate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. A T-cell clone that caused cytolysis of autologous thyroid cells has been reported in a patient with Hashimoto's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/39\">",
"     39",
"    </a>",
"    ]. This is the likely mechanism for induction of thyroid epithelial cell apoptosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     The V-gene repertoire of the T-cell antigen receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of antigen receptors on the surface of T cells consist of two non-covalently linked chains (alpha and beta b), each with variable (V), diversity (D) and junctional (J) regions and with common constant (C alpha and C beta) regions. The V, D and J genes code for the site on the receptor that recognizes an HLA-antigen complex, affording antigen specificity. In addition to the many V (&gt;100) and J (&gt;50) genes present in the genome, random nucleotide additions and deletions to the D region add immense complexity to the receptor repertoire, causing this region, referred to as the third complementarity-determining region (CDR3), to be the major locus of antigen recognition [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although some patients display a restricted (oligoclonal) T cell repertoire, many different V genes coding for the T-cell antigen receptor are usually present in T cells from the thyroid and peripheral blood of patients with Hashimoto's thyroiditis (",
"    <a class=\"graphic graphic_figure graphicRef69608 \" href=\"UTD.htm?18/56/19342\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/41\">",
"     41",
"    </a>",
"    ]. This finding suggests that many antigenic epitopes are involved in the pathogenesis of the disease by the time the patient's pathologic material is available for examination. In contrast, the number of V genes coding for T-cell antigen receptors in T cells from patients with Graves' hyperthyroidism is usually much more limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=see_link\">",
"     \"Pathogenesis of Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Immune regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is now no doubt that the immune system exerts some of its overall control via regulatory \"suppressor\" cells (CD4+CD25+Foxp3+) exerting cell-cell and cytokine mediated suppression (so-called Treg cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/42\">",
"     42",
"    </a>",
"    ]. Patients with Hashimoto's thyroiditis may have reduced numbers or inadequate function of such circulating CD4+CD25+ regulatory cells but this remains to be determined. Immune suppression can be exerted in a variety of other ways including the direct effects of cytokines and the influence of \"anergized\" T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/43\">",
"     43",
"    </a>",
"    ]. However, there are many other mechanisms, especially anergy itself and deletion of cells by apoptosis that contribute to explain antigen-specific tolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     POTENTIAL MECHANISMS OF THYROID INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several mechanisms have been proposed for the pathogenesis of Hashimoto's thyroiditis. These include the current major hypotheses for all autoimmune diseases - molecular mimicry and bystander activation including the involvement of thyroid-cell expression of HLA antigens and activation of thyroid-cell apoptosis by a Fas ligand-Fas interaction (",
"    <a class=\"graphic graphic_table graphicRef54613 \" href=\"UTD.htm?14/46/15083\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Molecular mimicry",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to this proposal, Hashimoto's disease is caused by the immune response to a foreign antigen that is structurally similar to an endogenous substance. As an example, both bacteria and humans have heat shock proteins. During the course of a bacterial infection, the host has an antibody- and T-cell response to the microbe's heat shock protein [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/44\">",
"     44",
"    </a>",
"    ]. These antibodies and T-cells may then cross-react with the host's heat shock protein. If the mimicked protein were a thyroid antigen on the thyroid, thyroiditis could ensue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bystander activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The arrival of a thyroid-cell virus or activated non-specific lymphocytes within the thyroid may cause the local release of cytokines, which in themselves may activate resident local thyroid-specific T cells. This bystander effect hypothesis has support from studies in an animal model of insulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/45\">",
"     45",
"    </a>",
"    ] and a model of experimental autoimmune thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Thyroid-cell expression of HLA antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;MHC class II molecules are present on thyroid follicular cells from patients with Hashimoto's thyroiditis, but not normal subjects (",
"    <a class=\"graphic graphic_picture graphicRef57542 \" href=\"UTD.htm?36/18/37158\">",
"     picture 1",
"    </a>",
"    ). Expression of these molecules on thyroid follicular cells can be induced by interferon gamma and other products of T cells, when the T cells are activated (eg, by a viral infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/47\">",
"     47",
"    </a>",
"    ]; expression can also be induced by viruses directly [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Thyroid cells expressing MHC class II molecules would be able to present antigens, either foreign or self, to T cells, thereby activating the T cells. The following observations provide indirect support for this hypothesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction of MHC class II molecules on thyroid follicular cells by interferon gamma can induce autoimmune thyroiditis in susceptible mice [",
"      <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thyroid follicular cells expressing MHC class II molecules can present viral peptide antigens to cloned human T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autologous thyroid cells can bind to cloned thyroid antigen-specific T cells in the absence of more conventional antigen-presenting cells [",
"      <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings strongly support the view that infection may induce the expression of MHC class II molecules on human thyroid cells and that these cells may act as antigen-presenting cells, thereby initiating a thyroid autoimmune response. Intrathyroidal dendritic cells and B cells also may serve as antigen-presenting cells and may provide important costimulatory molecules for effective antigen presentation. The induction of Graves' disease in mice using fibroblasts expressing TSH receptor antigen and MHC class II molecules is further evidence for this mechanism of disease causation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A transgenic mouse expressing thyroid cell gamma interferon has been shown to develop less, rather than more, experimental autoimmune thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/54\">",
"     54",
"    </a>",
"    ]. The meaning of this observation is uncertain because of the potential interference in thyroid antigen expression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Thyroid cell apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid-cell death in Hashimoto's disease is the central pathological phenomenon. Normal thyroid epithelial cells express a variety of death receptors, including Fas. Activation of the Fas-ligand-Fas signaling system could contribute to the follicular cell destruction characteristic of Hashimoto's thyroiditis. In autoimmune thyroiditis, thyroid follicular cells are induced to express functional Fas and also Fas ligand by cytokine stimulation from antigen-presenting cells and Th1 cells (eg, IL-1). This may cause self-apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/55\">",
"     55",
"    </a>",
"    ]. In one study, for example, apoptosis occurred in thyroid cells from patients with Hashimoto's thyroiditis expressing Fas or normal thyroid cells in which Fas was induced by IL-1b, after the cells were exposed to other thyroid cells constitutively expressing Fas ligand [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/55\">",
"     55",
"    </a>",
"    ]. Thus, any event that led to local production of IL-1b might initiate thyroid-cell induced thyroid cell apoptosis. More likely, however, the accumulated and activated T cells expressing Fas ligand may induce apoptosis of the thyrocytes directly by interacting with Fas on the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/56\">",
"     56",
"    </a>",
"    ]. This is an important way of mediating autoimmune cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     GENETIC SUSCEPTIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is now clear that there is genetic susceptibility to Hashimoto's thyroiditis and much has been learned in recent years concerning the susceptibility genes for this disorder in particular and for autoimmune thyroid disease in general [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/58\">",
"     58",
"    </a>",
"    ]. Evidence for genetic susceptibility to Hashimoto's thyroiditis includes the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The disease clusters in families, sometimes alone and sometimes in combination with Graves' disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The sibling recurrence risk is &gt;20 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The concordance rate in monozygotic twins is 30 to 60 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/60\">",
"       60",
"      </a>",
"      ] despite random combinations of T cell receptor and antibody V genes at the time of recombination.",
"     </li>",
"     <li>",
"      It occurs with increased frequency in patients with Down's syndrome and Turner's syndrome.",
"     </li>",
"     <li>",
"      There is an association, albeit relatively weak, with certain HLA alleles such as DR3.",
"     </li>",
"     <li>",
"      There is linkage to certain alleles of the gene for CTLA-4, a T-cell surface molecule involved in T-cell activation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/61\">",
"       61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=see_link\">",
"       \"Major histocompatibility complex (MHC) structure and function\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The thyroglobulin gene has been linked to autoimmune thyroid disease and has been suggested to code for Tg forms with different immune reactivity [",
"      <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PRECIPITATING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection, stress, sex steroids, pregnancy, iodine intake, and radiation exposure are the known possible precipitating factors for Hashimoto's thyroiditis. Fetal microchimerism within the maternal thyroid is also a possibility (",
"    <a class=\"graphic graphic_table graphicRef54613 \" href=\"UTD.htm?14/46/15083\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;No infection is known to cause or even be closely associated with Hashimoto's thyroiditis in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/62\">",
"     62",
"    </a>",
"    ], although thyroiditis can be induced in experimental animals by certain viral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/63\">",
"     63",
"    </a>",
"    ]. Patients with subacute granulomatous thyroiditis (presumed to be a viral infection) and congenital rubella may have thyroid antibodies for a few months after their illnesses, and the infections could initiate expression of MHC class II molecules in the thyroid gland. However, neither disorder is known to be commonly followed by chronic thyroiditis although evidence of thyroid autoimmunity may persist [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second case of hyperthyroidism described by Parry in 1825 was a 21-year-old woman whose symptoms began four months after she had been thrown accidentally down the stairs in a wheel chair. Subsequently, stress of various types has been linked to Graves' hyperthyroidism. The proposed mechanisms include induction of immune suppression by non-antigen-specific mechanisms, perhaps due to the effects of cortisol or corticotropin-releasing hormone on immune cells, followed by immune hyperactivity leading to autoimmune thyroid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/65\">",
"     65",
"    </a>",
"    ]. Such a mechanism might be operative in postpartum thyroiditis, which occurs three to nine months after delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/15/248?source=see_link\">",
"     \"Postpartum thyroiditis\"",
"    </a>",
"    .) However, there is currently no evidence linking emotional or psychologic stress to Hashimoto's thyroiditis most probably because of the long natural history of the disease requiring a large part of the gland to be damaged before thyroid function is compromised. Any major stress will have occurred many years before.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Sex steroids and pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;More women than men have Hashimoto's thyroiditis, suggesting a role for sex steroids. However, older women may be more likely to have Hashimoto's thyroiditis than younger women, suggesting that the presence or absence of estrogen may not be the important factor. Yet, in chickens, androgens protect against thyroiditis induced by immunization with Tg [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another possible explanation for female predominance is skewed X-chromosome inactivation, which was found in 34 percent of female twins with autoimmune thyroid disease and only 11 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. It is possible that the self-antigens on the inactivated X-chromosome might not be expressed sufficiently to allow tolerance.",
"   </p>",
"   <p>",
"    During pregnancy, there is a marked increase in CD4+CD25+ regulatory T cells which lead to diminished function of both T-cells and B-cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/69\">",
"     69",
"    </a>",
"    ] and the rebound from this immunosuppression is thought to contribute to the development of postpartum thyroiditis. Pregnancy-associated immune suppression is associated with a shift to Th2 T cells and a shift in cytokine profiles [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of local factors at the immune cell-trophoblast interface are also known to be important modulators of immune function in pregnancy. The trophoblast cells located in the placenta, and subject to maternal immune surveillance, serve as physical barriers between mother and fetus, and have been shown to express several immune modulating molecules, such as HLA-G, FasL, and indoleamine 2,3-dioxygenase as well as secreting a variety of cytokines. HLA-G is one of the members of the MHC class I family and is known to inhibit natural killer function and dendritic cell maturation. Fas ligand interacts with Fas antigen and induces apoptotic cell death of fetal antigen-reactive maternal lymphocytes. Indoleamine 2,3-dioxygenase, which catalyzes tryptophane in lymphocytes, has proven to be critical in the maintenance of allogeneic pregnancy in the mouse. Other than these local modulators, progesterone produced by the placenta affects cytokine profiles across the whole maternal immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Approximately 20 percent of patients with postpartum thyroiditis go on to develop classical Hashimoto's disease in later years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Iodine intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild iodine deficiency is associated with a lower prevalence of Hashimoto's disease and hypothyroidism, while excessive intake is associated with a higher prevalence. As an example, in China, autoimmune thyroiditis was found in 0.3 percent of those with mildly deficient iodine intake and 1.3 percent of those with excessive iodine intake [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Radiation exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the tragic Chernobyl nuclear accident, the exposed children developed a high frequency of thyroid autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/75\">",
"     75",
"    </a>",
"    ]. All the evidence suggests that the presence of thyroid antibodies increases the risk of developing thyroid dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Whether background radiation to which we are all exposed has any role in susceptibility to autoimmune thyroid disease is unknown.",
"   </p>",
"   <p>",
"    In a population based study of 4299 subjects, 160 had an occupational exposure to ionizing radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/76\">",
"     76",
"    </a>",
"    ]. Nearly 60 percent of the subjects worked in a nuclear power plant, while the rest were either medical or laboratory workers. Ten percent of the female subjects with radiation exposure met criteria for autoimmune thyroid disease (anti-TPO antibodies greater than 200",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    and hypoechogenicity on ultrasound) compared to 3.4 percent of those without an exposure. Subjects with greater than five years of exposure to ionizing radiation were at particularly high risk. It will be important in future studies to determine if there is a dose-response relationship to radiation exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Fetal microchimerism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal cells have been identified within maternal thyroid glands in patients with autoimmune thyroid. Such cells may initiate graft versus host reactions with the thyroid gland and play a significant role in the development of Hashimoto's thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27833/abstract/35,77-80\">",
"     35,77-80",
"    </a>",
"    ]. To date, however, this remains hypothetical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hashimoto's thyroiditis is characterized clinically by gradual thyroid failure, goiter formation, or both, due to autoimmune-mediated destruction of the thyroid gland involving apoptosis of thyroid epithelial cells. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two major forms of the Hashimoto&rsquo;s thyroiditis are goitrous autoimmune thyroiditis and atrophic autoimmune thyroiditis, with the common pathologic feature being lymphocytic infiltration (",
"      <a class=\"graphic graphic_picture graphicRef57542 \" href=\"UTD.htm?36/18/37158\">",
"       picture 1",
"      </a>",
"      ) and the common serological feature being the presence of high serum concentrations of antibodies to thyroid peroxidase and thyroglobulin (",
"      <a class=\"graphic graphic_table graphicRef76522 \" href=\"UTD.htm?31/7/31867\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The usual course of Hashimoto's thyroiditis is gradual loss of thyroid function. Among patients with this disorder who have mild (subclinical) hypothyroidism, exhibited as slight increases in TSH and the presence of thyroid antibodies, overt hypothyroidism occurs at a rate of about 5 percent per year. Overt hypothyroidism, once present, is permanent in nearly all cases, except in some children and postpartum women in whom it is often transient. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      B cells from thyroid tissue of patients with Hashimoto's thyroiditis are activated, as indicated by their ability to secrete thyroid antibodies spontaneously in vitro. T cells in patients with Hashimoto's thyroiditis react with processed thyroid antigens and peptides derived from these antigens. These activated T cells secrete cytokines which themselves activate a variety of other immune cells. T cells have two roles in this disease: a role in antibody production (a Th2 type of function) and a role in the apoptotic destruction of thyroid cells by activating cytotoxic T cells (a Th1 function) (",
"      <a class=\"graphic graphic_table graphicRef53741 \" href=\"UTD.htm?2/55/2939\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Role of B cells'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'The role of T cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several mechanisms have been proposed for the pathogenesis of Hashimoto's thyroiditis. These include molecular mimicry and bystander activation including the involvement of thyroid-cell expression of HLA antigens and activation of thyroid-cell apoptosis by a Fas ligand-Fas interaction (",
"      <a class=\"graphic graphic_table graphicRef54613 \" href=\"UTD.htm?14/46/15083\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Potential mechanisms of thyroid injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause of Hashimoto's thyroiditis is thought to be a combination of genetic susceptibility and environmental factors (",
"      <a class=\"graphic graphic_table graphicRef54613 \" href=\"UTD.htm?14/46/15083\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Genetic susceptibility'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Precipitating factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/1\">",
"      Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/2\">",
"      Tamai H, Ohsako N, Takeno K, et al. Changes in thyroid function in euthyroid subjects with a family history of Graves' disease: a follow-up study of 69 patients. J Clin Endocrinol Metab 1980; 51:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/3\">",
"      Kraiem Z, Baron E, Kahana L, et al. Changes in stimulating and blocking TSH receptor antibodies in a patient undergoing three cycles of transition from hypo to hyper-thyroidism and back to hypothyroidism. Clin Endocrinol (Oxf) 1992; 36:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/4\">",
"      Hashimoto, H. Zur kenntniss der lymphomatosen verandererung der schilddruse (struma lymphomatosa). Arch Klin Chirugie 1912; 97:219.",
"     </a>",
"    </li>",
"    <li>",
"     Livolsi VA. Surgical pathology of the thyroid, Saunders, Philadelphia 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/6\">",
"      Zimmerman RS, Brennan MD, McConahey WM, et al. Hashimoto's thyroiditis. An uncommon cause of painful thyroid unresponsive to corticosteroid therapy. Ann Intern Med 1986; 104:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/7\">",
"      Fatourechi V, McConahey WM, Woolner LB. Hyperthyroidism associated with histologic Hashimoto's thyroiditis. Mayo Clin Proc 1971; 46:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/8\">",
"      Takasu N, Yamada T, Sato A, et al. Graves' disease following hypothyroidism due to Hashimoto's disease: studies of eight cases. Clin Endocrinol (Oxf) 1990; 33:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/9\">",
"      Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/10\">",
"      Huber G, Staub JJ, Meier C, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab 2002; 87:3221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/11\">",
"      Heufelder AE, Hay ID. Evidence for autoimmune mechanisms in the evolution of invasive fibrous thyroiditis (Riedel's struma). Clin Investig 1994; 72:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/12\">",
"      Marinkovic T, Garin A, Yokota Y, et al. Interaction of mature CD3+CD4+ T cells with dendritic cells triggers the development of tertiary lymphoid structures in the thyroid. J Clin Invest 2006; 116:2622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/13\">",
"      Matsuoka N, Unger P, Ben-Nun A, et al. Thyroglobulin-induced murine thyroiditis assessed by intrathyroidal T cell receptor sequencing. J Immunol 1994; 152:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/14\">",
"      Kotani T, Umeki K, Hirai K, Ohtaki S. Experimental murine thyroiditis induced by porcine thyroid peroxidase and its transfer by the antigen-specific T cell line. Clin Exp Immunol 1990; 80:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/15\">",
"      Ban Y, Greenberg DA, Concepcion E, et al. Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proc Natl Acad Sci U S A 2003; 100:15119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/16\">",
"      Hutchings PR, Cooke A, Dawe K, et al. A thyroxine-containing peptide can induce murine experimental autoimmune thyroiditis. J Exp Med 1992; 175:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/17\">",
"      Magnusson RP, Chazenbalk GD, Gestautas J, et al. Molecular cloning of the complementary deoxyribonucleic acid for human thyroid peroxidase. Mol Endocrinol 1987; 1:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/18\">",
"      Libert F, Lefort A, Gerard C, et al. Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies. Biochem Biophys Res Commun 1989; 165:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/19\">",
"      Misrahi M, Loosfelt H, Atger M, et al. Cloning, sequencing and expression of human TSH receptor. Biochem Biophys Res Commun 1990; 166:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/20\">",
"      Nagayama Y, Kaufman KD, Seto P, Rapoport B. Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor. Biochem Biophys Res Commun 1989; 165:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/21\">",
"      Nagayama Y, Rapoport B. The thyrotropin receptor 25 years after its discovery: new insight after its molecular cloning. Mol Endocrinol 1992; 6:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/22\">",
"      Abe E, Marians RC, Yu W, et al. TSH is a negative regulator of skeletal remodeling. Cell 2003; 115:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/23\">",
"      Haraguchi K, Shimura H, Kawaguchi A, et al. Effects of thyrotropin on the proliferation and differentiation of cultured rat preadipocytes. Thyroid 1999; 9:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/24\">",
"      McGregor AM, Ibbertson HK, Smith BR, Hall R. Carbimazole and autoantibody synthesis in Hashimoto's thyroiditis. Br Med J 1980; 281:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/25\">",
"      Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003; 139:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/26\">",
"      McLachlan SM, Feldt-Rasmussen U, Young ET, et al. IgG subclass distribution of thyroid autoantibodies: a 'fingerprint' of an individual's response to thyroglobulin and thyroid microsomal antigen. Clin Endocrinol (Oxf) 1987; 26:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/27\">",
"      Chiovato L, Bassi P, Santini F, et al. Antibodies producing complement-mediated thyroid cytotoxicity in patients with atrophic or goitrous autoimmune thyroiditis. J Clin Endocrinol Metab 1993; 77:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/28\">",
"      Kohno Y, Yamaguchi F, Saito K, et al. Anti-thyroid peroxidase antibodies in sera from healthy subjects and from patients with chronic thyroiditis: differences in the ability to inhibit thyroid peroxidase activities. Clin Exp Immunol 1991; 85:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/29\">",
"      Chin HS, Chin DK, Morgenthaler NG, et al. Rarity of anti- Na+/I- symporter (NIS) antibody with iodide uptake inhibiting activity in autoimmune thyroid diseases (AITD). J Clin Endocrinol Metab 2000; 85:3937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/30\">",
"      ADAMS DD. The presence of an abnormal thyroid-stimulating hormone in the serum of some thyrotoxic patients. J Clin Endocrinol Metab 1958; 18:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/31\">",
"      Smith BR, Hall R. Thyroid-stimulating immunoglobulins in Graves' disease. Lancet 1974; 2:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/32\">",
"      Konishi J, Iida Y, Kasagi K, et al. Primary myxedema with thyrotrophin-binding inhibitor immunoglobulins. Clinical and laboratory findings in 15 patients. Ann Intern Med 1985; 103:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/33\">",
"      Kraiem Z, Lahat N, Glaser B, et al. Thyrotrophin receptor blocking antibodies: incidence, characterization and in-vitro synthesis. Clin Endocrinol (Oxf) 1987; 27:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/34\">",
"      Kraiem Z, Cho BY, Sadeh O, et al. The IgG subclass distribution of TSH receptor blocking antibodies in primary hypothyroidism. Clin Endocrinol (Oxf) 1992; 37:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/35\">",
"      Ando T, Davies TF. Clinical Review 160: Postpartum autoimmune thyroid disease: the potential role of fetal microchimerism. J Clin Endocrinol Metab 2003; 88:2965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/36\">",
"      Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/37\">",
"      Grubeck-Loebenstein B, Buchan G, Chantry D, et al. Analysis of intrathyroidal cytokine production in thyroid autoimmune disease: thyroid follicular cells produce interleukin-1 alpha and interleukin-6. Clin Exp Immunol 1989; 77:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/38\">",
"      Fisfalen ME, Palmer EM, Van Seventer GA, et al. Thyrotropin-receptor and thyroid peroxidase-specific T cell clones and their cytokine profile in autoimmune thyroid disease. J Clin Endocrinol Metab 1997; 82:3655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/39\">",
"      Mackenzie WA, Davies TF. An intrathyroidal T-cell clone specifically cytotoxic for human thyroid cells. Immunology 1987; 61:101.",
"     </a>",
"    </li>",
"    <li>",
"     Davis MM, Buxbaum J. T-cell receptor use in human autoimmune diseases, New York Academy of Sciences, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/41\">",
"      Davies TF, Concepcion ES, Ben-Nun A, et al. T-cell receptor V gene use in autoimmune thyroid disease: direct assessment by thyroid aspiration. J Clin Endocrinol Metab 1993; 76:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/42\">",
"      Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/43\">",
"      Romagnani, S, Del Prete, GF, Maggi, F, et al. Human Th1 and Th2 subsets. Int Arch Allergy Immunol 1992; 99:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/44\">",
"      Heufelder AE, Wenzel BE, Gorman CA, Bahn RS. Detection, cellular localization, and modulation of heat shock proteins in cultured fibroblasts from patients with extrathyroidal manifestations of Graves' disease. J Clin Endocrinol Metab 1991; 73:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/45\">",
"      Horwitz MS, Bradley LM, Harbertson J, et al. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 1998; 4:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/46\">",
"      Arata N, Ando T, Unger P, Davies TF. By-stander activation in autoimmune thyroiditis: studies on experimental autoimmune thyroiditis in the GFP+ fluorescent mouse. Clin Immunol 2006; 121:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/47\">",
"      Bottazzo, GF, Todd, I, Pujol-Borrell, R. Hypotheses on genetic contributions to the etiology of diabetes mellitus. Immunol Today 1984; 5:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/48\">",
"      Neufeld DS, Platzer M, Davies TF. Reovirus induction of MHC class II antigen in rat thyroid cells. Endocrinology 1989; 124:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/49\">",
"      Khoury EL, Pereira L, Greenspan FS. Induction of HLA-DR expression on thyroid follicular cells by cytomegalovirus infection in vitro. Evidence for a dual mechanism of induction. Am J Pathol 1991; 138:1209.",
"     </a>",
"    </li>",
"    <li>",
"     Davies TF. The role of human thyroid cell Ia (DR) antigen in thyroid autoimmunity. In: Autoimmunity and the thyroid, Walfish PG, Wall JR, Volpe R (Eds), Academic Press, New York 1985. p.51.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/51\">",
"      Londei M, Bottazzo GF, Feldmann M. Human T-cell clones from autoimmune thyroid glands: specific recognition of autologous thyroid cells. Science 1985; 228:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/52\">",
"      Kimura H, Davies TF. Thyroid-specific T cells in the normal Wistar rat. II. T cell clones interact with cloned wistar rat thyroid cells and provide direct evidence for autoantigen presentation by thyroid epithelial cells. Clin Immunol Immunopathol 1991; 58:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/53\">",
"      Shimojo N, Kohno Y, Yamaguchi K, et al. Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule. Proc Natl Acad Sci U S A 1996; 93:11074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/54\">",
"      Barin JG, Afanasyeva M, Talor MV, et al. Thyroid-specific expression of IFN-gamma limits experimental autoimmune thyroiditis by suppressing lymphocyte activation in cervical lymph nodes. J Immunol 2003; 170:5523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/55\">",
"      Giordano C, Stassi G, De Maria R, et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 1997; 275:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/56\">",
"      Stassi G, Di Liberto D, Todaro M, et al. Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. Nat Immunol 2000; 1:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/57\">",
"      Davies TF. A new role for methimazole in autoimmune thyroid disease: inducing T cell apoptosis. Thyroid 2000; 10:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/58\">",
"      Tomer Y, Barbesino G, Greenberg DA, et al. Mapping the major susceptibility loci for familial Graves' and Hashimoto's diseases: evidence for genetic heterogeneity and gene interactions. J Clin Endocrinol Metab 1999; 84:4656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/59\">",
"      Villanueva R, Greenberg DA, Davies TF, Tomer Y. Sibling recurrence risk in autoimmune thyroid disease. Thyroid 2003; 13:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/60\">",
"      Brix TH, Kyvik KO, Heged&uuml;s L. A population-based study of chronic autoimmune hypothyroidism in Danish twins. J Clin Endocrinol Metab 2000; 85:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/61\">",
"      Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev 2003; 24:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/62\">",
"      Tomer Y, Davies TF. Infection, thyroid disease, and autoimmunity. Endocr Rev 1993; 14:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/63\">",
"      Srinivasappa J, Garzelli C, Onodera T, et al. Virus-induced thyroiditis. Endocrinology 1988; 122:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/64\">",
"      Weetman AP, Smallridge RC, Nutman TB, Burman KD. Persistent thyroid autoimmunity after subacute thyroiditis. J Clin Lab Immunol 1987; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/65\">",
"      Bendtzen K, Buschard K, Diamant M, et al. Possible role of IL-1, TNF-alpha, and IL-6 in insulin-dependent diabetes mellitus and autoimmune thyroid disease. Thyroid Cell Group. Lymphokine Res 1989; 8:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/66\">",
"      Gause WC, Marsh JA. Effect of testosterone treatments for varying periods on autoimmune development and on specific infiltrating leukocyte populations in the thyroid gland of obese strain chickens. Clin Immunol Immunopathol 1986; 39:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/67\">",
"      Brix TH, Knudsen GP, Kristiansen M, et al. High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. J Clin Endocrinol Metab 2005; 90:5949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/68\">",
"      Yin X, Latif R, Tomer Y, Davies TF. Thyroid epigenetics: X chromosome inactivation in patients with autoimmune thyroid disease. Ann N Y Acad Sci 2007; 1110:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/69\">",
"      Somerset DA, Zheng Y, Kilby MD, et al. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology 2004; 112:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/70\">",
"      Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today 1997; 18:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/71\">",
"      Davies TF. The thyroid immunology of the postpartum period. Thyroid 1999; 9:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/72\">",
"      Weetman AP. The immunology of pregnancy. Thyroid 1999; 9:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/73\">",
"      Othman S, Phillips DI, Parkes AB, et al. A long-term follow-up of postpartum thyroiditis. Clin Endocrinol (Oxf) 1990; 32:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/74\">",
"      Walsh JP, Ward LC, Burke V, et al. Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial. J Clin Endocrinol Metab 2006; 91:2624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/75\">",
"      Pacini F, Vorontsova T, Molinaro E, et al. Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout. Lancet 1998; 352:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/76\">",
"      V&ouml;lzke H, Werner A, Wallaschofski H, et al. Occupational exposure to ionizing radiation is associated with autoimmune thyroid disease. J Clin Endocrinol Metab 2005; 90:4587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/77\">",
"      Klintschar M, Schwaiger P, Mannweiler S, et al. Evidence of fetal microchimerism in Hashimoto's thyroiditis. J Clin Endocrinol Metab 2001; 86:2494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/78\">",
"      Srivatsa B, Srivatsa S, Johnson KL, et al. Microchimerism of presumed fetal origin in thyroid specimens from women: a case-control study. Lancet 2001; 358:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/79\">",
"      Imaizumi M, Pritsker A, Unger P, Davies TF. Intrathyroidal fetal microchimerism in pregnancy and postpartum. Endocrinology 2002; 143:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27833/abstract/80\">",
"      Fugazzola L, Cirello V, Beck-Peccoz P. Microchimerism and endocrine disorders. J Clin Endocrinol Metab 2012; 97:1452.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7854 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_11_27833=[""].join("\n");
var outline_f27_11_27833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INTRATHYROIDAL LYMPHOCYTIC INFILTRATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      THYROID ANTIGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thyroglobulin and thyroid peroxidase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      The TSH receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ROLE OF B CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antibodies to Tg and TPO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antibodies to the TSH receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Function of thyroid antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      THE ROLE OF T CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      The V-gene repertoire of the T-cell antigen receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Immune regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      POTENTIAL MECHANISMS OF THYROID INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Molecular mimicry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bystander activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Thyroid-cell expression of HLA antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Thyroid cell apoptosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      GENETIC SUSCEPTIBILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PRECIPITATING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Sex steroids and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Iodine intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Radiation exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Fetal microchimerism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7854\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7854|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/29/27088\" title=\"figure 1\">",
"      Thyroid hormone synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/42/12960\" title=\"figure 2\">",
"      Structure of the TSH receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/54/13165\" title=\"figure 3\">",
"      TSH receptor antibody function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/56/19342\" title=\"figure 4\">",
"      TcR V genes in Hashimotos",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7854|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/18/37158\" title=\"picture 1\">",
"      Hashimotos thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7854|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/7/31867\" title=\"table 1\">",
"      Prevalence antithyroid Ab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/55/2939\" title=\"table 2\">",
"      T cell subsets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/46/15083\" title=\"table 3\">",
"      Mechs thyroid autoimm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24694?source=related_link\">",
"      Painless thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=related_link\">",
"      Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=related_link\">",
"      Pathogenesis of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/248?source=related_link\">",
"      Postpartum thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=related_link\">",
"      Thyroid hormone synthesis and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_11_27834="Physical examination of the shoulder";
var content_f27_11_27834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physical examination of the shoulder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/11/27834/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/11/27834/contributors\">",
"     Stephen M Simons, MD, FACSM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/11/27834/contributors\">",
"     J Bryan Dixon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/11/27834/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/11/27834/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/11/27834/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/11/27834/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/11/27834/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11044325\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of patients with shoulder dysfunction or pain can be difficult. Skillful examination of the shoulder is an integral part of this evaluation and is necessary to generate an appropriate differential diagnosis and to help determine whether advanced imaging is needed.",
"   </p>",
"   <p>",
"    The large number of shoulder examination techniques, often named for their originators, can be confusing. In addition, although these maneuvers are often taught as if they are pathognomonic for a particular pathology, their diagnostic accuracy is often uncertain and many studies designed to assess their test characteristics (eg, sensitivity, specificity) are difficult to interpret [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, multiple examination maneuvers may yield positive results in a patient with an acutely injured shoulder, thereby reducing specificity.",
"   </p>",
"   <p>",
"    This topic reviews the examination of the shoulder, including many special tests designed to detect particular lesions. A systematic approach to the patient with shoulder complaints and discussions of specific shoulder problems are found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32280?source=see_link\">",
"     \"Shoulder impingement syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44439?source=see_link\">",
"     \"Acromioclavicular joint disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33912?source=see_link\">",
"     \"Frozen shoulder (adhesive capsulitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26630?source=see_link\">",
"     \"Glenohumeral osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36425?source=see_link\">",
"     \"Radiologic evaluation of the painful shoulder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link&amp;anchor=H40#H40\">",
"     \"Overview of upper extremity peripheral nerve syndromes\", section on 'Proximal neuropathies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13248561\">",
"    <span class=\"h1\">",
"     ANATOMY AND BIOMECHANICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complex network of anatomic structures endows the human shoulder with tremendous mobility. These structures and the related biomechanics are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of the patient with shoulder complaints\", section on 'Anatomy and biomechanics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3617975\">",
"    <span class=\"h1\">",
"     TIPS FOR A PRODUCTIVE EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following tips may be helpful for performing the shoulder examination effectively and efficiently:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Observe the patient, noting their posture; watch how they carry and move the affected arm. (See",
"      <a class=\"local\" href=\"#H11044332\">",
"       'Inspection'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Make the patient comfortable. This helps to ensure natural arm motion and reduces the likelihood of guarding during the examination.",
"     </li>",
"     <li>",
"      Compare shoulders.",
"     </li>",
"     <li>",
"      Perform the shoulder examination systematically.",
"     </li>",
"     <li>",
"      Assess scapulothoracic function.",
"     </li>",
"     <li>",
"      Use patient demographics and the history to guide the functional examination.",
"     </li>",
"     <li>",
"      Remember referred pain: Is the shoulder really causing their pain, or is it their cervical spine, gallbladder, spleen, or heart?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Help the patient to relax as much as possible during the examination. A relaxed patient is more likely to display authentic movement patterns and to allow the clinician to perform functional tests with little or no voluntary guarding. Minimize the patient&rsquo;s discomfort by having them take or administering appropriate analgesics prior to the examination. Although a clear view is important, the examiner needs to find a balance between exposing the shoulders and making the patient feel comfortable. When examining women, a tank top or sports bra often is preferred, but tucking the examination gown fabric into bra straps may be sufficient.",
"   </p>",
"   <p>",
"    Shoulder mobility and strength vary widely among patients and thus comparing shoulders is often crucial to performing an accurate examination. Inspect both shoulders from different perspectives; be certain you can see the relevant areas completely. Perform tests of strength and function on both shoulders and compare results.",
"   </p>",
"   <p>",
"    Use a systematic approach to examine the shoulder. Perform the essential elements of the examination (inspection, palpation, tests of motion and strength) in the same order and manner each time. This will make you more facile with the examination and prevent you from missing things. As an example, some clinicians palpate the shoulder starting at the sternoclavicular joint and then work systematically from front to back.",
"   </p>",
"   <p>",
"    It is important to assess scapulothoracic function, particularly given the multitude of patients who spend many hours using a computer and as a result develop weakness and dysfunction of the muscles that control the scapula. Such dysfunction is the root cause of shoulder pain in many patients. (See",
"    <a class=\"local\" href=\"#H1181467\">",
"     'Scapulothoracic motion and strength'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Keep in mind the &ldquo;casualty or culprit&rdquo; concept for chronic shoulder pain or overuse syndromes. Briefly stated, the site of the pain may not be the source of the problem. As an example, tests for impingement may be positive, but it does not follow that the supraspinatus and acromion are the ultimate cause of pain. The impingement may be caused by weakness of the scapular retractors, excessive tightness of the pectoralis muscles, weakness of the muscles that provide core stability, or some other abnormality that predisposes the rotator cuff to impingement. The examination findings may be accurate but incomplete, and further investigation is often necessary to clarify the primary root cause of an overuse syndrome.",
"   </p>",
"   <p>",
"    When deciding what examination techniques to perform, pay attention to patient demographics and history. The patient&rsquo;s age, occupation, athletic activities, and history of present illness determine to a large extent the likelihood of different shoulder ailments. As an example, labral tears are relatively common among overhead athletes, but unlikely in older sedentary patients. Performing a battery of examination tests looking for a labral tear in an octogenarian with chronic shoulder weakness is unlikely to be productive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72837670\">",
"    <span class=\"h1\">",
"     NEUROVASCULAR ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with acute or recent traumatic injuries, neurologic complaints (eg, weakness, paresthesias), or unusual presentations, a careful neurovascular assessment is essential; among patients without trauma or neurologic complaints, a focused neurovascular examination confirming basic motor function and sensation and adequate blood flow is sufficient.",
"   </p>",
"   <p>",
"    In the patient with a history of trauma and shoulder dysfunction or pain, neurovascular considerations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical spine fracture and spinal cord injury",
"     </li>",
"     <li>",
"      Brachial plexus neurapraxia (ie, &ldquo;stinger&rdquo; or &ldquo;burner&rdquo;)",
"     </li>",
"     <li>",
"      Axillary nerve injury (often associated with anterior glenohumeral dislocation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A cervical fracture can present as acute shoulder pain due to radiculopathy. Cervical injury is typically associated with high-velocity or sports-related trauma. However, among elder patients, cervical injuries can occur from minor trauma, such as a fall from standing. Assume the presence of a cervical spine injury in any elder patient with minor trauma who complains of neck pain or radicular symptoms, including shoulder pain, and either perform the appropriate work-up or transfer the patient to a site where this work-up can be completed. The assessment and management of cervical spine injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=see_link\">",
"     \"Evaluation and acute management of cervical spinal column injuries in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurapraxia of the brachial plexus (often referred to as a &ldquo;burner&rdquo; or &ldquo;stinger&rdquo;) occurs frequently in American football players. Patients with a stinger usually complain of a burning pain in the upper trapezius or shoulder region that radiates into the upper arm. It is often associated with weakness and paresthesias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H10#H10\">",
"     \"Brachial plexus syndromes\", section on 'Burner syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute anterior shoulder dislocation may be associated with an axillary nerve injury, but this is not common. Integrity of the axillary nerve should be assessed following acute shoulder dislocations by testing sensation over that lateral deltoid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10378?source=see_link\">",
"     \"Shoulder dislocation and reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurovascular pathology should also be ruled out in the patient with nontraumatic shoulder pain. Examine the neck and rule out pathology of the cervical spine as the cause of referred shoulder pain. Often cervical nerve root irritation presents predominately as arm pain, although radiation to neck may be present. Associated paresthesias, weakness, and reduced reflexes may be present. Pain can worsen with extension and rotation of the neck to the side of pain (so-called Spurling&rsquo;s position) or by movements that increase tension on neural structures, including abduction of the shoulder and extension of the arm. This combination of shoulder pain, weakness, and aggravation by shoulder motion can lead to misdiagnosis of the problem as an intrinsic shoulder injury. The presentation and evaluation of patients with possible cervical spine disorders unrelated to trauma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=see_link\">",
"     \"Evaluation of the patient with neck pain and cervical spine disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compression of any of the peripheral nerves around the shoulder can cause pain, paresthesias, or weakness distal to the site of injury. Compressive neuropathies at the shoulder can involve the suprascapular, long thoracic, or axillary nerves. These compressive neuropathies are described briefly below but a more thorough discussion is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link&amp;anchor=H40#H40\">",
"     \"Overview of upper extremity peripheral nerve syndromes\", section on 'Proximal neuropathies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compression of the suprascapular nerve is the most common neuropathy associated with shoulder pain. It can be caused by repetitive traction on the nerve at the suprascapular notch in overhead athletes or by compression at the spinoglenoid notch, most often from a paralabral cyst or an abnormally thickened transverse scapular ligament or one containing nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Suprascapular neuropathy causes posterior shoulder pain and produces atrophy and weakness of the supraspinatus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infraspinatus muscles.",
"   </p>",
"   <p>",
"    Compression of the long thoracic nerve causes paralysis of the serratus anterior muscle. Classically, the syndrome is caused by prolonged compression of the nerve when a heavy load is carried over the shoulder, but injury can also occur from a direct blow or from heavy or repetitive work with the involved arm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Symptoms include acute pain in the extremity or posterior chest wall followed by decreased shoulder range of motion, weakness with scapular retraction and external rotation of the shoulder, and scapular winging.",
"   </p>",
"   <p>",
"    The axillary nerve can be injured with anterior shoulder dislocations or by direct compression. Compression can occur from the quadrilateral space syndrome, which develops when fibrous adhesions, muscle, or osteophytes compress the axillary nerve within the space, or from direct trauma to the posterior shoulder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/10-16\">",
"     10-16",
"    </a>",
"    ]. The quadrilateral space is bounded by the teres minor superiorly, long head of the triceps medially, teres major inferiorly, and the medial border of the humerus laterally. Quadrilateral space syndrome is characterized by posterior shoulder pain, focal tenderness, and paresthesias in a small area inferior to the acromion. Weakness of the deltoid and external rotators of the shoulder may be seen. Axillary nerve compression may be associated with compromise of the posterior humeral circumflex artery in overhead athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/14\">",
"     14",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Vascular conditions, including thoracic outlet syndrome and axillary vein thrombosis, can cause shoulder pain. The term thoracic outlet syndrome (TOS) describes a variety of upper extremity syndromes involving compression of the neurovascular structures that pass from the neck to the axilla. Symptoms can include shoulder or neck pain, weakness or easy fatigability of the arm, and paresthesias of the arm or hand. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H24#H24\">",
"     \"Brachial plexus syndromes\", section on 'Thoracic outlet syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Axillary vein thrombosis is most often due to heavy, prolonged use of the arm (so-called effort thrombosis), but can occur from PICC lines or other central venous catheters, or from TOS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Symptoms include acute pain, swelling of the shoulder and arm, change in skin color, and temperature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=see_link\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It should be noted that it is common for overhead athletes to present with mild intermittent neurovascular complaints, often secondary to an underlying non-neurologic shoulder disorder, such as impingement or subtle instability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11044332\">",
"    <span class=\"h1\">",
"     INSPECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspection is an important but often overlooked part of the shoulder examination.",
"   </p>",
"   <p>",
"    Before focusing on the shoulder, note the patient&rsquo;s posture and general appearance, which sometimes allows insight into the cause of shoulder dysfunction or underlying factors that may be contributing to their symptoms. In the setting of acute injury, guarding and self-imposed immobilization of the arm suggest significant injury. The clinician may perform a limited exam and then choose to proceed promptly to imaging studies. As examples, the patient with an anterior glenohumeral dislocation typically holds their arm in slight abduction with external rotation using their opposite hand, while the patient with an acute acromioclavicular sprain often has a step-off at the joint and holds their arm to their side. &nbsp;",
"   </p>",
"   <p>",
"    Watch the way the patient takes off their coat or dons an examining gown. Unilateral abnormalities in motion, such as an inability to lower the arm smoothly or use of the functional arm to help lower the injured one (possible supraspinatus tear) or use of accessory muscles to raise the arm (possible impingement syndrome or supraspinatus tear), may provide diagnostic clues.",
"   </p>",
"   <p>",
"    The patient&rsquo;s posture is often revealing. One posture often associated with shoulder pain involves the head and chin thrust forward with the shoulders rounded and protracted (ie, the chest is collapsed) (",
"    <a class=\"graphic graphic_picture graphicRef83224 \" href=\"UTD.htm?13/7/13424\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/21\">",
"     21",
"    </a>",
"    ]. Many patients who work primarily at a desk assume this posture due to dysfunction of the scapular stabilizing muscles. Athletes who assume this posture frequently have pectoralis muscles that are tight or significantly stronger than the antagonists and scapular retractors (latissimus dorsi, upper trapezius, rhomboids), which are often weak and stretched. If the scapular retractors are extremely weak, winging of one or both scapulae may be observed.",
"   </p>",
"   <p>",
"    Insight may be gained from the patient&rsquo;s general appearance. Although the vast majority of patients seeking medical attention for shoulder symptoms have shoulder pathology, the ill-appearing patient without a distinct history of shoulder injury raises concern for referred pain from cardiac, biliary, or intra-abdominal conditions.",
"   </p>",
"   <p>",
"    After looking at the patient&rsquo;s posture and general appearance, inspect the shoulder region looking for any abnormality. This may include an obvious deformity, such as the classic &ldquo;Popeye&rdquo; deformity of the upper arm suggesting rupture of the long head biceps tendon (",
"    <a class=\"graphic graphic_picture graphicRef80748 \" href=\"UTD.htm?28/62/29664\">",
"     picture 2",
"    </a>",
"    ), a subtle asymmetry, such as a difference in shoulder height, or a lesion, such as a surgical scar. Observe and compare the area around the patient&rsquo;s glenohumeral joints, looking for abnormal contours, possibly from muscle atrophy or frank dislocation. Compare the bony prominences of the scapulae, acromioclavicular joint, clavicles, and sternoclavicular joints for signs of trauma or degenerative change.",
"   </p>",
"   <p>",
"    Obvious deformity is common with traumatic shoulder injuries, such as a high grade acromioclavicular separation (",
"    <a class=\"graphic graphic_picture graphicRef82015 \" href=\"UTD.htm?24/1/24592\">",
"     picture 3",
"    </a>",
"    ) or a clavicle fracture. However, deformities or asymmetries from nontraumatic shoulder pathology are usually more subtle. Look carefully at the elevation of the patient&rsquo;s shoulders and the position of their scapulae. Motion at the scapular thoracic articulation plays an important role in shoulder function and assessing scapulothoracic function is an important part of the shoulder examination. Asymmetric positioning of the scapulae suggests problems with this articulation. (See",
"    <a class=\"local\" href=\"#H1181467\">",
"     'Scapulothoracic motion and strength'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    The patient should be viewed from behind to assess scapular positioning. This can be done with the patient&rsquo;s arms at their sides or in a push up position with their hands against a wall. Scapular position is described as elevated, depressed, retracted (rotated back on the chest wall), or protracted (rotated forward on the chest wall) (",
"    <a class=\"graphic graphic_figure graphicRef50894 \" href=\"UTD.htm?33/47/34554\">",
"     figure 1",
"    </a>",
"    ). An elevated, protracted scapula is the most common dysfunctional position and is often described as &ldquo;winging&rdquo; (",
"    <a class=\"graphic graphic_picture graphicRef68399 \" href=\"UTD.htm?1/47/1791\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57411 \" href=\"UTD.htm?37/12/38080\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef83145 \" href=\"UTD.htm?6/19/6448\">",
"     movie 1",
"    </a>",
"    ). Although scapular winging is classically associated with dysfunction of the long thoracic nerve, muscular dysfunction, rather than true nerve injury, is usually the cause.",
"   </p>",
"   <p>",
"    Look for atrophy of the deltoid, supraspinatus, or infraspinatus muscles. Deltoid atrophy renders the acromial borders more prominent. Atrophy of the supraspinatus and infraspinatus in the older patient suggests the presence of a large, chronic rotator cuff tear. In the younger patient, such atrophy raises concern for suprascapular nerve injury. (See",
"    <a class=\"local\" href=\"#H72837670\">",
"     'Neurovascular assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Note the appearance of the skin, including the presence and location of ecchymosis, striae, depigmentation, or scarring. Surgical scars should prompt questions about prior shoulder injuries and surgery. An abnormal-appearing scar suggests the possibility of a collagen disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11044346\">",
"    <span class=\"h1\">",
"     PALPATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpate the shoulders systematically, comparing each side. We suggest starting with the neck to rule out cervical pathology. Spasm of the paracervical and superior trapezius muscles is a nonspecific finding consistent with numerous cervical problems, including radiculopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=see_link&amp;anchor=H22#H22\">",
"     \"Evaluation of the patient with neck pain and cervical spine disorders\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If referred pain from an intra-abdominal source is suspected, examine the abdomen carefully. In patients with shoulder trauma, gentle palpation can be used to identify areas of focal tenderness or deformity. As examples, a step-off in the clavicle would be consistent with a fracture, while tenderness at the acromioclavicular (AC) joint suggests an injury of the AC ligament. Glenohumeral dislocation can manifest as a palpable concavity in the subacromial space along with a bony prominence anteriorly (from the displaced humeral head).",
"   </p>",
"   <p>",
"    For patients with nontraumatic intrinsic shoulder problems, at a minimum, the clinician should systematically palpate the common and important sites of pathology. Moving from the most proximal and posterior to distal and anterior structures, these sites include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical spine",
"     </li>",
"     <li>",
"      Scapular spine and adjacent musculature",
"     </li>",
"     <li>",
"      Acromion and the subacromial space",
"     </li>",
"     <li>",
"      Bicipital groove, and greater and lesser tuberosities of the humerus",
"     </li>",
"     <li>",
"      Clavicle, including sternoclavicular (SC) and acromioclavicular (AC) joints",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The subscapular bursa can be palpated at the junction of the superior-medial angle of the scapula and the closest underlying rib (",
"    <a class=\"graphic graphic_picture graphicRef83225 \" href=\"UTD.htm?19/9/19600\">",
"     picture 5",
"    </a>",
"    ). Exposure of this bursa requires full adduction of the ipsilateral arm, which is accomplished by having the patient hold their opposite shoulder.",
"   </p>",
"   <p>",
"    The acromion process of the scapula is covered by the deltoid muscle. The supraspinatus tendon attaches to the greater tubercle, located just under the anterior third of the acromion. The subacromial structures may be indirectly examined by palpating directly below the acromion (",
"    <a class=\"graphic graphic_picture graphicRef65889 \" href=\"UTD.htm?36/16/37120\">",
"     picture 6",
"    </a>",
"    ). Alternatively, these structures can be moved anteriorly and better palpated by extending the shoulder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/12\">",
"     12",
"    </a>",
"    ]. This is accomplished by gently lifting the elbow of the adducted arm posteriorly (",
"    <a class=\"graphic graphic_picture graphicRef77672 \" href=\"UTD.htm?36/11/37041\">",
"     picture 7",
"    </a>",
"    ). Tenderness is consistent with impingement syndrome, rotator cuff tendinopathy, rotator cuff tear, subacromial bursitis, muscle contusion, or a humeral lesion.",
"   </p>",
"   <p>",
"    The bicipital groove can be identified by locating the greater tuberosity of the humerus and then moving the fingers slightly medially into the groove (",
"    <a class=\"graphic graphic_picture graphicRef70699 \" href=\"UTD.htm?1/57/1938\">",
"     picture 8",
"    </a>",
"    ). This examination is best done with the shoulder externally rotated.",
"   </p>",
"   <p>",
"    Tenderness of the acromioclavicular and sternoclavicular joints is assessed as follows. The anterior, lateral, and posterior edges of the acromion are demarcated. The AC joint is palpated at the juncture of the acromion and distal clavicle, approximately 4 cm proximally from the lateral edge of the acromion (",
"    <a class=\"graphic graphic_picture graphicRef55667 \" href=\"UTD.htm?42/10/43183\">",
"     picture 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62599 \" href=\"UTD.htm?6/48/6913\">",
"     picture 10",
"    </a>",
"    ). The SC joint is palpated at the juncture of the proximal end of the clavicle and the lateral edge of the sternum, approximately 2 to 3 cm from the midline of the body. Tenderness at the AC joint may be the only palpable finding for those suffering chronic joint pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11044360\">",
"    <span class=\"h1\">",
"     RANGE OF MOTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5844675\">",
"    <span class=\"h2\">",
"     Approach to shoulder motion assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Range of motion (ROM) testing helps to determine the site and nature of intrinsic shoulder pain (",
"    <a class=\"graphic graphic_table graphicRef52351 \" href=\"UTD.htm?2/27/2491\">",
"     table 1",
"    </a>",
"    ). Although a healthy shoulder has extensive mobility, ROM varies among patients and thus it is important to compare shoulders (",
"    <a class=\"graphic graphic_table graphicRef70854 \" href=\"UTD.htm?27/36/28236\">",
"     table 2",
"    </a>",
"    ). Full, painless ROM requires a normal glenohumeral joint, intact rotator cuff tendons, and functional rotator cuff muscles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of the patient with shoulder complaints\", section on 'Anatomy and biomechanics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician should develop a routine and repeatable examination procedure. The clinician should be prepared to modify the approach to the patient as certain painful, acute injuries may preclude adhering to a rigid protocol.",
"   </p>",
"   <p>",
"    Generally, active motion is assessed before passive. However, passive ROM is evaluated first when active motion is severely limited or painful. Active motions are those motions performed by the patient independent of the examiner. Passive motions are those motions performed by the examiner without patient assistance.",
"   </p>",
"   <p>",
"    The examiner should begin by watching the patient perform full flexion and elevation; full abduction and elevation; internal and external rotation with elbows at their side; internal and external rotation at 90 degrees of abduction in the neutral plane; and repeated abduction and elevation with the examiner watching scapular motion from behind the patient. If any of these are limited the examiner repeats each of these with passive motion to assess whether the limitation is structural.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18511193\">",
"    <span class=\"h2\">",
"     Active range of motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examiner should begin by observing active motions performed by the patient. These are performed as primary plane motions of flexion, extension, adduction, abduction, and internal rotation, external rotation with the shoulder starting from a neutral (arm at side) position. Internal and external rotation motions are then repeated with the shoulder abducted to 90 degrees.",
"   </p>",
"   <p>",
"    Active range of motion can also be assessed by having the patient perform each shoulder motion (flexion, extension, abduction, adduction, internal, and external rotation) unilaterally or by performing bilateral motions simultaneously, which enables the clinician to compare sides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33912?source=see_link\">",
"     \"Frozen shoulder (adhesive capsulitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26630?source=see_link\">",
"     \"Glenohumeral osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although distinct, glenohumeral and scapulothoracic motion are interdependent and they should be assessed both independently and together. In the normal shoulder, for every 30 degrees of glenohumeral abduction there is a corresponding 12 degrees of scapulothoracic rotation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Note that symptoms at one articulation may be caused by dysfunction at the other. As an example, rotator cuff pathology may be caused by weakness in the scapular stabilizing muscles. Conversely, the scapular stabilizers may be subjected to overuse in the setting of reduced glenohumeral mobility.",
"   </p>",
"   <p>",
"    Assess internal rotation of the shoulder with the patient&rsquo;s arm at 90 degrees of abduction while stabilizing the scapula. This positioning isolates glenohumeral internal rotation. When examining overhead athletes, look for compensatory loss of internal rotation and increased external rotation.",
"   </p>",
"   <p>",
"    In addition to the standard motion tests described above, Apley &ldquo;scratch&rdquo; tests can provide an easy and reproducible way to assess shoulder motion. However, they should be performed as an adjunct to standard range of motion tests as they do not adequately assess all shoulder movements (",
"    <a class=\"graphic graphic_picture graphicRef55077 \" href=\"UTD.htm?9/24/9604\">",
"     picture 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/25\">",
"     25",
"    </a>",
"    ]. The Apley tests are performed as follows (",
"    <a class=\"graphic graphic_movie graphicRef82878 \" href=\"UTD.htm?32/63/33791\">",
"     movie 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To assess external rotation and abduction, the patient is asked to reach behind their head and touch the superior medial tip of the opposite scapula. A patient with normal function can reach approximately the level of the T4 spinous process.",
"     </li>",
"     <li>",
"      To assess internal rotation and adduction, the patient is asked to reach behind their back and touch the inferior tip of the opposite scapula. A patient with normal function can reach approximately the level of the T8 spinous process.",
"     </li>",
"     <li>",
"      To assess adduction further, the patient is asked to reach across their chest and touch the opposite shoulder. A patient with acromioclavicular pathology or impingement will have difficulty with this maneuver.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18511206\">",
"    <span class=\"h2\">",
"     Passive range of motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;If active motion is limited, passive range of motion performed by the examiner should be assessed for each major movement of the shoulder. Such testing helps the clinician to distinguish between motion limitations caused by pain and those caused by a structural constraint (eg, adhesive capsulitis or glenohumeral arthritis).",
"   </p>",
"   <p>",
"    Range of Motion limitations may be a clue to various shoulder pathologies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute injury (eg, glenohumeral dislocation, fracture)",
"     </li>",
"     <li>",
"      Significant rotator cuff tear or labral tear",
"     </li>",
"     <li>",
"      Pain from rotator cuff tendinopathy or, less commonly, acute inflammation",
"     </li>",
"     <li>",
"      Adhesive capsulitis (ie, frozen shoulder)",
"     </li>",
"     <li>",
"      Glenohumeral joint arthritis (osteoarthritis or inflammatory)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most patients, the degree of impairment correlates with the severity of these conditions. Side-to-side comparison provides the most practical and objective assessment of motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1180003\">",
"    <span class=\"h1\">",
"     EXAMINATION FOR ROTATOR CUFF PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18531072\">",
"    <span class=\"h2\">",
"     Overview and evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotator cuff injury is among the most common causes of shoulder pain. The rotator cuff tendons, particularly the supraspinatus tendon, are uniquely susceptible to subacromial impingement and dominate the conditions affecting the shoulder, especially in patients over the age of 30. Rotator cuff tendinopathy almost always represents a chronic injury of the supraspinatus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infraspinatus tendons. Although rotator cuff tendinopathy may occur as an isolated problem, it is often accompanied by subacromial bursitis.",
"   </p>",
"   <p>",
"    Tendinopathy usually develops as a consequence of repetitive activity, generally performed at or above shoulder height, which leads to tendon degeneration and microvascular insult. Relevant shoulder anatomy and biomechanics and the diagnosis and management of rotator cuff tendinopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of the patient with shoulder complaints\", section on 'Anatomy and biomechanics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systematic reviews of studies that assess shoulder examination tests report a wide range of approaches and methodological quality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. This variation precludes meaningful meta-analysis of tests for rotator cuff integrity. Analyses of the 15 relevant studies included in one review found that only eight met quality criteria and no individual examination technique included was consistently diagnostic of rotator cuff injury. This highlights the difficulty recommending single examination tests for rotator cuff injury. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11044410\">",
"    <span class=\"h2\">",
"     Assessment of abduction and the supraspinatus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The supraspinatus muscle and tendon play major roles in shoulder abduction and stabilization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The role of the supraspinatus in abduction is synergistically coordinated with the deltoid, periscapular, and trapezius muscles. In addition, the supraspinatus dynamically stabilizes the humeral head within the glenoid fossa during abduction. Without adequate retraction and stabilization of the humeral head, upward",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    forward migration of the head occurs, which may contribute to impingement.",
"   </p>",
"   <p>",
"    Inadequate supraspinatus function may occur for a variety of reasons including tendon tears, tendon thickening, tendinitis, and pain-related neuroinhibition. Independent of supraspinatus pathology, subacromial or subdeltoid bursitis may contribute to symptoms of pain or weakness.",
"   </p>",
"   <p>",
"    Of the three abductors of the shoulder (deltoid, supraspinatus, and superior trapezius muscles), the supraspinatus plays a primary role in the initial abduction of the arm (to approximately 30 degrees), but is involved throughout abduction. Thus, isometric testing of the arm early in abduction may better assess the strength and integrity of the supraspinatus tendon.",
"   </p>",
"   <p>",
"    Tests purported to isolate supraspinatus function are controversial and studies of them are limited. Based upon this limited evidence and our clinical experience, we perform the following examination tests to assess supraspinatus function:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Isometric strength &nbsp;",
"     </li>",
"     <li>",
"      Active painful arc and drop arm tests",
"     </li>",
"     <li>",
"      Empty can test",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supraspinatus isometric strength is assessed by having the patient abduct the arm to about 20 degrees in a neutral plane and having the patient resist continuous pressure for 30 seconds while the examiner attempts to adduct the arm (",
"    <a class=\"graphic graphic_picture graphicRef56697 \" href=\"UTD.htm?26/26/27041\">",
"     picture 12",
"    </a>",
"    ). Continuous pressure for a relatively prolonged period fatigues the deltoid muscle, which also contributes to the initiation of abduction. This isometric test of supraspinatus strength is highly sensitive but nonspecific for the diagnosis of supraspinatus tendon injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/32\">",
"     32",
"    </a>",
"    ]. Note that the severity of functional impairment during testing does",
"    <strong>",
"     not",
"    </strong>",
"    correlate well with the size of a tendon tear.",
"   </p>",
"   <p>",
"    The integrity of the supraspinatus tendon can be assessed with the \"drop arm\" test and the active painful arc test. The active painful arc test (not to be confused with the Neer test, an impingement test performed passively and described separately) simply involves having the patient actively abduct their arm from a neutral position. Pain with active abduction beyond 90 degrees marks a positive test (",
"    <a class=\"graphic graphic_picture graphicRef70787 \" href=\"UTD.htm?0/11/177\">",
"     picture 13",
"    </a>",
"    ). The drop arm test assesses the ability of the patient to lower his or her arms from a fully abducted position. A positive test occurs when the patient is unable to lower the affected arm with the same smooth coordinated motion as the unaffected arm (",
"    <a class=\"graphic graphic_movie graphicRef82880 \" href=\"UTD.htm?38/24/39296\">",
"     movie 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The \"empty can\" (or Jobe's) test is another important way of evaluating supraspinatus function. Many authors consider this the gold standard for evaluating supraspinatus function as this position makes the supraspinatus the primary muscle opposing downward motion of the arm. It is performed by having the patient place a straight arm in about 90 degrees of abduction and 30 degrees of forward flexion, and then internally rotating the arm completely (ie, thumb pointing down) (",
"    <a class=\"graphic graphic_picture graphicRef74738 \" href=\"UTD.htm?1/60/1987\">",
"     picture 14",
"    </a>",
"    ). The patient then resists the clinician's attempts to depress the arm. Pain without weakness is consistent with tendinopathy, while pain with weakness is consistent with partial or complete tendon tear.",
"   </p>",
"   <p>",
"    When pain limits the ability to evaluate strength in abduction, the clinician can assess the integrity of the axillary nerve by having the patient fully adduct the shoulder and then abduct against some resistance, while he or she feels for muscle contraction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Assuming the absence of nerve injury (such injury is uncommon unless there is a history of trauma), weakness that manifests with any of the tests described here suggests the presence of at least a partial supraspinatus tear. However, scapular dyskinesis places additional strain on the supraspinatus and may inhibit its normal motion, and this may be the underlying cause of weakness.",
"   </p>",
"   <p>",
"    To determine whether scapular dyskinesis is contributing to supraspinatus-related symptoms, repeat the tests above while ensuring the scapula is properly retracted. This is done by pressing the scapula against the patient&rsquo;s back while the patient performs the test. If strength improves with scapular stabilization, weakness is likely due to scapular dysfunction and not to an injury of the supraspinatus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/21\">",
"     21",
"    </a>",
"    ]. Scapular stabilization is described in greater detail separately. (See",
"    <a class=\"local\" href=\"#H1181467\">",
"     'Scapulothoracic motion and strength'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11044417\">",
"    <span class=\"h2\">",
"     Assessment of external rotation and the infraspinatus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infraspinatus muscle is primarily responsible for external rotation of the shoulder, with the teres minor muscle contributing to a minor degree. Isometric testing of the infraspinatus tendon in neutral position is used to assess the strength and integrity of the tendon, as well as to elicit pain indicative of injury. This test can be performed by having the patient attempt to externally rotate their adducted arm while the clinician resists the movement with their hand (",
"    <a class=\"graphic graphic_picture graphicRef57983 \" href=\"UTD.htm?23/2/23585\">",
"     picture 15",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef82882 \" href=\"UTD.htm?25/58/26529\">",
"     movie 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11044424\">",
"    <span class=\"h2\">",
"     Assessment of internal rotation and the subscapularis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subscapularis is the rotator cuff muscle primarily responsible for internal rotation of the shoulder. Strength of the subscapularis can be assessed using the push-off (or Gerber's lift-off) test. This test is performed by having the patient place one hand behind their back and push posteriorly against resistance (",
"    <a class=\"graphic graphic_picture graphicRef71635 \" href=\"UTD.htm?42/9/43155\">",
"     picture 16",
"    </a>",
"    ). As with other strength tests, the essential distinction is between pain with weakness (significant tendon tear) and pain without weakness (tendinopathy or minor tendon tear).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1180134\">",
"    <span class=\"h2\">",
"     Testing for rotator cuff tear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many textbooks and clinicians have long advocated using the physical examination to determine the presence of rotator cuff pathology, well-performed studies to support particular examination techniques or approaches are scarce. Based upon the best available evidence and our clinical experience, we suggest using three tests in combination to determine whether a rotator cuff tear exists:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Painful arc sign (",
"      <a class=\"graphic graphic_picture graphicRef70787 \" href=\"UTD.htm?0/11/177\">",
"       picture 13",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Drop arm test (",
"      <a class=\"graphic graphic_movie graphicRef82880 \" href=\"UTD.htm?38/24/39296\">",
"       movie 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Weakness in external rotation (",
"      <a class=\"graphic graphic_picture graphicRef57983 \" href=\"UTD.htm?23/2/23585\">",
"       picture 15",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef82882 \" href=\"UTD.htm?25/58/26529\">",
"       movie 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If all three tests are positive, a significant rotator cuff tear is likely; if all three are negative, a significant tear is unlikely. The presence of a rotator cuff tear is difficult to determine in patients whose examination reveals only one or two positive tests. Diagnostic imaging is often needed to clarify the presence or absence of a full thickness rotator cuff tear in such cases. The performance of these tests is described separately. (See",
"    <a class=\"local\" href=\"#H11044410\">",
"     'Assessment of abduction and the supraspinatus'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11044417\">",
"     'Assessment of external rotation and the infraspinatus'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This approach is based primarily upon a prospective observational study of 552 patients who were systematically evaluated using eight common shoulder examination tests and then underwent diagnostic arthroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/35\">",
"     35",
"    </a>",
"    ]. Logistic regression analysis found that the combination of a positive painful arc sign, positive drop arm test, and weakness in external rotation accurately predicted full-thickness rotator cuff tear (LR 15.6), while a combination of three negative tests made the diagnosis unlikely (LR 0.16). This study is among the few well-performed trials to assess shoulder examination techniques that include a sufficient number of patients to draw meaningful conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar study assessed the accuracy of 23 clinical tests in 400 patients who subsequently underwent arthroscopic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/37\">",
"     37",
"    </a>",
"    ]. According to this study, patients with shoulder pain who demonstrated supraspinatus and infraspinatus weakness and a positive impingement sign had a 98 percent chance of having a full thickness tear. Among patients 60 years or older with positive findings of any two of these three tests, there was again a 98 percent chance of tear. The study did not include descriptions of the techniques used for clinical testing, making it difficult to replicate the protocol.",
"   </p>",
"   <p>",
"    The concept of muscle lag provides the basis for several published tests of rotator cuff integrity, including the external rotation lag sign, internal rotation lag sign, drop or dropping sign, belly press test or Napoleon sign, and the belly off test [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/33,38,39\">",
"     33,38,39",
"    </a>",
"    ]. These tests exploit the biomechanical length-tension curve of muscle force generation and the antagonistic actions of the rotator cuff muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/33\">",
"     33",
"    </a>",
"    ]. Further study is required before muscle lag tests can be recommended to diagnose rotator cuff tear.",
"   </p>",
"   <p>",
"    To assess muscle lag, the muscle is passively placed in its maximally shortened position. When placed in this position, the ability of the muscle to exert force is minimized. The patient is then asked to maintain that position with active contraction. The difference between this passive and active range of motion is called the lag. Lag represents an inability of the muscle to resist the antagonistic force of the opposing rotator cuff muscle and is thought to identify subtle decreases in rotator cuff strength suggestive of a tear. Loss of strength or integrity in the antagonistic muscles, decreases in passive range of motion, or neurologically mediated strength deficits can confound results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5844119\">",
"    <span class=\"h1\">",
"     SPECIAL TESTS FOR SHOULDER IMPINGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of shoulder impingement syndrome (SIS) includes a range of clinical findings attributable to the compression of structures around the glenohumeral joint when the patient raises their arm. SIS does not refer to an injury of any specific structure, although supraspinatus injury is most common. Over time, compressed structures cause persistent pain and dysfunction. The symptoms of SIS are similar to those of rotator cuff tendinopathy, namely pain with overhead activity. The diagnosis and management of SIS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32280?source=see_link\">",
"     \"Shoulder impingement syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple prospective observational studies report that physical examination techniques for the shoulder are sensitive for the presence of SIS, but cannot reliably distinguish among specific causes of pain and dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/32,35,40-42\">",
"     32,35,40-42",
"    </a>",
"    ]. The Neer and Hawkins-Kennedy impingement tests described below demonstrate overall sensitivities ranging from approximately 75 to 90 percent and are the primary tests we use to diagnose shoulder impingement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5844126\">",
"    <span class=\"h2\">",
"     Passive painful arc (Neer) test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"passive painful arc maneuver\" (passively flexing the glenohumeral joint while simultaneously preventing shoulder shrugging) is used to assess the degree of impingement (",
"    <a class=\"graphic graphic_picture graphicRef76237 \" href=\"UTD.htm?43/7/44149\">",
"     picture 17",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef82879 \" href=\"UTD.htm?3/13/3281\">",
"     movie 5",
"    </a>",
"    ). Voluntary guarding by the patient while the maneuver is performed often manifests as shoulder shrugging. The severity of impingement and rotator cuff tendinopathy is determined by the angle at which the arc becomes painful.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain at 90 degrees is consistent with mild impingement.",
"     </li>",
"     <li>",
"      Pain at 60 to 70 degrees is consistent with moderate impingement.",
"     </li>",
"     <li>",
"      Pain at 45 degrees or below is consistent with severe impingement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5844133\">",
"    <span class=\"h2\">",
"     Flexion with internal rotation (Hawkins-Kennedy) test",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this test, the clinician stabilizes the shoulder with one hand and, with the patient's elbow flexed 90 degrees, internally rotates the shoulder using the other hand (",
"    <a class=\"graphic graphic_picture graphicRef60425 \" href=\"UTD.htm?19/27/19891\">",
"     picture 18",
"    </a>",
"    ). Shoulder pain elicited by internal rotation represents a positive test.",
"   </p>",
"   <p>",
"    The empty can test is also used by some clinicians to assess impingement. It is described separately. The empty can test or the infraspinatus tests can be used as confirmatory tests to increase specificity for impingement. The specificity may be as great as 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5844140\">",
"    <span class=\"h2\">",
"     Scapular assistance test",
"    </span>",
"    &nbsp;&mdash;&nbsp;This test is used to determine whether scapular dyskinesis is contributing to shoulder impingement, although few studies have been performed to determine its accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/43\">",
"     43",
"    </a>",
"    ]. The test is performed by assisting scapular motion during abduction and forward flexion of the arm. To perform the test, the clinician places one hand on the superior medial border of the scapula while the other hand is placed on the inferior medial scapular border. As the patient actively raises their arm into positions that typically cause impingement, the examiner maintains the posterior tilt, upward rotation, and external rotation of normal scapular motion (",
"    <a class=\"graphic graphic_movie graphicRef83146 \" href=\"UTD.htm?22/24/22913\">",
"     movie 6",
"    </a>",
"    ). A positive test occurs when assistance reduces impingement complaints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1181467\">",
"    <span class=\"h1\">",
"     SCAPULOTHORACIC MOTION AND STRENGTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coordination of motion at the glenohumeral joint and the scapulothoracic articulation is important for normal shoulder function. Normally, once the shoulder is abducted more than 20 degrees, further abduction occurs at these articulations in a 2:1 ratio; for every 2 degrees of abduction at the glenohumeral joint, the scapulothoracic articulation moves 1 degree. Normal motion is smooth and symmetric. The biomechanics and anatomy of the shoulder are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of the patient with shoulder complaints\", section on 'Anatomy and biomechanics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians can assess scapulothoracic motion and abduction by observing the undressed patient from behind while simultaneous shoulder abduction is performed. Another technique is to feel the inferior tip of each scapula as the patient abducts the arms. Normal motion is smooth and symmetric. The clinician can also measure the migration of the scapular tip away from the mid-thoracic line after repeated abduction to detect any progressive scapular winging and internal rotation of the shoulder. &nbsp;",
"   </p>",
"   <p>",
"    Patients can compensate for decreased glenohumeral motion by using scapulothoracic motion, which is capable of up to 90 degrees of abduction. Such compensation manifests as shoulder shrugging. Abnormal motion most often occurs either to compensate for an injury that limits glenohumeral movement or because the stabilizing muscles of the scapula are weak, in which case there may be no asymmetry.",
"   </p>",
"   <p>",
"    Scapular instability, whether from nerve damage or muscle weakness alone, can be evaluated by either the push-off or stabilization tests. In the former, the patient pushes against a wall, as if performing an upright push-up. Instability manifests as scapular winging (",
"    <a class=\"graphic graphic_picture graphicRef68399 \" href=\"UTD.htm?1/47/1791\">",
"     picture 4",
"    </a>",
"    ). Although there is no high quality evidence to support these tests, we have found them to be useful.",
"   </p>",
"   <p>",
"    In the scapular stabilization test, the patient flexes his or her shoulder, while the examiner manually compresses the patient's scapula against the ribcage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/44\">",
"     44",
"    </a>",
"    ]. Alternatively, the patient can stabilize the scapula by standing with their back against a wall and pressing their scapula into the wall while abducting the glenohumeral joint. Elimination of pain and improved shoulder motion (shoulder flexion &ge;150 degrees) and strength suggests scapular instability is contributing to the patient's symptoms. Evaluation of supraspinatus strength can be performed with and without scapular stabilization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11044410\">",
"     'Assessment of abduction and the supraspinatus'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11044487\">",
"    <span class=\"h1\">",
"     SPECIAL TESTS FOR SHOULDER INSTABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glenohumeral joint has a ball and socket structure. In contrast to the deep rigid socket of the hip joint, the socket of the glenohumeral joint is shallow, like a golf ball perched on a tee. The shallowness of the joint allows for the extensive motion necessary for many sports and everyday activities, but also requires that a number of dynamic (eg, rotator cuff muscles) and static (eg, labrum) structures provide stability.",
"   </p>",
"   <p>",
"    Glenohumeral instability due to weakness or laxity in some of these structures may cause shoulder discomfort in young throwing athletes, people with weak shoulder musculature, and patients who have sustained a rotator cuff tear. Instability may be multi or unidirectional; anterior and inferior laxities are most common. Several tests are used to assess this problem [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11044494\">",
"    <span class=\"h2\">",
"     Sulcus sign",
"    </span>",
"    &nbsp;&mdash;&nbsp;Downward movement of the humeral head is influenced by the tone and bulk of the deltoid, the tone and thickness of the supraspinatus muscle and tendon, and the structure and integrity of the glenohumeral capsule.",
"   </p>",
"   <p>",
"    The sulcus sign maneuver evaluates the looseness of the glenohumeral joint, and can help to determine a patient's tolerance for Codman pendulum exercises (",
"    <a class=\"graphic graphic_picture graphicRef56542 \" href=\"UTD.htm?38/16/39183\">",
"     picture 19",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef82883 \" href=\"UTD.htm?43/44/44736\">",
"     movie 7",
"    </a>",
"    ). The following findings may be noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No movement can be seen in patients with extreme guarding or muscle tension, or an overly developed deltoid muscle.",
"     </li>",
"     <li>",
"      Approximately 0.5 to 1 cm of movement is normal.",
"     </li>",
"     <li>",
"      Movement of 2 cm or more is consistent with hypermobility (glenohumeral subluxation).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with benign glenohumeral hypermobility and disorders such as Ehlers Danlos can often voluntarily sublux the shoulder in multiple planes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2953?source=see_link\">",
"     \"Clinical manifestations and treatment of the hypermobility syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11044501\">",
"    <span class=\"h2\">",
"     Apprehension, relocation, and release tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;These tests work in combination and are most easily performed with the patient supine (",
"    <a class=\"graphic graphic_picture graphicRef69882 \" href=\"UTD.htm?17/3/17466\">",
"     picture 20",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef82884 \" href=\"UTD.htm?21/11/21681\">",
"     movie 8",
"    </a>",
"    ). To perform the apprehension test, the patient is asked to place the symptomatic arm in the throwing position (shoulder abducted and externally rotated). Next, the clinician braces the posterior shoulder with one hand while using the other hand to push back on the wrist with steady pressure, thereby increasing the abduction and external rotation of the shoulder (as if the clinician is attempting to dislocate the shoulder anteriorly). Any sensation of impending dislocation at any time on the part of the patient constitutes a positive test.",
"   </p>",
"   <p>",
"    The relocation test is begun at the end of the apprehension test and is performed by simply reversing the forces being exerted by the examiner. Forced abduction and external rotation are stopped, and the clinician moves the hand that was bracing the posterior shoulder to the anterior shoulder. The examiner then pushes the humerus posteriorly (as if he or she was attempting to relocate the shoulder). The resolution of either pain or the sensation of impending dislocation on the part of the patient represents a positive test.",
"   </p>",
"   <p>",
"    The release test is performed at the end of the relocation test when the clinician abruptly stops pushing the humerus posteriorly. Again, any sensation of impending dislocation on the part of the patient constitutes a positive test.",
"   </p>",
"   <p>",
"    A meta-analysis of these tests found both the relocation and release tests to have reasonable sensitivity (85 percent) and specificity (87 percent) for the detection of glenohumeral instability [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/36\">",
"     36",
"    </a>",
"    ]. However, the authors warn that most of the studies reviewed involved patients in orthopedic clinics, and it remains uncertain whether their findings apply to more general populations. A subsequent systematic review reported that positive apprehension, relocation, and release tests are &ldquo;diagnostic of anterior instability,&rdquo; based primarily upon the results of three high quality trials, but stated that data were insufficient to perform a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/26\">",
"     26",
"    </a>",
"    ]. The authors emphasized that using apprehension as the marker for a positive test, rather than pain, substantially improved test performance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95588956\">",
"    <span class=\"h2\">",
"     Load and shift test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The load and shift test measures anterior and posterior glenohumeral laxity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The test is positive if there is significant translocation of the humeral head anteriorly or posteriorly in the glenoid fossa when applying a force in the respective direction.",
"    <br/>",
"    <br/>",
"    The standard load and shift test is performed by applying an axial load to the glenohumeral joint (ie, pressing the humeral head into the glenoid) and then attempting to translocate the humeral head anteriorly and then posteriorly. The acromion is held in a fixed position with the clinician&rsquo;s opposite hand while the maneuver is performed.",
"   </p>",
"   <p>",
"    A modified version of the shift and load test is performed with the patient supine and their shoulder abducted 90 degrees. Again, the examiner applies an axial load by pressing the humeral head into the glenoid, and then attempts to translocate the humeral head. Performing the test with the patient supine allows the scapula to be stabilized by the examining table, thereby making it easier to sublux the humeral head. The modified test may be easier to perform if the patient is larger or more muscular than the examiner.",
"   </p>",
"   <p>",
"    Translocation is scored as follows: Grade 1 is translation of 0 to 1 cm; Grade 2 is translation of 1 to 2 cm, or to the glenoid rim; Grade 3 is subluxation beyond the edge of the glenoid rim; Grade 4 is a complete dislocation. The test should be performed on both shoulders to compare the affected and normal sides. While a positive load and shift test suggests instability, the apprehension, relocation, and anterior release tests are better predictors of arthroscopically evident instability [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11044508\">",
"    <span class=\"h1\">",
"     SPECIAL TESTS FOR BICEPS TENDON PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of the biceps tendon includes evaluation for a spectrum of disorders ranging from mild tendinopathy to complete tendon rupture. Biceps tendon injuries occur more often in patients who engage in frequent pulling, lifting, reaching, or throwing for work or recreation. Degenerative tendinosis and biceps tendon rupture are usually seen in older patients, while isolated tendinopathy usually presents in young or middle aged patients. The examination techniques used to diagnose biceps tendon pathology, in addition to the relevant anatomy, presentation, diagnosis, and management of biceps tendon injuries, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25991?source=see_link\">",
"     \"Biceps tendinopathy and tendon rupture\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11044515\">",
"    <span class=\"h1\">",
"     SPECIAL TESTS FOR LABRAL (SLAP) PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4844162\">",
"    <span class=\"h2\">",
"     Overview and test descriptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder pain due to pathology of the superior labrum has been known for several decades [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/48\">",
"     48",
"    </a>",
"    ]; the acronym SLAP (referring to injury of the superior labrum anterior to posterior) was created in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/49\">",
"     49",
"    </a>",
"    ]. Clinical evaluation of SLAP lesions is problematic because they usually do not occur in isolation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The biceps tendon anchors to the superior glenoid labrum. Thus, evaluation of SLAP lesions and injuries of the proximal biceps tendon are inextricably linked. Several mechanisms can produce SLAP lesions but among the most common are falls onto the shoulder, lifting a heavy object, traumatic dislocation, and overuse from overhead sports or heavy work [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many examination tests for detecting SLAP lesions have been described but studies of individual techniques are extremely limited by methodology, variations among patient populations, and other factors. Several systematic reviews have concluded that no single physical examination technique can accurately diagnose a SLAP injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/53-57\">",
"     53-57",
"    </a>",
"    ]. In addition, there are no conclusive studies about which combination of techniques are most useful.",
"   </p>",
"   <p>",
"    Several of the more commonly used techniques and studies of their accuracy are described here; our suggested approach to assessing possible SLAP lesions is described below. (See",
"    <a class=\"local\" href=\"#H11044606\">",
"     'Suggested approach to SLAP testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <strong>",
"     Active compression test (O&rsquo;Brien&rsquo;s sign)",
"    </strong>",
"     The active compression test has two parts and is performed with the patient standing. To prepare, the patient flexes their shoulder 90 degrees with the elbow in full extension. Then, they adduct the arm 10 degrees (ie, move it slightly toward the midline). Once properly positioned, the patient internally rotates their arm until the thumb points downward. The examiner then pushes the arm toward the floor while the patient resists by maintaining their arm in the starting position. This first part of the test may elicit deep shoulder pain or a clicking sensation in the glenohumeral region. The maneuver is then repeated with the patient&rsquo;s arm fully supinated. The test is positive if the pain or click is reduced or eliminated during the second part of the test.",
"   </p>",
"   <p>",
"    <strong>",
"     Crank test",
"    </strong>",
"     To perform the crank test, the patient stands and abducts their arm 160 degrees while keeping the arm in the plane of the scapula [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/58\">",
"     58",
"    </a>",
"    ]. The elbow is flexed 90 degrees. The examiner then applies an axial load to the humerus with one hand while rotating the arm internally and externally with the other (",
"    <a class=\"graphic graphic_movie graphicRef82885 \" href=\"UTD.htm?23/9/23698\">",
"     movie 9",
"    </a>",
"    ). Pain, a clicking sensation during the maneuver, or reproduction of symptoms similar to those experienced at work or sport indicates a positive test. The test may be performed with the patient prone.",
"   </p>",
"   <p>",
"    <strong>",
"     Biceps load test (Kim 1)",
"    </strong>",
"     The first biceps load test is intended to detect SLAP injuries in patients with chronic shoulder dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/59\">",
"     59",
"    </a>",
"    ]. The test is performed with the patient supine and the examiner seated alongside holding the patient&rsquo;s wrist and elbow. The patient&rsquo;s arm is positioned with the shoulder abducted 90 degrees to the side, the elbow flexed 90 degrees, and the arm fully supinated. The examiner then steadily rotates the shoulder externally in a manner similar to the apprehension test (",
"    <a class=\"graphic graphic_movie graphicRef82886 \" href=\"UTD.htm?35/25/36241\">",
"     movie 10",
"    </a>",
"    ). Rotation is stopped when the patient feels as if the shoulder will dislocate. The patient then flexes the elbow while the examiner resists. The test is positive if the last maneuver provokes pain or continued apprehension about dislocation.",
"   </p>",
"   <p>",
"    <strong>",
"     Biceps load test (Kim 2)",
"    </strong>",
"     The second biceps load test is intended for patients without recurrent dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/60\">",
"     60",
"    </a>",
"    ]. The patient and examiner positions are the same as for the first biceps load test. However, in the second test, the shoulder is abducted 120 degrees before the shoulder is maximally externally rotated, again with the elbow flexed to 90 degrees and the arm supinated. The patient is then asked to flex the elbow while the examiner resists (",
"    <a class=\"graphic graphic_movie graphicRef82887 \" href=\"UTD.htm?35/61/36817\">",
"     movie 11",
"    </a>",
"    ). The test is positive if pain develops when the patient flexes their elbow or increases when the examiner applies resistance.",
"   </p>",
"   <p>",
"    <strong>",
"     Pain provocation test",
"    </strong>",
"     This test is similar to the biceps load tests (",
"    <a class=\"graphic graphic_movie graphicRef82888 \" href=\"UTD.htm?2/43/2737\">",
"     movie 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/61\">",
"     61",
"    </a>",
"    ]. The patient sits with the examiner standing behind them. The examiner holds the patient&rsquo;s wrist with their ipsilateral hand while the contralateral hand gently braces the patient&rsquo;s shoulder. The shoulder is abducted to 90 to 100 degrees directly to the side with the elbow flexed 90 degrees. The arm is then maximally externally rotated and while maintaining this position the arm is then maximally pronated and supinated. The test is positive if maximal pronation elicits or worsens pain.",
"   </p>",
"   <p>",
"    <strong>",
"     Anterior slide test",
"    </strong>",
"     For the anterior slide test, the patient stands or sits and places their hands on their iliac crest (ie, &ldquo;hands on hips&rdquo;) with their thumbs placed posteriorly (",
"    <a class=\"graphic graphic_movie graphicRef82889 \" href=\"UTD.htm?40/26/41378\">",
"     movie 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/62\">",
"     62",
"    </a>",
"    ]. The examiner stands behind the patient&rsquo;s affected shoulder and places the hand closest to the patient atop the patient&rsquo;s shoulder with the index finger over the anterior glenohumeral joint. The examiner places their other hand on the patient&rsquo;s elbow and then applies a superiorly directed force to the elbow and shoulder while the patient resists. A positive test produces pain, a popping or clicking sensation, or mimics the patient&rsquo;s symptoms.",
"   </p>",
"   <p>",
"    <strong>",
"     Compression-rotation test",
"    </strong>",
"     For the compression-rotation test, the patient lays supine with their shoulder abducted 90 degrees directly to the side and their elbow flexed at 90 degrees (",
"    <a class=\"graphic graphic_movie graphicRef82890 \" href=\"UTD.htm?37/57/38801\">",
"     movie 14",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/49\">",
"     49",
"    </a>",
"    ]. The examiner pushes the humerus into the glenoid by applying an axial load and then rotates the humerus internally and externally. A positive test produces a catching, popping, or snapping sensation. This test is analogous to the MacMurray&rsquo;s test for meniscus lesions of the knee. &nbsp;",
"   </p>",
"   <p>",
"    <strong>",
"     Upper cut test",
"    </strong>",
"     The upper cut test is performed by a standing patient with their arm by their side and their shoulder in neutral position [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/63\">",
"     63",
"    </a>",
"    ]. The patient then flexes their elbow 90 degrees, supinates their arm, and makes a fist. Next, the patient rapidly brings fist to their chin, simulating a boxing &ldquo;upper cut&rdquo; motion, while the examiner resists this motion with their hand placed atop the fist (",
"    <a class=\"graphic graphic_movie graphicRef82891 \" href=\"UTD.htm?15/34/15905\">",
"     movie 15",
"    </a>",
"    ). Pain or an uncomfortable popping sensation indicates a positive test.",
"   </p>",
"   <p>",
"    <strong>",
"     Modified dynamic labral shear test",
"    </strong>",
"     The modified dynamic labral shear test is performed with the patient standing, their shoulder abducted to 120 degrees, arm kept in the scapular plane, elbow flexed to 90 degrees, and their shoulder externally rotated until they feel tightness in the shoulder (",
"    <a class=\"graphic graphic_movie graphicRef82892 \" href=\"UTD.htm?8/2/8226\">",
"     movie 16",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/63\">",
"     63",
"    </a>",
"    ]. The examiner then pushes the proximal humerus anteriorly, thereby providing a shear force to the glenohumeral joint, while lowering the arm from 120 degrees to 60 degrees of abduction using the other hand. External rotation is maintained throughout. A positive test elicits pain or a painful clicking or catching sensation at the posterior joint line when the arm is abducted between 120 degrees and 90 degrees.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11044606\">",
"    <span class=\"h2\">",
"     Suggested approach to SLAP testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;No single examination maneuver or combination of tests has been shown to identify superior labral lesions with high sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/53-57,64\">",
"     53-57,64",
"    </a>",
"    ]. In addition, the plethora of available tests for SLAP lesions can be overwhelming for the clinician, not to mention the patient, who has a painful shoulder and may become annoyed by all the manipulation. Thus, we do not perform all the tests described above.",
"   </p>",
"   <p>",
"    Ultimately, the diagnosis of a SLAP lesion is made using the history, imaging studies, and sometimes arthroscopy, in addition to the physical examination. The specific examination maneuvers for detecting SLAP lesions should be approached with the intention of determining the need for imaging or surgical intervention. Based upon the available evidence and our clinical experience, we perform the following examination maneuvers in the following order to assess for SLAP injuries:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Active compression test (see",
"      <a class=\"local\" href=\"#H4844162\">",
"       'Overview and test descriptions'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Crank test (see",
"      <a class=\"local\" href=\"#H4844162\">",
"       'Overview and test descriptions'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Speeds test (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25991?source=see_link&amp;anchor=H7#H7\">",
"       \"Biceps tendinopathy and tendon rupture\", section on 'Physical examination'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although often described as a test of biceps tendon pathology, Speeds test is useful for assessing SLAP lesions, and when performed following the first two tests it is most specific [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/54\">",
"     54",
"    </a>",
"    ]. Additional tests for detecting SLAP lesions may be performed for difficult cases that remain unclear after these three tests are performed.",
"   </p>",
"   <p>",
"    Given the limitations of the available research, it is not surprising that a number of approaches to the clinical diagnosis of SLAP lesions have been advocated. A prospective study of several examination tests in a population of overhead throwing athletes with an expected high prevalence of SLAP lesions concluded that earlier studies of individual tests were exceedingly optimistic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/64\">",
"     64",
"    </a>",
"    ]. Its authors suggest that the best approach to the clinical diagnosis of SLAP lesions would include a combination tests designed to detect SLAP lesions and biceps tendon injuries.",
"   </p>",
"   <p>",
"    One research group suggests that combining two of three sensitive tests (active compression test, apprehension test, compression-rotation test) with one of the three more specific tests (Speeds, Yergasons, biceps-load II) yields a sensitivity of 70 percent and specificity of 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/65\">",
"     65",
"    </a>",
"    ]. Another group suggests that the most useful combinations of tests to rule in the diagnosis of labral tear, in descending order, are (1) history of popping, clicking, or catching and positive anterior slide test; (2) positive anterior slide and crank tests; (3) history of popping, clicking, or catching and positive crank test; and (4) positive anterior slide and active compression tests [",
"    <a class=\"abstract\" href=\"UTD.htm?27/11/27834/abstract/66\">",
"     66",
"    </a>",
"    ]. Another researcher suggests that labral lesions are best identified by a combination of the modified dynamic labral shear and active compression maneuvers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11044613\">",
"    <span class=\"h1\">",
"     EXAMINATION OF THE ACROMIOCLAVICULAR JOINT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder function depends upon movement at three joints, including the acromioclavicular (AC) joint, and one articulation. Common conditions afflicting the AC joint include acute injuries (often referred to as &ldquo;shoulder separation&rdquo;), idiopathic osteoarthritis, post-traumatic arthritis, and osteolysis. Focal pain and tenderness at the AC joint and increased pain when the patient reaches across their body are common findings. Conditions that can mimic AC pathology include rotator cuff disease and labral tears. Conditions affecting the AC joint and examination of this joint are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44439?source=see_link&amp;anchor=H9685319#H9685319\">",
"     \"Acromioclavicular joint disorders\", section on 'Examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10663?source=see_link\">",
"     \"Acromioclavicular joint injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11044662\">",
"    <span class=\"h1\">",
"     EXAMINATION OF THE STERNOCLAVICULAR JOINT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma, such as a fall onto the shoulder or a direct blow to the area around the superior sternum and medial clavicle, can cause sternoclavicular (SC) dislocations or fractures. Injuries or deformities of the SC joint are typically identified by palpation. Most dislocations are anterior and are easily recognized as an anterior prominence adjacent to the manubrium. Posterior dislocations are more difficult to diagnose and potentially more dangerous, as vascular structures traveling behind the clavicle may be injured. Localized joint swelling may obscure the posterior position of the clavicle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link&amp;anchor=H2471727#H2471727\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\", section on 'Sternoclavicular dislocation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3618723\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many maneuvers are used to assess shoulder function and these are often taught as if they are pathognomonic for a particular pathology. However, the diagnostic accuracy of these tests is often limited. Tips for performing a focused and productive shoulder examination are provided in the text. (See",
"      <a class=\"local\" href=\"#H3617975\">",
"       'Tips for a productive examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with recent traumatic injuries, neurologic complaints (eg, weakness, paresthesias), or unusual presentations, a careful neurovascular assessment is essential; among patients without such complaints, a focused neurovascular examination confirming basic motor function and sensation and adequate blood flow is sufficient. Neurovascular injuries associated with shoulder complaints include: cervical spine fracture and spinal cord injury, brachial plexus neurapraxia, and axillary nerve injury (often associated with anterior glenohumeral dislocation). (See",
"      <a class=\"local\" href=\"#H72837670\">",
"       'Neurovascular assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inspection is an important but often overlooked part of the shoulder examination. Make note of the patient&rsquo;s posture, including how they hold the affected arm, the appearance of the entire shoulder including the posterior glenohumeral and scapulothoracic regions, and any deformity, asymmetry, or skin abnormality. (See",
"      <a class=\"local\" href=\"#H11044332\">",
"       'Inspection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Palpate the shoulders systematically, comparing each side. We suggest starting with the neck to rule out cervical pathology. At a minimum, the clinician should palpate the following sites: cervical spine, scapular spine and adjacent musculature, acromion and the subacromial space, bicipital groove, and greater and lesser tuberosities of the humerus, and the clavicle, including sternoclavicular (SC) and acromioclavicular (AC) joints. (See",
"      <a class=\"local\" href=\"#H11044346\">",
"       'Palpation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Range of motion (ROM) testing helps to determine the site and nature of intrinsic shoulder pain (",
"      <a class=\"graphic graphic_table graphicRef52351 \" href=\"UTD.htm?2/27/2491\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef70854 \" href=\"UTD.htm?27/36/28236\">",
"       table 2",
"      </a>",
"      ). Although a healthy shoulder has extensive mobility, ROM varies among patients and thus it is important to compare shoulders. Full, painless active ROM requires a normal glenohumeral joint, intact rotator cuff tendons, and functional rotator cuff muscles. (See",
"      <a class=\"local\" href=\"#H11044360\">",
"       'Range of motion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rotator cuff injury is among the most common causes of shoulder pain, especially in patients over the age of 30. Examination maneuvers to assess the rotator cuff and shoulder impingement, an important risk factor for rotator cuff injury, are described in the text. (See",
"      <a class=\"local\" href=\"#H1180003\">",
"       'Examination for rotator cuff pathology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5844119\">",
"       'Special tests for shoulder impingement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coordination of motion at the glenohumeral joint and the scapulothoracic articulation is important for normal shoulder function. Among patients who work primarily at a desk, scapulothoracic dysfunction is a common contributor to shoulder pain. Assessment of scapulothoracic function is described in the text. (See",
"      <a class=\"local\" href=\"#H1181467\">",
"       'Scapulothoracic motion and strength'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glenohumeral instability due to weakness or laxity in some of the structures that stabilize the joint may cause shoulder discomfort in young throwing athletes, people with weak shoulder musculature, and patients who have sustained a rotator cuff tear. (See",
"      <a class=\"local\" href=\"#H11044487\">",
"       'Special tests for shoulder instability'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/1\">",
"      Reider B. Physical examination. Am J Sports Med 2004; 32:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/2\">",
"      Bayramolu A, Demiry&uuml;rek D, T&uuml;ccar E, et al. Variations in anatomy at the suprascapular notch possibly causing suprascapular nerve entrapment: an anatomical study. Knee Surg Sports Traumatol Arthrosc 2003; 11:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/3\">",
"      Ferretti A, Cerullo G, Russo G. Suprascapular neuropathy in volleyball players. J Bone Joint Surg Am 1987; 69:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/4\">",
"      Ringel SP, Treihaft M, Carry M, et al. Suprascapular neuropathy in pitchers. Am J Sports Med 1990; 18:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/5\">",
"      Fritz RC, Helms CA, Steinbach LS, Genant HK. Suprascapular nerve entrapment: evaluation with MR imaging. Radiology 1992; 182:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/6\">",
"      Ferretti A, De Carli A, Fontana M. Injury of the suprascapular nerve at the spinoglenoid notch. The natural history of infraspinatus atrophy in volleyball players. Am J Sports Med 1998; 26:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/7\">",
"      Ilfeld F, Holder H. Winged scapula: Case occurring in soldier from knapsack. JAMA 1942; 120:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/8\">",
"      Goodman CE. Unusual nerve injuries in recreational activities. Am J Sports Med 1983; 11:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/9\">",
"      Schultz JS, Leonard JA Jr. Long thoracic neuropathy from athletic activity. Arch Phys Med Rehabil 1992; 73:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/10\">",
"      Bateman JE. Nerve injuries about the shoulder in sports. J Bone Joint Surg Am 1967; 49:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/11\">",
"      Kessler KJ, Uribe JW. Complete isolated axillary nerve palsy in college and professional football players: a report of six cases. Clin J Sport Med 1994; 4:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/12\">",
"      McAdams TR, Dillingham MF. Surgical decompression of the quadrilateral space in overhead athletes. Am J Sports Med 2008; 36:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/13\">",
"      Hoskins WT, Pollard HP, McDonald AJ. Quadrilateral space syndrome: a case study and review of the literature. Br J Sports Med 2005; 39:e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/14\">",
"      Redler MR, Ruland LJ 3rd, McCue FC 3rd. Quadrilateral space syndrome in a throwing athlete. Am J Sports Med 1986; 14:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/15\">",
"      McClelland D, Hoy G. A case of quadrilateral space syndrome with involvement of the long head of the triceps. Am J Sports Med 2008; 36:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/16\">",
"      McClelland D, Paxinos A. The anatomy of the quadrilateral space with reference to quadrilateral space syndrome. J Shoulder Elbow Surg 2008; 17:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/17\">",
"      Roche-Nagle G, Ryan R, Barry M, Brophy D. Effort thrombosis of the upper extremity in a young sportsman: Paget-Schroetter syndrome. Br J Sports Med 2007; 41:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/18\">",
"      Chaudhry MA, Hajarnavis J. Paget-von Schr&ouml;tter syndrome: primary subclavian-axillary vein thrombosis in sport activities. Clin J Sport Med 2003; 13:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/19\">",
"      Spencer FA, Emery C, Lessard D, et al. Upper extremity deep vein thrombosis: a community-based perspective. Am J Med 2007; 120:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/20\">",
"      Spiezia L, Simioni P. Upper extremity deep vein thrombosis. Intern Emerg Med 2010; 5:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/21\">",
"      Kibler WB, Sciascia A. Current concepts: scapular dyskinesis. Br J Sports Med 2010; 44:300.",
"     </a>",
"    </li>",
"    <li>",
"     Codman EA. Normal motions of the shoulder joint. In: The Shoulder, Thomas Todd, Boston 1934. p.32.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/23\">",
"      Freedman L, Munro RR. Abduction of the arm in the scapular plane: scapular and glenohumeral movements. A roentgenographic study. J Bone Joint Surg Am 1966; 48:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/24\">",
"      Poppen NK, Walker PS. Normal and abnormal motion of the shoulder. J Bone Joint Surg Am 1976; 58:195.",
"     </a>",
"    </li>",
"    <li>",
"     Hoppenfeld S. Physical examination of the shoulder. In: Physical Examination of the Spine and Extremities, Prentice Hall, Upper Saddle River 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/26\">",
"      Hegedus EJ, Goode A, Campbell S, et al. Physical examination tests of the shoulder: a systematic review with meta-analysis of individual tests. Br J Sports Med 2008; 42:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/27\">",
"      Moen MH, de Vos RJ, Ellenbecker TS, Weir A. Clinical tests in shoulder examination: how to perform them. Br J Sports Med 2010; 44:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/28\">",
"      Beaudreuil J, Nizard R, Thomas T, et al. Contribution of clinical tests to the diagnosis of rotator cuff disease: a systematic literature review. Joint Bone Spine 2009; 76:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/29\">",
"      Hughes PC, Taylor NF, Green RA. Most clinical tests cannot accurately diagnose rotator cuff pathology: a systematic review. Aust J Physiother 2008; 54:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/30\">",
"      MULDER JD. FUNCTION OF THE SUPRASPINATUS MUSCLE AND ITS RELATION TO THE SUPRASPINATUS SYNDROME. AN EXPERIMENTAL STUDY IN MAN. J Bone Joint Surg Br 1963; 45:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/31\">",
"      Escamilla RF, Yamashiro K, Paulos L, Andrews JR. Shoulder muscle activity and function in common shoulder rehabilitation exercises. Sports Med 2009; 39:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/32\">",
"      Leroux JL, Thomas E, Bonnel F, Blotman F. Diagnostic value of clinical tests for shoulder impingement syndrome. Rev Rhum Engl Ed 1995; 62:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/33\">",
"      Hertel R, Ballmer FT, Lombert SM, Gerber C. Lag signs in the diagnosis of rotator cuff rupture. J Shoulder Elbow Surg 1996; 5:307.",
"     </a>",
"    </li>",
"    <li>",
"     Garrick JF, Webb DR. Shoulder girdle injuries. In: Sports Injuries: Diagnosis and Management, 2nd, WB Saunders, Philadelphia 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/35\">",
"      Park HB, Yokota A, Gill HS, et al. Diagnostic accuracy of clinical tests for the different degrees of subacromial impingement syndrome. J Bone Joint Surg Am 2005; 87:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/36\">",
"      Luime JJ, Verhagen AP, Miedema HS, et al. Does this patient have an instability of the shoulder or a labrum lesion? JAMA 2004; 292:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/37\">",
"      Murrell GA, Walton JR. Diagnosis of rotator cuff tears. Lancet 2001; 357:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/38\">",
"      Walch G, Boulahia A, Calderone S, Robinson AH. The 'dropping' and 'hornblower's' signs in evaluation of rotator-cuff tears. J Bone Joint Surg Br 1998; 80:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/39\">",
"      Scheibel M, Magosch P, Pritsch M, et al. The belly-off sign: a new clinical diagnostic sign for subscapularis lesions. Arthroscopy 2005; 21:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/40\">",
"      Cali M, Akg&uuml;n K, Birtane M, et al. Diagnostic values of clinical diagnostic tests in subacromial impingement syndrome. Ann Rheum Dis 2000; 59:44.",
"     </a>",
"    </li>",
"    <li>",
"     McFarland EG. Examination of the Shoulder: The Complete Guide, Kim TK, Park HB, Rassi GE, et al (Eds), Thieme Medical, New York 2006. p.142.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/42\">",
"      MacDonald PB, Clark P, Sutherland K. An analysis of the diagnostic accuracy of the Hawkins and Neer subacromial impingement signs. J Shoulder Elbow Surg 2000; 9:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/43\">",
"      Rabin A, Irrgang JJ, Fitzgerald GK, Eubanks A. The intertester reliability of the Scapular Assistance Test. J Orthop Sports Phys Ther 2006; 36:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/44\">",
"      Warner JJ, Navarro RA. Serratus anterior dysfunction. Recognition and treatment. Clin Orthop Relat Res 1998; :139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/45\">",
"      Kibler WB, Sciascia A, Dome D. Evaluation of apparent and absolute supraspinatus strength in patients with shoulder injury using the scapular retraction test. Am J Sports Med 2006; 34:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/46\">",
"      Tzannes A, Murrell GA. Clinical examination of the unstable shoulder. Sports Med 2002; 32:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/47\">",
"      Tzannes A, Paxinos A, Callanan M, Murrell GA. An assessment of the interexaminer reliability of tests for shoulder instability. J Shoulder Elbow Surg 2004; 13:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/48\">",
"      Andrews JR, Carson WG Jr, McLeod WD. Glenoid labrum tears related to the long head of the biceps. Am J Sports Med 1985; 13:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/49\">",
"      Snyder SJ, Karzel RP, Del Pizzo W, et al. SLAP lesions of the shoulder. Arthroscopy 1990; 6:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/50\">",
"      Stenson WB, SE Snyder, RP Karzel, et al. Long-term clinical follow-up of isolated SLAP lesions of the shoulder. Arch Am Acad Orthop Surg 1997; 1:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/51\">",
"      Kim TK, Queale WS, Cosgarea AJ, McFarland EG. Clinical features of the different types of SLAP lesions: an analysis of one hundred and thirty-nine cases. J Bone Joint Surg Am 2003; 85-A:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/52\">",
"      Maffet MW, Gartsman GM, Moseley B. Superior labrum-biceps tendon complex lesions of the shoulder. Am J Sports Med 1995; 23:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/53\">",
"      Calvert E, Chambers GK, Regan W, et al. Special physical examination tests for superior labrum anterior posterior shoulder tears are clinically limited and invalid: a diagnostic systematic review. J Clin Epidemiol 2009; 62:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/54\">",
"      Meserve BB, Cleland JA, Boucher TR. A meta-analysis examining clinical test utility for assessing superior labral anterior posterior lesions. Am J Sports Med 2009; 37:2252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/55\">",
"      Walton DM, Sadi J. Identifying SLAP lesions: a meta-analysis of clinical tests and exercise in clinical reasoning. Phys Ther Sport 2008; 9:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/56\">",
"      Dessaur WA, Magarey ME. Diagnostic accuracy of clinical tests for superior labral anterior posterior lesions: a systematic review. J Orthop Sports Phys Ther 2008; 38:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/57\">",
"      Jones GL, Galluch DB. Clinical assessment of superior glenoid labral lesions: a systematic review. Clin Orthop Relat Res 2007; 455:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/58\">",
"      Liu SH, Henry MH, Nuccion SL. A prospective evaluation of a new physical examination in predicting glenoid labral tears. Am J Sports Med 1996; 24:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/59\">",
"      Kim SH, Ha KI, Han KY. Biceps load test: a clinical test for superior labrum anterior and posterior lesions in shoulders with recurrent anterior dislocations. Am J Sports Med 1999; 27:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/60\">",
"      Kim SH, Ha KI, Ahn JH, et al. Biceps load test II: A clinical test for SLAP lesions of the shoulder. Arthroscopy 2001; 17:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/61\">",
"      Mimori K, Muneta T, Nakagawa T, Shinomiya K. A new pain provocation test for superior labral tears of the shoulder. Am J Sports Med 1999; 27:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/62\">",
"      Kibler WB. Specificity and sensitivity of the anterior slide test in throwing athletes with superior glenoid labral tears. Arthroscopy 1995; 11:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/63\">",
"      Ben Kibler W, Sciascia AD, Hester P, et al. Clinical utility of traditional and new tests in the diagnosis of biceps tendon injuries and superior labrum anterior and posterior lesions in the shoulder. Am J Sports Med 2009; 37:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/64\">",
"      Parentis MA, Glousman RE, Mohr KS, Yocum LA. An evaluation of the provocative tests for superior labral anterior posterior lesions. Am J Sports Med 2006; 34:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/65\">",
"      Oh JH, Kim JY, Kim WS, et al. The evaluation of various physical examinations for the diagnosis of type II superior labrum anterior and posterior lesion. Am J Sports Med 2008; 36:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/11/27834/abstract/66\">",
"      Walsworth MK, Doukas WC, Murphy KP, et al. Reliability and diagnostic accuracy of history and physical examination for diagnosing glenoid labral tears. Am J Sports Med 2008; 36:162.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13814 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_11_27834=[""].join("\n");
var outline_f27_11_27834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3618723\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11044325\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13248561\">",
"      ANATOMY AND BIOMECHANICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3617975\">",
"      TIPS FOR A PRODUCTIVE EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H72837670\">",
"      NEUROVASCULAR ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11044332\">",
"      INSPECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11044346\">",
"      PALPATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11044360\">",
"      RANGE OF MOTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5844675\">",
"      Approach to shoulder motion assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18511193\">",
"      Active range of motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18511206\">",
"      Passive range of motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1180003\">",
"      EXAMINATION FOR ROTATOR CUFF PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18531072\">",
"      Overview and evidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11044410\">",
"      Assessment of abduction and the supraspinatus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11044417\">",
"      Assessment of external rotation and the infraspinatus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11044424\">",
"      Assessment of internal rotation and the subscapularis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1180134\">",
"      Testing for rotator cuff tear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5844119\">",
"      SPECIAL TESTS FOR SHOULDER IMPINGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5844126\">",
"      Passive painful arc (Neer) test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5844133\">",
"      Flexion with internal rotation (Hawkins-Kennedy) test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5844140\">",
"      Scapular assistance test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1181467\">",
"      SCAPULOTHORACIC MOTION AND STRENGTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11044487\">",
"      SPECIAL TESTS FOR SHOULDER INSTABILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11044494\">",
"      Sulcus sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11044501\">",
"      Apprehension, relocation, and release tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95588956\">",
"      Load and shift test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11044508\">",
"      SPECIAL TESTS FOR BICEPS TENDON PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11044515\">",
"      SPECIAL TESTS FOR LABRAL (SLAP) PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4844162\">",
"      Overview and test descriptions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11044606\">",
"      Suggested approach to SLAP testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11044613\">",
"      EXAMINATION OF THE ACROMIOCLAVICULAR JOINT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11044662\">",
"      EXAMINATION OF THE STERNOCLAVICULAR JOINT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3618723\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13814\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13814|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/47/34554\" title=\"figure 1\">",
"      Scapular motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/12/38080\" title=\"figure 2\">",
"      Right winged scapula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13814|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/7/13424\" title=\"picture 1\">",
"      Rounded protracted shoulder posture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/62/29664\" title=\"picture 2\">",
"      Biceps tendon rupture2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/1/24592\" title=\"picture 3\">",
"      Deformity from Type III AC joint injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/47/1791\" title=\"picture 4\">",
"      Winging of scapula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/9/19600\" title=\"picture 5\">",
"      Palpation subscapular bursa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/16/37120\" title=\"picture 6\">",
"      Subacromial palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/11/37041\" title=\"picture 7\">",
"      Subacromial palpation with extension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/57/1938\" title=\"picture 8\">",
"      Biceps tendon palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/10/43183\" title=\"picture 9\">",
"      AC joint tenderness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/48/6913\" title=\"picture 10\">",
"      AC joint palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/24/9604\" title=\"picture 11\">",
"      Apley scratch tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/26/27041\" title=\"picture 12\">",
"      Supraspinatus isometric strength test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/11/177\" title=\"picture 13\">",
"      Painful arc sign for rotator cuff pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/60/1987\" title=\"picture 14\">",
"      Jobes test of supraspinatus strength",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/2/23585\" title=\"picture 15\">",
"      External rotation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/9/43155\" title=\"picture 16\">",
"      Gerbers test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/7/44149\" title=\"picture 17\">",
"      Neers test for shoulder impingement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/27/19891\" title=\"picture 18\">",
"      Hawkins Kennedy test for shoulder impingement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/16/39183\" title=\"picture 19\">",
"      Sulcus sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/3/17466\" title=\"picture 20\">",
"      Apprehension relocation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13814|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?6/19/6448\" title=\"movie 1\">",
"      Push off demonstrating winging of scapula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?32/63/33791\" title=\"movie 2\">",
"      Apley scratch tests for shoulder motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?38/24/39296\" title=\"movie 3\">",
"      Drop arm test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?25/58/26529\" title=\"movie 4\">",
"      External rotation testing of shoulder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?3/13/3281\" title=\"movie 5\">",
"      Passive Painful Arc Neer Test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?22/24/22913\" title=\"movie 6\">",
"      Scapular assistance maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?43/44/44736\" title=\"movie 7\">",
"      Sulcus sign for glenohumeral instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?21/11/21681\" title=\"movie 8\">",
"      Apprehension relocation release tests for shoulder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?23/9/23698\" title=\"movie 9\">",
"      Crank test for SLAP lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?35/25/36241\" title=\"movie 10\">",
"      Kim biceps load test one for SLAP lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?35/61/36817\" title=\"movie 11\">",
"      Kim biceps load test two for SLAP lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?2/43/2737\" title=\"movie 12\">",
"      Pain provocation test for SLAP lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/26/41378\" title=\"movie 13\">",
"      Anterior slide test for SLAP lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?37/57/38801\" title=\"movie 14\">",
"      Compression rotation test for SLAP lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?15/34/15905\" title=\"movie 15\">",
"      Upper cut test for SLAP lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?8/2/8226\" title=\"movie 16\">",
"      Modified dynamic labral shear test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13814|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/27/2491\" title=\"table 1\">",
"      Shoulder range of motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/36/28236\" title=\"table 2\">",
"      Glenohumeral joint movements",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44439?source=related_link\">",
"      Acromioclavicular joint disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10663?source=related_link\">",
"      Acromioclavicular joint injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25991?source=related_link\">",
"      Biceps tendinopathy and tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=related_link\">",
"      Clinical features and diagnosis of cervical radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2953?source=related_link\">",
"      Clinical manifestations and treatment of the hypermobility syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=related_link\">",
"      Evaluation and acute management of cervical spinal column injuries in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=related_link\">",
"      Evaluation of the patient with neck pain and cervical spine disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33912?source=related_link\">",
"      Frozen shoulder (adhesive capsulitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26630?source=related_link\">",
"      Glenohumeral osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=related_link\">",
"      Presentation and diagnosis of rotator cuff tears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=related_link\">",
"      Primary (spontaneous) upper extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36425?source=related_link\">",
"      Radiologic evaluation of the painful shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=related_link\">",
"      Rotator cuff tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10378?source=related_link\">",
"      Shoulder dislocation and reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32280?source=related_link\">",
"      Shoulder impingement syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_11_27835="Drug thrombocytopenia criteria";
var content_f27_11_27835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for assessing reports of drug-induced thrombocytopenia and levels of evidence for a causal relationship of the drug to thrombocytopenia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. The candidate drug (a) preceded",
"thrombocytopenia",
"        <strong>",
"         AND",
"        </strong>",
"        (b) recovery from thrombocytopenia was complete",
"and sustained after the drug was discontinued.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. The candidate drug was (a) the only drug used prior to the onset of thrombocytopenia",
"        <strong>",
"         OR",
"        </strong>",
"        (b) other drugs were continued or reintroduced after discontinuation of",
"the candidate drug with a sustained normal platelet count.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Other etiologies for thrombocytopenia were excluded.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Reexposure to the candidate drug resulted in recurrent thrombocytopenia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Level of evidence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Definite (Level I): criteria 1, 2, 3, and 4 met",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Probable (Level II): criteria 1, 2, and 3 met",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possible: criterion 1 met",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unlikely: criterion 1 not met",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from George, JN, Raskob, GE, Shah, SR, et al. Ann Intern Med 1998; 129:886.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_11_27835=[""].join("\n");
var outline_f27_11_27835=null;
var title_f27_11_27836="Inherited uncong hyperbili";
var content_f27_11_27836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Principal differential characteristics of inherited unconjugated hyperbilirubinemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Crigler-Najjar syndrome type I",
"       </td>",
"       <td class=\"subtitle1\">",
"        Crigler-Najjar syndrome type II",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gilbert's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver histology",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum bilirubin concentration",
"       </td>",
"       <td>",
"        20-50 mg/dL",
"       </td>",
"       <td>",
"        &lt;20 mg/dL",
"       </td>",
"       <td>",
"        Usually &lt;3 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Routine liver function tests",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45-min plasma BSP retention",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Usually normal; may be elevated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bile",
"       </td>",
"       <td>",
"        Usually pale; contains small amounts of unconjugated bilirubin",
"       </td>",
"       <td>",
"        Increased proportion of bilirubin monoglucuronide",
"       </td>",
"       <td>",
"        Increased proportion of bilirubin monoglucuronide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic bilirubin UDP- glucuronosyltransferase activity",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Markedly reduced",
"       </td>",
"       <td>",
"        Reduced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Effect of phenobarbital on serum bilirubin",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Reduction",
"       </td>",
"       <td>",
"        Reduction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mode of inheritance",
"       </td>",
"       <td>",
"        Autosomal recessive",
"       </td>",
"       <td>",
"        Autosomal recessive",
"       </td>",
"       <td>",
"        Autosomal recessive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prevalence",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Common (approximately 9 percent of Caucasians are homozygous for a variant TATAA box; 4 to 5 percent have hyperbilirubinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prognosis",
"       </td>",
"       <td>",
"        Kernicterus , unless vigorously treated",
"       </td>",
"       <td>",
"        Usually benign, kernicterus occurs rarely",
"       </td>",
"       <td>",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Animal model",
"       </td>",
"       <td>",
"        Homozygous Gunn rat",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Bolivian squirrel monkey",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_11_27836=[""].join("\n");
var outline_f27_11_27836=null;
var title_f27_11_27837="Survival autoimmune hepatitis";
var content_f27_11_27837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Survival in classic autoimmune hepatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 277px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of survival, using death and liver transplantation as endpoints, in patients with autoimmune hepatitis according to the presence or absence of cirrhosis. Survival is excellent in both groups at 10 years but falls off substantially in the patients with cirrhosis between 10 and 20 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Roberts SK, Therneau TM, Czaja AJ. Gastroenterology 1996; 110:848.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_11_27837=[""].join("\n");
var outline_f27_11_27837=null;
var title_f27_11_27838="Calculator: Rockall score for upper gastrointestinal bleeding";
var content_f27_11_27838=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"RockallScore_form\" name=\"RockallScore_form\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Rockall score for upper gastrointestinal bleeding",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Age",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"RockallScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &lt;60 years old (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"RockallScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           60-79 years old (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"RockallScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &gt;=80 years old (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Hemodynamic Shock",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"RockallScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None with systolic BP &gt;=100 mmHg and pulse &lt;100/min (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"RockallScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Tachcardic with pulse &gt;=100/min but systolic BP &gt;=100 mmHg (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"RockallScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Hypotension with systolic BP &lt;100 mmHg (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Major Comorbidities",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"RockallScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"RockallScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Cardiac failure, ischemic heart disease or similar major comorbidity (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"RockallScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Renal failure, hepatic failure or disseminated cancer (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Diagnosis",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"RockallScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Mallory-Weiss tear, but no major lesions and no stigmata of recent bleed (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"RockallScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Other nonmalignant gastrointestinal diagnoses (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"RockallScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Upper gastrointestinal tract malignancy (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Recent hemorrhage",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"RockallScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           None (or dark area only) (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"RockallScore_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Blood found in upper gastrointestinal tract (clot adherence, spurting or visible vessel) (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       A score of 2 or less is associated with a low risk of further bleeding or death.",
"      </li>",
"      <li>",
"       Please see appropriate UpToDate topic reviews for further information.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage.",
"        <i>",
"         Gut",
"        </i>",
"        . 1996 Mar;38(3):316-21.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"RockallScore_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_11_27838=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function RockallScore_fx() {",
"with(document.RockallScore_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 0;",
"}",
"if (cc1[1].checked){",
"Score = Score + 1;",
"}",
"if (cc1[2].checked){",
"Score = Score + 2;",
"}",
"if (cc2[0].checked){",
"Score = Score + 0;",
"}",
"if (cc2[1].checked){",
"Score = Score + 1;",
"}",
"if (cc2[2].checked){",
"Score = Score + 2;",
"}",
"if (cc3[0].checked){",
"Score = Score + 0;",
"}",
"if (cc3[1].checked){",
"Score = Score + 2;",
"}",
"if (cc3[2].checked){",
"Score = Score + 3;",
"}",
"if (cc4[0].checked){",
"Score = Score + 0;",
"}",
"if (cc4[1].checked){",
"Score = Score + 1;",
"}",
"if (cc4[2].checked){",
"Score = Score + 2;",
"}",
"if (cc5[0].checked){",
"Score = Score + 0;",
"}",
"if (cc5[1].checked){",
"Score = Score + 2;",
"}",
"cctotal.value = Score;",
"}",
"}",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f27_11_27838=null;
var title_f27_11_27839="Tracheal stenosis gross";
var content_f27_11_27839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tracheal stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Resected surgical specimen demonstrates a critically narrowed segmant of the trachea, with an internal diameter of only 5-6mm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hermes Grillo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_11_27839=[""].join("\n");
var outline_f27_11_27839=null;
